axgn_Current_Folio

0001558370-15-001476.txt : 20150806 0001558370-15-001476.hdr.sgml : 20150806 20150806160730 ACCESSION NUMBER: 0001558370-15-001476 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150806 DATE AS OF CHANGE: 20150806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 151033167 BUSINESS ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 10-Q 1 axgn-20150630x10q.htm 10-Q axgn_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to______________

Commission file number: 001-36046

AxoGen, Inc.

(Exact name of registrant as specified in its charter)


Minnesota		41-1301878
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)


13631 Progress Blvd., Suite 400, Alachua, FL		32615
(Address of principal executive offices)		(Zip Code)

386-462-6800

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☐

Non-Accelerated filer ☐ (Do not check if a smaller reporting company)		Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

As of August 5, 2015 the registrant had 24,932,392 shares of common stock outstanding.

Table of Contents


Part I - Financial Information
Item 1.	Financial Statements	2

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19

Item 4.	Controls and Procedures	20


Part II - Other Information

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosures	21

Item 5.	Other Information	21

Item 6.	Exhibits	22

	Signature Page	23

Forward-Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission (including this Form 10-Q), in press releases, and in other communications to shareholders or the investment community, the Company may provide forward-looking statements concerning possible or anticipated future results of operations or business developments. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential, regulatory environment, sales and marketing strategies, liquidity, capital resources or operating performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this Form 10-Q should be evaluated together with the many uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Table of Contents

PART 1 — FINANCIAL INFORMATION

ITEM 1 — CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AxoGen, Inc.

Condensed Consolidated Balance Sheets


	June 30,		December 31,
	2015		2014
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	15,622,932	$	8,215,791
Accounts receivable, net of allowance for doubtful accounts of approximately $148,000 and $94,000 respectively		3,838,023		2,872,308
Inventory		3,539,957		3,213,620
Prepaid expenses and other		241,108		109,369
Total current assets		23,242,020		14,411,088
Property and equipment, net		663,910		619,028
Intangible assets		608,539		577,174
Deferred financing costs		908,684		793,499
	$	25,423,153	$	16,400,789
Liabilities and Shareholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses	$	3,408,122	$	2,431,194
Current deferred revenue		14,118		14,118
Total current liabilities		3,422,240		2,445,312

Note Payable - Revenue Interest Purchase Agreement		25,426,647		25,085,777
Long Term Deferred Revenue		104,589		115,380
Total liabilities		28,953,476		27,646,469
Commitments and contingencies
Shareholders’ equity (deficit):
Common stock, $.01 par value; 50,000,000 shares authorized; 24,932,392 and 19,488,814 shares issued and outstanding		249,323		194,888

Additional paid-in capital		93,102,681		78,675,686
Accumulated deficit		(96,882,327)		(90,116,254)
Total shareholders’ equity (deficit)		(3,530,323)		(11,245,680)
	$	25,423,153	$	16,400,789

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)


	Three Months Ended				Six Months Ended
	June 30,		June 30,		June 30,		June 30,
	2015		2014		2015		2014
Revenues	$	6,417,253	$	4,214,193	$	11,368,569	$	7,352,449
Cost of goods sold		1,039,841		887,820		2,022,722		1,589,121
Gross profit		5,377,412		3,326,373		9,345,847		5,763,328
Costs and expenses:
Sales and marketing		4,812,262		3,354,912		8,744,783		6,075,619
Research and development		736,399		555,758		1,407,435		1,368,373
General and administrative		1,982,020		1,713,447		3,890,602		3,608,222
Total costs and expenses		7,530,681		5,624,117		14,042,820		11,052,214
Loss from operations		(2,153,269)		(2,297,744)		(4,696,973)		(5,288,886)
Other income (expense):
Interest expense		(1,023,774)		(1,392,098)		(2,018,522)		(2,583,415)
Interest expense — deferred financing costs		(31,210)		(52,217)		(64,956)		(103,432)
Other income (expense)		17,380		588		14,378		(5,303)
Total other income (expense)		(1,037,604)		(1,443,727)		(2,069,100)		(2,692,150)
Net Loss	$	(3,190,873)	$	(3,741,471)	$	(6,766,073)	$	(7,981,036)
Weighted Average Common Shares outstanding — basic and diluted		24,928,435		17,461,332		23,729,558		17,422,773
Loss Per Common share — basic and diluted	$	(0.13)	$	(0.21)	$	(0.29)	$	(0.46)

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)


	Six Months Ended June 30,
	2015		2014
Cash flows from operating activities:
Net loss	$	(6,766,073)	$	(7,981,036)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		87,610		67,887
Amortization of intangible assets		22,710		22,099
Amortization of deferred financing costs		64,957		103,432
Stock-based compensation		696,625		474,144
Stock grant for service		—		60,125
Interest added to note payable		340,870		1,878,894
Change in assets and liabilities:
Accounts receivable		(965,715)		(633,254)
Inventory		(326,337)		(12,004)
Prepaid expenses and other		(131,739)		151,744
Accounts payable and accrued expenses		976,928		155,113
Deferred revenue		(10,791)		(7,143)

Net cash used for operating activities		(6,010,955)		(5,719,999)

Cash flows from investing activities:
Purchase of property and equipment		(132,492)		(283,476)
Acquisition of intangible assets		(54,075)		(30,305)

Net cash used for investing activities		(186,567)		(313,781)

Cash flows from financing activities:
Proceeds from issuance of common stock		13,770,734		—
Debt issuance costs		(180,142)		—
Proceeds from exercise of stock options		14,071		134,362

Net cash provided by financing activities		13,604,663		134,362

Net increase / (decrease) in cash and cash equivalents		7,407,141		(5,899,418)
Cash and cash equivalents, beginning of year		8,215,791		20,069,750

Cash and cash equivalents, end of period	$	15,622,932	$	14,170,332

Supplemental disclosures of cash flow activity:
Cash paid for interest	$	1,649,881	$	664,546

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of June 30, 2015 and December 31, 2014 and for the three and six month periods ended June 30, 2015 and 2014. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2014, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2014. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

2. Organization and Business

Business Summary

AxoGen, Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

3. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor. Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as product being shipped from our facility via courier to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. In the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Table of Contents

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $148,000 and $94,000 at June 30, 2015 and December 31, 2014, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:


	June 30,		December 31,
	2015		2014
Finished goods	$	2,403,791	$	2,072,235
Work in process		240,054		331,891
Raw materials		896,112		809,494
	$	3,539,957	$	3,213,620

Inventories were net of reserve of approximately $653,000 and $404,000 at June 30, 2015 and December 31, 2014, respectively.

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not

Table of Contents

that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:


Six months ended June 30,	2015		2014
Expected term (in years)	4		4
Expected volatility	76.24	%	79.80	%
Risk free rate	1.21	%	1.20	%
Expected dividends	—	%	—	%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2015 and 2014 as they were deemed insignificant.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Table of Contents

Recent Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis" ("ASU 2015-02") which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

4. Property and Equipment

Property and equipment consist of the following:


	June 30,		December 31,
	2015		2014
	(unaudited)
Furniture and equipment	$	955,743	$	873,824

Table of Contents

Leasehold improvements		300,697		285,697
Processing equipment		1,230,285		1,194,712
Less: accumulated depreciation and amortization		(1,822,815)		(1,735,205)

Property and equipment	$	663,910	$	619,028

5. Intangible Assets

The Company’s intangible assets consist of the following:


	June 30,		December 31,
	2015		2014
	(unaudited)
License agreements	$	860,006	$	850,859
Patents		124,924		79,996
Less: accumulated amortization		(376,391)		(353,681)
Intangible assets, net	$	608,539	$	577,174

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2015, the patents were fully amortized, and the remaining patents of $124,924 were pending patent costs and were not amortizable. Amortization expense was approximately $11,000 and $11,000 for the three months ended June 30, 2015 and 2014, respectively, and approximately $23,000 and $22,000 for the six months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, future amortization of license agreements for the next five years is expected to be $25,000 for the remainder of 2015 and $48,000 for 2016 through 2020.

License Agreements

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone

Table of Contents

fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

Royalty fees were approximately $121,000 and $85,000 during the three months ended June 30, 2015 and 2014, respectively, and were $217,000 and $145,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consists of the following:


	June 30,		December 31,
	2015		2014
Accounts payable	$	1,838,425	$	1,160,859
Miscellaneous accruals		205,809		105,315
Accrued compensation		1,363,888		1,165,020
Accounts Payable and Accrued Expenses	$	3,408,122	$	2,431,194

7. Notes Payable

Notes Payable consists of the following:


	June 30,		December 31,
	2015		2014
Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.	$	25,426,647	$	25,085,777
Long-term portion	$	25,426,647	$	25,085,777

Note Payable

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 million to $2.5 million per quarter to begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%. The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was

Table of Contents

terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract. The Company has no further obligations under the Royalty Contract.

On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL. The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a (“Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80% AxoGen has to maintain certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations. In the event of default per the terms of the Term Loan Agreement Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.

Table of Contents

at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

The Company records interest using its best estimate of the effective interest rate. This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks. The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement. From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams. Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

8. Stock Options

The Company granted stock options to purchase 295,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the six months ended June 30, 2015. Stock-based compensation expense was $328,376 and $216,602 for the three months ended June 30, 2015 and 2014, respectively and $696,625 and $474,144 for the six months ended June 30, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,996,000 at June 30, 2015.

9. Public Offering of Common Stock

On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share. The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.

The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.

As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.

10. Commitments and Contingencies

Commercial Lease

On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc. (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas. The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year. The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.

Processing Agreement

Under an Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health,

Table of Contents

Virginia Beach, Virginia. As a result of business requirements of LifeNet Health and their need for additional space, on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the LifeNet Agreement effective February 27, 2016. AxoGen has entered into an agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) as a result this termination.

11. Subsequent Events

License and Services Agreement

On August 6, 2015, AxoGen Corporation (“AxoGen”) entered into a License and Services Agreement (the “Agreement”) with CTS. Headquartered in Dayton, Ohio, CTS is a nonprofit quality, ethical provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts. CTS, an accredited member of the AATB, is one of the largest nonprofit tissue banks in the United States having in 2014 distributed more than 355,000 tissue grafts to over 5,000 hospitals, physicians and surgeons. Pursuant to the Agreement, AxoGen will process and package its Avance® Nerve Graft using its employees and equipment located at CTS. It is anticipated that processing currently being performed at LifeNet Health, will be transferred completely to the CTS facility by the end of first quarter of 2016.

The Agreement is for a 5 year term, subject to earlier termination by either party for cause, or after the two year anniversary of the Agreement without cause, upon 180 days’ notice. Under the Agreement AxoGen pays CTS a facility fee for clean room/processing, storage and office space. CTS also provides services in support of AxoGen’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support. The service fee is based on a per donor batch rate. It is anticipated that the Company will have approximately $400,000 of capital expenditures for the placement of equipment and build-out at this facility.

Table of Contents

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, all references in this report to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. and its wholly owned subsidiary AxoGen Corporation (“AC”).

OVERVIEW

AxoGen, Inc. (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

Revenue from the distribution of these products is the main contributor to AxoGen’s total reported sales and has been the key component of its growth to date. AxoGen revenues increased in the first six months of 2015 compared to 2014 primarily as a result of sales to new accounts, increased product usage by existing accounts and a price increase effective March 1, 2015. AxoGen has continued to broaden and strengthen its sales and marketing activity with a focus on the execution of its sales operations. This is expected to have a continued positive contribution to its revenue growth in the long term.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2015 and 2014

Revenues

Revenues for the three months ended June 30, 2015 increased 52.3% to approximately $6,417,000 as compared to approximately $4,214,000 for the three months ended June 30, 2014. Additionally, revenues for the six months ended June 30, 2015 increased 54.6% to approximately $11,369,000 as compared to approximately $7,352,000 for the six months ended June 30, 2014. This increase was primarily a result of increased product usage by existing accounts and sales to new accounts. Also contributing to the increase, AxoGen recognized approximately $128,000 and $57,000 of grant revenue in the three months ended June 30, 2015 and 2014, respectively and $270,000 and $119,000 of grant revenue in the six months ended June 30, 2015 and 2014, respectively.

Gross Profit

Gross profit for the three months ended June 30, 2015 increased 61.7% to approximately $5,377,000 as compared to approximately $3,326,000 for the three months ended June 30, 2014. Such increase in aggregate dollars was primarily attributable to the increased revenues in the second quarter of 2015, and to a lesser extent by an improvement in gross margin. Gross margin improved to 83.8% for the three months ended June 30, 2015 as compared to 78.9% for the same period in 2014 as a result of processing efficiencies and favorable product mix as a result of changes both within and between product lines.

Gross profit for the six months ended June 30, 2015 increased 62.2% to approximately $9,346,000 as compared to approximately $5,763,000 for the six months ended June 30, 2014. Such increase in aggregate dollars was primarily attributable to the increased revenues in the first six months of 2015, and to a lesser extent by an improvement in gross margin. Gross margin improved to 82.2% for the six months ended June 30, 2015 as compared to 78.4% for the same period in 2014 as a result of processing efficiencies and changes in product mix as a result of changes both within and between product lines.

Table of Contents

Costs and Expenses

Total cost and expenses increased 33.9% to approximately $7,531,000 for the three months ended June 30, 2015 as compared to approximately $5,624,000 for the three months ended June 30, 2014. These increases were primarily due to increased sales and marketing activities along with an increase in research and development as the Company began its clinical trial for the Avance© Nerve Graft.

Total cost and expenses increased 27.1% to approximately $14,043,000 for the six months ended June 30, 2015 as compared to approximately $11,052,000 for the six months ended June 30, 2014. These increases were primarily due to increasing sales and marketing activities along with increases in employee compensation. These increases were also attributable to expenses associated with being a public company, facility costs and research and development costs associated with the Company’s preparation for, and start of, its clinical trial for Avance® Nerve Graft.

Sales and marketing expenses increased 43.4% to approximately $4,812,000 for the three months ended June 30, 2015 as compared to approximately $3,355,000 for the three months ended June 30, 2014. This increase was primarily due to the costs associated with the continued expansion of our direct sales force and surgeon education programs, and to a lesser extent increased support for both our direct sales force and independent distributors.. As a percentage of revenues, sales and marketing expenses were 75.0% for the three months ended June 30, 2015 compared to 79.6% for the three months ended June 30, 2014. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Sales and marketing expenses increased 43.9% to approximately $8,745,000 for the six months ended June 30, 2015 as compared to approximately $6,076,000 for the six months ended June 30, 2014. This increase was primarily due to the costs associated with the continued expansion of the direct sales force and surgeon education programs, and to a lesser extent increased support for both AxoGen’s direct sales force and independent distributors. As a percentage of revenues, sales and marketing expenses were 76.9% for the six months ended June 30, 2015 compared to 82.6% for the six months ended June 30, 2014. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 15.7% to approximately $1,982,000 for the three months ended June 30, 2015 as compared to approximately $1,713,000 for the three months ended June 30, 2014. Such increase was primarily a result of increased expenses related to payroll. Certain costs associated with being a public company and bank charges related to sales activity also increased, offset by a reduction in travel expenses and certain outside service costs. As a percentage of revenues, general and administrative expenses were 30.9% for the three months ended June 30, 2015 as compared to 40.7% for the three months ended June 30, 2014. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 7.8% to approximately $3,891,000 for the six months ended June 30, 2015 as compared to approximately $3,608,000 for the six months ended June 30, 2014. The increase was primarily a result of increased expenses related to payroll. Bank charges related to sales activity also increased, offset by a reduction in certain outside service costs. As a percentage of revenues, general and administrative expenses were 34.2% for the six months ended June 30, 2015 as compared to 49.1% for the six months ended June 30, 2014. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Research and development expenses increased approximately 32.4% to approximately $736,000 in the three months ended June 30, 2015 as compared to approximately $556,000 for the three months ended June 30, 2014. Research and development costs increased 2.9% to approximately $1,407,000 in the six months ended June 30, 2015 as compared to approximately $1,368,000 for the six months ended June 30, 2014. Research and development includes AxoGen’s product development and clinical efforts substantially focused on its biological license application (“BLA”) for the Avance® Nerve Graft. This activity varies from quarter to quarter due to the timing of certain projects. A substantial portion of the research and development expenses in 2014 and thus far in 2015, relate to expenditures for such clinical activity including preparation for, and the start of, the pivotal clinical trial to support the BLA, and hiring additional personal to support both clinical and product development activity. It is expected that costs associated with the BLA will continue to increase as more patients are enrolled in the trial over approximately the next two years. Although AxoGen’s

Table of Contents

products are developed for sale in their current use, it does conduct limited research and product development efforts focused on new products and new applications to existing products. AxoGen has become more active in pursuing research grants to support this research. This AxoGen product pipeline development also contributed to a portion of the research and development expenses in 2015, with grant revenue offsetting a portion of this activity.

Other Income and Expenses

Interest expense decreased 26.4% to approximately $1,024,000 for the three months ended June 30, 2015 as compared to approximately $1,392,000 for the three months ended June 30, 2014. Interest expense decreased 21.8% to approximately $2,019,000 for the six months ended June 30, 2015 as compared to approximately $2,583,000 for the six months ended June 30, 2014. This decrease was due to the difference in the interest related to the Revenue Interest Agreement with Three Peaks as compared to the interest related to the Royalty Contract and the interest accrued related to PDL. As a result of the accounting treatment for the Three Peaks and the PDL transaction, interest expense included approximately $177,000 and $1,031,000 for the three months ended June 30, 2015 and 2014, respectively, and approximately $369,000 and $1,917,000 for the six months ended June 30, 2015 and 2014, respectively, of non-cash expense that is based upon the terms of the Three Peaks and PDL transactions and increases in AxoGen revenues. Other than the $369,000 and $1,917,000 non-cash expense, the remaining $1,650,000 and $665,000 in interest expense for the six months ended June 30, 2015 and 2014, respectively, is related to cash paid for interest on the Term Loan Agreement and note payable.

Interest expense—deferred financing costs decreased 40.4% to approximately $31,000 for the three months ended June 30, 2015 as compared to approximately $52,000 for the three months ended June 30, 2014. Interest expense—deferred financing costs decreased 36.9% to approximately $65,000 for the six months ended June 30, 2015 as compared to approximately $103,000 for the six months ended June 30, 2014. This decrease is primarily due to lower deferred financing cost amortization associated with the Three Peaks agreement as compared to the PDL agreement.. Additionally, the deferred financing fees associated with the Three Peaks agreement are spread out over 10 years compared to 8 years for the PDL agreement.

Income Taxes

The Company had no income tax expenses or income tax benefit for each of the three months and six months ended June 30, 2015 and 2014 due to incurrence of net operating loss in each of these periods.

Effect of Inflation

Inflation has not had a significant impact on the Company’s operations or cash flow.

Liquidity and Capital Resources

Note Payable

Table of Contents

As a result of the accounting treatment for the PDL transaction, interest expense for the six months ended June 30, 2014 included approximately $1,917,000 of non-cash expense that was to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $1,917,000 of non-cash expense was derived from taking the effective interest on the put in 2014 on the PDL agreement less the actual cash payment made to PDL for the six months. Other than the $1,917,000 non-cash expense, the remaining $665,000 in interest expense for the six months ended June 30, 2014 is related to cash paid for interest on the note payable with PDL.

Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to maintain certain covenants including those covenants under the Term Loan.

Table of Contents

Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share. Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

As a result of the accounting treatment for the Three Peaks transaction, interest expense for the six months ended June 30, 2015 included approximately $369,000 of non-cash expense that is expected to be paid in the future based upon the terms of the Three Peaks transaction and increases in AxoGen revenues. The $369,000 of non-cash expense was derived from taking the imputed interest on the Three Peaks agreement less the actual cash payment made to Three Peaks for the six months. Other than the $369,000 non-cash expense, the remaining $1,650,000 in interest expense for the six months ended June 30, 2015 is related to cash paid for interest on the Term Loan with Three Peaks.

The Company had no material commitments for capital expenditures at June 30, 2015. However, it is anticipated that the Company will have approximately $400,000 of capital expenditures for the placement of equipment and build-out at CTS over the next two quarters.

Public Offering of Common Stock

Cash Flow Information

AxoGen had working capital of approximately $19.82 million and a current ratio of 6.79 at June 30, 2015, compared to working capital of $11.97 million and a current ratio of 5.89 at December 31, 2014. The increase in working capital and the current ratio at June 30, 2015 as compared to December 31, 2014 was primarily due to the public offering in February. In February 2015 AxoGen completed a public offering of 5,437,200 shares of Common Stock at $2.75 per share resulting in gross proceeds to AxoGen from the offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at

Table of Contents

approximately $1.4 million. The Company believes it has sufficient cash resources to meet its liquidity requirements for at least the next 12 months.

AxoGen’s future capital requirements depend on a number of factors, including, without limitation, continued adoption of our products by surgeons and growth of our revenues, continued expansion and development of our direct sales force, expenses associated with our professional education programs, maintaining our gross margins, expenses related to our facilities for production and distribution of products and general market conditions. AxoGen could face increasing capital needs which could be substantial depending on the extent to which AxoGen is unable to increase revenues.

If AxoGen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional equity would result in dilution to AxoGen’s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain action, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.

During the six months ended June 30, 2015, the Company had a net increase in cash and cash equivalents of approximately $7,407,000 as compared to a net decrease of cash and cash equivalents of approximately $5,899,000 in the six months ended June 30, 2014. The Company’s principal sources and uses of funds are explained below:

Cash used in operating activities

The Company used approximately $6,011,000 of cash for operating activities in the six months ended June 30, 2015, as compared to using approximately $5,720,000 of cash for operating activities in the six months ended June 30, 2014. This increase in cash used in operating activities is primarily attributable to the increase in accounts receivable and inventory accompanied by the net loss generated in the six months ended June 30, 2015, offset by the increase in our accounts payable and accrued expenses.

Cash used for investing activities

Investing activities for the six months ended June 30, 2015 used approximately $187,000 of cash as compared to using approximately $314,000 of cash in the six months ended June 30, 2014. This decrease in use is principally attributable to the non recurrence of purchases of certain fixed assets for the expansion of the headquarters office and the opening of the worldwide distribution facility in Burleson, Texas that occurred in the period in 2014.

Cash provided by financing activities

Financing activities in the six months ended June 30, 2015 provided approximately $13,605,000 of cash as compared to providing approximately $134,000 of cash in the six months ended June 30, 2014. The increase was due to proceeds received from the public offering consummated in February 2015 compared to the exercise of stock options in the same period of 2014.

Off-Balance Sheet Arrangements

AxoGen does not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be

Table of Contents

disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2015 and concluded that our disclosure controls and procedures were effective.

Changes in Internal Controls Over Financial Reporting

During the six months ended June 30, 2015, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d–15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

UNITED STATES

PART II –OTHER INFORMATION

ITEM 1 – Legal Proceedings

The Company is not a party to any material litigation as of June 30, 2015.

ITEM 1A - RISK FACTORS

The Company faces a number of risks and uncertainties. In addition to the other information in this report and the Company’s other filings with the Securities and Exchange Commission, readers should consider carefully the risk factors discussed in Part I “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2014. There have been no material changes to these risk factors. If any of these risks actually occur, the Company’s business, results of operations or financial condition could be materially adversely affected.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5 - OTHER INFORMATION

None.

Table of Contents

ITEM 6 - EXHIBITS


Exhibit Number		Description

10.1		Commercial Lease dated April 21, 2015 by and between AxoGen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 22, 2015).
10.2		Amendment No. 1 to Boone Business Park Commercial Lease dated April 21, 2015 by and between AxoGen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on April 22, 2015).


31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

† Filed herewith.

†† Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		AXOGEN, INC.


Dated August 6, 2015		/s/ Karen Zaderej
		Karen Zaderej
		Chief Executive Officer
		(Principal Executive Officer)


		/s/ Gregory G. Freitag
		Gregory G. Freitag
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX


Exhibit Number		Description

10.1		Commercial Lease dated April 21, 2015 by and between AxoGen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 22, 2015).
10.2		Amendment No. 1 to Boone Business Park Commercial Lease dated April 21, 2015 by and between AxoGen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on April 22, 2015).


31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

† Filed herewith.

†† Furnished herewith.

EX-31.1 2 axgn-20150630ex311c930bc.htm EX-31.1 Ex_311

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Karen Zaderej, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 6, 2015
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer

EX-31.2 3 axgn-20150630ex3127f4ffa.htm EX-31.2 Ex_312

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Gregory G. Freitag, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 6, 2015
	/s/ Gregory G. Freitag
	Gregory G. Freitag
	Chief Financial Officer

EX-32 4 axgn-20150630xex32.htm EX-32 Ex_32

EXHIBIT 32

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)

In connection with the Quarterly Report on Form 10-Q (the “Report”) of AxoGen, Inc. (the “Company”), Karen Zaderej, Chief Executive Officer of the Company and Gregory G. Freitag, Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her/his knowledge that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 6, 2015
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer
	(Principal Executive Officer)


	/s/ Gregory G. Freitag
	Gregory G. Freitag
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 5 axgn-20150630.xml EX-101.INS 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 2014-11-12 0000805928 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2014-04-01 2014-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-06-30 0000805928 us-gaap:LeaseholdImprovementsMember 2015-06-30 0000805928 us-gaap:EquipmentMember 2015-06-30 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2015-06-30 0000805928 us-gaap:LeaseholdImprovementsMember 2014-12-31 0000805928 us-gaap:EquipmentMember 2014-12-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2014-12-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-08-13 2012-10-05 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-08-13 2012-08-14 0000805928 us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember axgn:LicenseAndServicesAgreementMember 2015-08-05 2015-08-05 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2015-06-30 0000805928 axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2015-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-12-31 0000805928 axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2014-12-31 0000805928 us-gaap:PatentsMember 2015-01-01 2015-06-30 0000805928 us-gaap:PatentsMember 2015-06-30 0000805928 us-gaap:LicensingAgreementsMember 2015-06-30 0000805928 us-gaap:PatentsMember 2014-12-31 0000805928 us-gaap:LicensingAgreementsMember 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-10-04 2012-10-05 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-13 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2015-01-01 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-12-01 2014-12-31 0000805928 2015-02-13 0000805928 axgn:ThreePeaksCapitalMember 2014-11-12 0000805928 axgn:PDLEquitySaleMember 2014-11-12 0000805928 2014-06-30 0000805928 2013-12-31 0000805928 2015-04-01 2015-06-30 0000805928 2014-04-01 2014-06-30 0000805928 2014-01-01 2014-06-30 0000805928 2015-08-05 0000805928 2015-01-01 2015-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-10-05 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2014-12-31 0000805928 2015-02-13 2015-02-13 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 2015-02-05 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2015-06-30 0000805928 us-gaap:SubsequentEventMember axgn:LicenseAndServicesAgreementMember 2015-08-05 2015-08-05 0000805928 us-gaap:PatentsMember 2014-01-01 2014-12-31 0000805928 us-gaap:LicensingAgreementsMember 2015-01-01 2015-06-30 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MinimumMember 2014-10-01 2014-12-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-10-01 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 2014-11-12 0000805928 axgn:JaColeMember 2015-04-21 0000805928 axgn:JaColeMember 2015-04-21 2015-04-21 0000805928 axgn:AgeOver90DaysMember 2015-06-30 0000805928 axgn:Age61To90DaysMember 2015-06-30 0000805928 axgn:AgeOver90DaysMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0000805928 axgn:Age61To90DaysMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0000805928 axgn:Age61To90DaysMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0000805928 us-gaap:MinimumMember 2015-01-01 2015-06-30 0000805928 2015-02-05 2015-02-05 0000805928 2015-06-30 0000805928 2014-12-31 iso4217:USD xbrli:shares axgn:product axgn:item utr:sqft xbrli:pure xbrli:shares iso4217:USD 1165020 1363888 709200 P60D P90D P61D P90D 0.05 0.20 60000 2100 0.01 7000000 2500000 1300000 15000 12500 105315 205809 124924 P180D P60D 2 P30D 5000 0 355000 0 4728000 30300000 0.0375 15000000 0.20 1 0.03 0.01 0.0995 0.0375 0.048 P3Y P5Y 0.03 0.1625 1.35 1.5 1.2 false --12-31 Q2 2015 2015-06-30 10-Q 0000805928 24932392 Yes Smaller Reporting Company AxoGen, Inc.

2431194

3408122

1160859

1838425

2872308

3838023

1735205

1822815

78675686

93102681

94000

148000

103432

64957

103432

52217

64956

31210

22099

11000

22710

11000

5400

16400789

25423153

14411088

23242020

20069750

14170332

8215791

15622932

-5899418

7407141

<div> <div style="margin-left:0pt;margin-right:0pt;"> 10.  Commitments and Contingencies   Commercial Lease On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc.  (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas.   The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year.  The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.   Processing Agreement Under an Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia.  As a result of business requirements of LifeNet Health and their need for additional space,  on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the LifeNet Agreement effective February 27, 2016.   AxoGen  has entered into an agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) as a result this termination.   </div> </div>

0.01

50000000

643382

1375969

19488814

5437200

24932392

19488814

24932392

1750000

3550000

194888

249323

1589121

887820

2022722

1039841

11052214

5624117

14042820

7530681

25000000

LIBOR

0.10

0.09

P8Y

P10Y

P6Y

793499

908684

14118

115380

104589

67887

87610

-0.46

-0.21

-0.29

-0.13

1996000

1400000

353681

376391

48000

25000

48000

850859

79996

860006

124924

577174

608539

P3Y

P20Y

P17Y

3608222

1713447

3890602

1982020

5763328

3326373

9345847

5377412

155113

976928

633254

965715

-7143

-10791

12004

326337

-151744

131739

<div> <div style="margin-left:0pt;margin-right:0pt;"> 5.    Intangible Assets   The Company’s intangible assets consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>860,006 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>850,859 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Patents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124,924 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79,996 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(376,391) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353,681) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>608,539 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>577,174 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2015, the patents were fully amortized, and the remaining patents of $124,924 were pending patent costs and were not amortizable. Amortization expense was approximately $11,000 and $11,000 for the three months ended June 30, 2015 and 2014, respectively, and approximately $23,000 and $22,000 for the six months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, future amortization of license agreements for the next five years is expected to be $25,000 for the remainder of 2015 and $48,000 for 2016 through 2020.   License Agreements   The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies; </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> · </td><td style="width:0pt;"></td><td align="left" valign="top"> Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.</td></tr></table></div>   Royalty fees were approximately $121,000 and $85,000 during the three months ended June 30, 2015 and 2014, respectively, and were $217,000 and $145,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations. </div> </div>

2583415

1392098

2018522

1023774

664546

1649881

2072235

2403791

3213620

3539957

<div> <div style="margin-left:0pt;margin-right:0pt;"> Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,403,791 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>240,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>896,112 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,539,957 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $653,000 and $404,000 at June 30, 2015 and December 31, 2014, respectively. </div> </div>

809494

896112

404000

653000

331891

240054

60125

27646469

28953476

16400789

25423153

2445312

3422240

25085777

25426647

<div> <div style="margin-left:0pt;margin-right:0pt;"> 7.    Notes Payable   Notes Payable consists of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,426,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Long-term portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,426,647 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Note Payable   On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.  The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 million to $2.5 million per quarter to begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%.  The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract.  The Company has no further obligations under the Royalty Contract.   On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL.  The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.   Term Loan Agreement and Revenue Interest Agreement   On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a (“Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.   In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%   AxoGen has to maintain certain covenants including those covenants under the Term Loan.   Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.   In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.  In the event of default per the terms of the Term Loan Agreement Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.     Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share.  Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.   The Company records interest using its best estimate of the effective interest rate.  This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.  The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.  From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.  Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.  Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes. </div> </div>

25085777

25426647

134362

13604663

-313781

-186567

-5719999

-6010955

-7981036

-3741471

-6766073

-3190873

-2692150

-1443727

-2069100

-1037604

-5288886

-2297744

-4696973

-2153269

-5303

588

14378

17380

1878894

340870

180142

30305

54075

400000

283476

132492

109369

241108

13770734

1750000

20800000

19050000

134362

14071

<div> <div style="margin-left:0pt;margin-right:0pt;"> 4.    Property and Equipment   Property and equipment consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955,743 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>873,824 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>300,697 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,230,285 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,822,815) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,735,205) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>663,910 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,028 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

873824

1194712

285697

955743

1230285

300697

619028

663910

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955,743 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>873,824 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>300,697 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,230,285 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,822,815) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,735,205) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>663,910 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,028 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

1368373

555758

1407435

736399

-90116254

-96882327

7352449

4214193

11368569

6417253

145000

85000

217000

121000

30000000

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,838,425 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,160,859 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Miscellaneous accruals </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205,809 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105,315 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,363,888 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,165,020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts Payable and Accrued Expenses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,408,122 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,431,194 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (unaudited) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>860,006 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>850,859 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Patents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124,924 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79,996 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(376,391) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353,681) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>608,539 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>577,174 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,403,791 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>240,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>896,112 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,539,957 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

6075619

3354912

8744783

4812262

474144

216602

696625

328376

P4Y

0.7980

0.7624

0.0120

0.0121

295500

<div> <div style="margin-left:0pt;margin-right:0pt;"> Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.24 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.80 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.21 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.20 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2015 and 2014 as they were deemed insignificant. </div> </div>

2.72

2.58

2.75

<div> <div style="margin-left:0pt;margin-right:0pt;"> 3.    Summary of Significant Accounting Policies   Revenue Recognition   Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor.  Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as product being shipped from our facility via courier to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. In the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.   Cash and Cash Equivalents and Concentration   For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.   Accounts Receivable and Concentration of Credit Risk   Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.   We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $148,000 and $94,000 at June 30, 2015 and December 31, 2014, respectively.   Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.   Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,403,791 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>240,054 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>896,112 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,539,957 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $653,000 and $404,000 at June 30, 2015 and December 31, 2014, respectively.   Income Taxes   The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.   The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.   Fair Value of Financial Instruments   The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.    Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:   <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.24 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.80 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.21 </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;padding-right:3.3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.20 </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:81.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2015 and 2014 as they were deemed insignificant.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Recent Accounting Pronouncements   In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.   In February 2015, the FASB issued Accounting Standards Update No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis" ("ASU 2015-02") which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.   In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.   In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.   In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year.  The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.   The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures. </div> </div>

-11245680

-3530323

<div> <div style="margin-left:0pt;margin-right:0pt;"> 9.   Public Offering of Common Stock   On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share.  The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.   The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.   As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market. </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;"> 11.  Subsequent Events   License and Services Agreement On August 6, 2015, AxoGen Corporation (“AxoGen”) entered into a License and Services Agreement (the “Agreement”) with CTS.  Headquartered in Dayton, Ohio, CTS is a nonprofit quality, ethical provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts.  CTS, an accredited member of the AATB, is one of the largest nonprofit tissue banks in the United States having in 2014 distributed more than 355,000 tissue grafts to over 5,000 hospitals, physicians and surgeons. Pursuant to the Agreement, AxoGen will process and package its Avance® Nerve Graft using its employees and equipment located at CTS.  It is anticipated that processing currently being performed at LifeNet Health, will be transferred completely to the CTS facility by the end of first quarter of 2016.      The Agreement is for a 5 year term, subject to earlier termination by either party for cause, or after the two year anniversary of the Agreement without cause, upon 180 days’ notice. Under the Agreement AxoGen pays CTS a facility fee for clean room/processing, storage and office space.  CTS also provides services in support of AxoGen’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.  The service fee is based on a per donor batch rate.  It is anticipated that the Company will have approximately $400,000 of capital expenditures for the placement of equipment and build-out at this facility.     </div> </div>

17422773

17461332

23729558

24928435

EX-101.SCH 6 axgn-20150630.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axgn-20150630_cal.xml EX-101.CAL EX-101.DEF 8 axgn-20150630_def.xml EX-101.DEF EX-101.LAB 9 axgn-20150630_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of year Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of approximately $54,000 and $59,000, respectively Accounts receivable, net of allowance for doubtful accounts of approximately $101,000 and $94,000, respectively Inventory, Net Inventory Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment Finite-Lived Intangible Assets, Net Intangible assets Intangible assets, net Deferred Finance Costs, Noncurrent, Net Deferred financing costs Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity (Deficit) Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts Payable and Accrued Expenses Deferred Revenue, Current Current Deferred Revenue Liabilities, Current Total current liabilities Notes Payable, Noncurrent Total Debt Note Payable - Revenue Interest Purchase Agreement Deferred Revenue, Noncurrent Long Term Deferred Revenue Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity (deficit): Common Stock, Value, Issued Common stock, $.01 par value; 50,000,000 shares authorized; 24,932,392 and 19,488,814 shares issued and outstanding Value of common stock sold Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders' equity (deficit) Liabilities and Equity Total Liabilities and Shareholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Allowance for doubtful accounts reserve balance Common Stock, Par or Stated Value Per Share Common stock, Par value Par value of common stock Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Shares of common stock sold Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenues Revenues Cost of Goods Sold Cost of goods sold Gross Profit Gross profit Costs and Expenses [Abstract] Costs and expenses: Selling and Marketing Expense. Sales and marketing Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense Interest expense Interest expense Amortization of Financing Costs and Discounts Interest expense-deferred financing costs Other Nonoperating Income (Expense) Other income (expense) Nonoperating Income (Expense) Total other income (expense) Net Loss Net loss Net Loss Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Common Shares outstanding - basic and diluted Earnings Per Share, Basic and Diluted Loss Per Common share - basic and diluted (in dollars per share) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation, Depletion and Amortization Depreciation Amortization of Intangible Assets Amortization of intangible assets Amortization of deferred financing costs Amortization of deferred financing costs Share-based Compensation Stock-based compensation Share-based compensation Issuance of Stock and Warrants for Services or Claims Stock grants Paid-in-Kind Interest Interest added to note Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used for operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Intangible Assets Acquisition of intangible assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Payments of Debt Issuance Costs Debt issuance costs Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase/(decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow activity: Interest Paid Cash paid for interest Basis of Presentation Basis of Accounting [Text Block] Basis of Presentation Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Notes Payable Long-term Debt [Text Block] Notes Payable Stock Options Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options Public Offering of Common Stock Stockholders' Equity Note Disclosure [Text Block] Public Offering of Common Stock Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Event Subsequent Events [Text Block] Subsequent Events Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents and Concentration Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable and Concentration of Credit Risk Inventory, Policy [Policy Text Block] Inventories Income Tax, Policy [Policy Text Block] Income Taxes Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Use of Estimates, Policy [Policy Text Block] Use of Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions for options granted Property, Plant and Equipment [Table Text Block] Schedule of Property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Notes payable Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Information by age of specific types of trade accounts and notes receivable. Accounts Notes and Loans Receivable Age [Axis] Represents information relating to age of specific types of trade accounts and notes receivable. Accounts Notes And Loans Receivable Age [Domain] Accounts Notes and Loans Receivable Age [Domain] Represents the specific types of trade accounts and notes receivable having age group of 61 to 90 days. Age61 To90 Days [Member] Age 61 to 90 Days Represents the specific types of trade accounts and notes receivable having age of over 90 days. Age Over90 Days [Member] Age Over 90 Days Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Receivable and Concentration of Credit Risk Represents the reserve for accounts deemed uncollectible, expressed as a percentage. Reserve for Accounts Receivable Deemed Uncollectible Percentage Reserve for accounts deemed uncollectible (as a percent) Represents the age of specific types of trade accounts and notes receivable. Allowance for Doubtful Accounts Receivable Age of Accounts Receivable Age of doubtful accounts Represents the valuation allowance for receivables due, that are expected to be uncollectible, expressed as a percentage. Allowance for Doubtful Accounts Receivable Percentage Reserve for doubtful accounts (as a percent) Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Work in Process, Net of Reserves Work in process Inventory, Raw Materials, Net of Reserves Raw materials Inventory Valuation Reserves Inventory valuation reserves Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free rate (as a percent) Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment and tangible personal property commonly used in offices. Furniture And Office Equipment [Member] Furniture and Office Equipment Leasehold Improvements [Member] Leasehold Improvements Equipment [Member] Processing equipment Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Gross Property and equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] Licensing Agreements Patents [Member] Patents Finite-Lived Intangible Assets [Line Items] Intangible assets Intangible assets consist of: Finite-Lived Intangible Assets, Gross Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Accumulated Amortization Less: accumulated amortization Finite-Lived Intangible Assets, Remaining Amortization Period Amortization period of intangible assets Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross. Nonamortizable Pending Patent Costs Non-amortizable pending costs Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Future amortization of license and patent agreements Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2019 Finite-Lived Intangible Assets, Amortization Expense, after Year Five 2020 Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling And Marketing Expense [Member] Sales and Marketing Expense Notice period for termination of license agreements. Notice Period for Termination of License Agreements License agreements extended period Royalty fees percentage under license agreements. Royalty Fees Percentage under License Agreements Royalty fees range under the license agreements Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements. Minimum Royalty of License Agreement Minimum royalty of agreements The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements. Percentage of Capping Royalties for Multiple Royalty Payments to Licensors Royalty stack cap for royalties paid to more than one licensor for sales of the same product Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement. Milestone Payment Contingent upon Receipt of Grant Milestone fee upon receiving a Phase II Small Business Innovation Research Represents the number of products under development. Number of Products Under Development Number of products under development Royalty Expense Royalty fees included in sales and marketing expense Accounts Payable and Accrued Liabilities Accounts Payable, Current Accounts payable Represents the miscellaneous accruals. Miscellaneous Accruals Current Miscellaneous accruals Represents the accrued compensation. Accrued Compensation Current Accrued compensation Schedule of Long-term Debt Instruments [Table] Legal Entity [Axis] Entity [Domain] Entity [Domain] Represents information pertaining to Oberland Capital Healthcare L.P. Oberland Capital Health Care [Member] Oberland Capital Healthcare L.P Represents information pertaining to Three Peaks Capital S.A.R.L., an affiliate of Oberland Capital Healthcare L.P. Three Peaks Capital [Member] Three Peaks Long-term Debt, Type [Axis] EX-101.PRE 10 axgn-20150630_pre.xml EX-101.PRE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`$2"!D>)6B0\O`$``"88```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_/3!Y!5!+ M`P04````"`!$@@9'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)` M#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`1((&1\3+)$.4`0``/!<``!H```!X;"]? M&?/ODKC;671NJN@^S]^;: MANWP?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9 ML^-IG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ- M?U28KPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T) MVJ2#-I`@RA49C-&;%;T9HSC-&;U;T M9HS>K.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@M MBMZ"T5L4O06CMRAZ"T9OF>@=*NO=Z3GZNBW#O6N^#5>+)GB'>+NZ^Z>,4]7[ MR(G6<=C)F?%Y=Q3'J9\AYM=%^>$#4$L#!!0````(`$2"!D<-?T1*J@(``%$* M```0````9&]C4')O<',O87!P+GAM;+U646_:,!#^*U:>NHPFMBIST&P7[]S`EEH30H\C!-"BR$#9L-OI?`YA M;4'%$'_,ZZ)!-'!=[O(\E8);J57T0PJC42>6C=8"TD'X&E`RJ/(41&&DW42= M"M-,E9BIX"D,J5>4\!2A0OU+EIBASG*N-F'U]%VJ9_R5S_0#M]!D[;^HJB^Y M@9B:[E6ODR7FVX;F3!UWN.1J`7$3^_;E3HLG,.@FO>I>=NA32[#+5[6!QU(M M)EP:C`8KVU^!L-IL;5K9H MVE;9,DYSM";ZK.%_I( M*U4+.4^!W2&^VK]UM.V&;,(WW&%=84J:@F09K;V'O M.RGF=`>R<9*`H0/@1*#;*R/=2NX!\[),6CTG7-]!L=_ M3`^I^P"6R]3OO$?=+?QH-W;XKM_S-L;7TRWL=8ZQL'6&`]A>]R3T`:^;Y_Z= M=;3>`#V_QZTW`+LX[@[PK^O-3_.K'^)P_P]D]!=02P,$%`````@`1((&1\#E M_K\^`0``:0,``!$```!D;V-0U?%UVXU;7?A^_CI-2.BZMAT=O M'7C4$*X.36T"EVZ1;!$=9RS(+30B3&*%BU\33$D&-31@,+!\DK.D>C8[8UM3LE%? ME=%Q+0(NK=)K#>JF&\M^IV)G!-^$DQS4T)[^_NF!,BSI*P]!#U5MVT[:&=7% M@7/VNGQXHK-)M0DHC(2H"IICYV"1G#N_S&[O5O=)-SWE6 MO!TG^^9O--ST0_Q;QV>#M%W46,.%NR6-HN72)X$4!.FU0VW-13C"?!$3+.S? M/T#BY:!>2)=M!UUKO0H5W:\Q.KZ621A'^_1S80RY8-[9)- MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQ MEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1 M]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++ M9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D> M/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO> M1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9= M=N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8 MT='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7 M\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I M=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;R MWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z M;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``> MLX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[ MM'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ M#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1. M"CS<_N\-L,+$CN'MB[\!4$L#!!0````(`$2"!D=WI:B41@(``-P)```-```` M>&PO-67-ZOZ34H$YPV21X:4S] M)0B:?$D%:2:JIA)62J4%,3#55=#4FI*BL4&"!],PG`6",(G36+9B+DR#6-NCGKV,^B_,>\37ECCHBY/&I9)CC:;8`VG`?6?=<<:61 M@4,`!0Z11%#O<4LXRS2S8$D$XVL/3RW@SJWW$TPJ[7+[#/MY)N&825=9@L/^ M>7ZZ;&1W@]T>XWQW>P"D<4V,H5K.88)Z>[&N87-22>I%.K\CWI4FZVAZM17@ M!LB;*5U0/62.\`9*8TY+`P&:54L[&E5;ZRAWNKD3>QYYQB)%5L3&A$+TY7@-7U&";S7-OTX8G\:*N'!)`-*EKOO[* M624%]6(]-%?][!A]=(`^C[>]6?C0;O!8#18)'^P+&S\8>[LPYI8]5DJ[L9TD*^_K<:_G\I6L MA/ML:JGQ7FEL)3R>VF7/E"7D\L+D326U[_%^?]2S4@D/1KL5U"[9T-Q[:*ZV M4A1N):6OU!I6"=#)R1BDI/D425,">";>JS!E0X&?:'22_`MEN=69:;0JYA-RMP?S8W$E;(4C3*W^!BM^^=)"D? M<#Y:,\)COT$^.`H,%YC(/=S+&[&8)/V$B<:;KZ"\M!?"RV_6-#7H);(25H)U M?AZVVSY9@88*GL.Z\W"P``7^:9*TQTJ&G?1>;*5-__\CIMOD;$O,A"[8I?9(85=Z M73Q,35@#/GQ5M"^V8\`#>U6DZU11T+G1A=1.%@R/G%%08%8*=B:4T+ED!,0) MB'\4E!%01D#9NT%SCS^X90(:$-#@HZ`A`0T):+@/.A,.'#,EFUGI,.DO4SPB MX:/]\*E="@W/;51;K[/&@9;.$<0A01SN(^9-50G[%-8PAZ4&_)<++/YIGIL& MBT]`1P1TM`^:6?R?6Y2E]>:N@3I81.*/2?SQ?OP5[EXO@ZOLU#D4DYK6IZKU M]X,WRW5L)IY$0(1%X$7;8%DN'REJQ]J(MM?&RW\<&D@M32.:SKW);]FT;CLB M#:16IA$M9\U"0@ M[.`F%-I]HBBJ:OH>5V,43J7E'Y66IQ1%I>5O21M=S$Z/C=G;E6A.FRRG/O.( MS]VH`451GWG$YVX4;;2<<C1K]6_@OI!2CJ-Z=^\XC?D?)O*#LIIV[SB-L= M&$[-YM1L'C&["W1,0=1K'O&ZT\BL3[^T5.XL(O<+(R/YR:C4V=M2;Q$9IQ#J M=1;Q^C7(SMBP,S?$C*:M/;X9:G(6,;FSR6?4Y(R:G$5,[FSR[("BJ,E9M%._ M://QS5&3L\/-+/E_?,0)&J>.(@S7KGT%3J=YF+CQ9_WI'`Q#3PWG/W$*GR1A M5,:IN%'J'*]-]0\CVH%R3=[.V"=_`5!+`P04````"`!$@@9':/N?%E`"``#S M!P``&````'AL+W=OV$Z=_7"V',R/@%+YQSS[5]EW*D[)TW&(O@ MHR,]WX>-$,,NBGC=X`[Q%SK@7OZY4M8A(9?L%O&!8731I(Y$,([SJ$-M'U:E MWGME54GO@K0]?F4!OW<=8O^.F-!Q'X+PN?'6WAJA-J*JC&;>I>UPSUO:!PQ? M]^$![$X@51"-^-WBD5OS0#E_IO1=+7Y>]F&L?,`$UT*90')XX!,F1%F2RG\G MHY^:BFC/G]:_Z^-*]\^(XQ,E?]J+:*2W<1A<\!7=B7BCXP\\G2%3!FM*N/X& M]9T+VCTI8="A#S.VO1Y'\R<%$\U-@!,!S@28>PG)1$AF@KFZR'BFS_4-"525 MC(X!,X\Q(/7F8)?(FZL#>1@>JE_ZNA2B*A]57$8/96:!.!H$U`@P(R)I>Q:` MZP)':-&A2^!D(Q*W0.(Y0:+IB::G;GKJH:>:GFIZYKP`&Y&[!3*/0&;1-TN! MW@@81*81VS@KX-:MDGM4D+"`KH;+U2&QMOC-6 MC@O(2K`4'HG"YJ=.B04D4K%M(773@ MR=X#@)8%&+O"]S1A3/S"M$A@4L`5+5\B@\36`LY4F3"35KSZ/KZ,!W9"0W>< M39C<8+X&6F35V`ZSF^X]/*CIO1>FF,Z[UY<*9" M5GI=JZ^4"BR=B%]D86AD!YX7!%^%FF[DG)F>9!:"#L\6._?YZC]02P,$%``` M``@`1((&1WZ^)(R=`P``(0\``!@```!X;"]W;W)K#]G/IK[TCYO3,%P?\KP_G'Q3]9_;J[^$ M,\]MUU1#V.U>\O[:^>HX%35UCD+HO*G.E\UN.QW[VNVV[>M0GR_^:Y?UKTU3 M=?_N?=W>'C>P>3_P[?QR&L8#^6Z;W^N.Y\9?^G-[R3K__+CY#1Y*5&-D2OQ] M]K>>;&EVW]S_DXG`*MV&1'_UR]UL.W]O:'7ZZA&!L\M'4__<\.K_W0 M-N\EFZRI?LZ_Y\OT>YO/6+&4\06X%."]`%2R0"X%\D-!/I--U_6E&JK=MFMO M63<_C&LU/G-XD.'.';)P,?UF/#7=KC&QV[[M4&WSM[&=*+*?(SA'N$09)8I[ M)`_]WR$P`8%3O9SK-5\O$_5RJE=SO8D1+_-%S!$S1:#0B$XB%RQIT"(4Q@$/ MI!)`B@)9%FB.%%-$6FD%2I:'YM`:E,+R/$6"IZ`\CN4I*$\AG2O8&UE&.02I M4?`\.L&C"8\4+(^FUZT`!'L;2QH#X:1V/(U)T!A*`RR-H302%0IDL4L:!#5Q MKSPOFR"RE(@=IWM+.M):.N!YHA@X@2LT+D'C*`T[2O>.=B-L&#\L#8T5QH!1 M/,WHWW5E"K%$0E01P:T\_I5:@;I6\ M6T%%LQ"`=TU!_UA M/&JM>.-_2(;9;8Q9H4II%JAG%>]9B/PI5&%YD<2Y,)/LREL(4IH%ZEG%>Q:H M0=&Z0BJC>:8H:;0*?VOS-J5;<&3>*LFW@"E#(C6DX@V)(AIJX7.(MU&4"U/6 MKKW/,&5(I(94O"&1>L])$*@M.TK**&FL-H6V*W[#Y'Z7S-S7)Z>M M#>]_?J)\B`H`'2;6"E?*NTB]R\_*/5*=?@I?;&+U"49)`%3A=JU,%TRI%ZEZ M%:_>)6/^_S47)5=>&PO=V]R:W-H965T&ULC51=CZ,@%/TK MQA]0$+&VC379<3/9?=AD,@^[SU1I-8/B`*VS_W[YL"Z=$'=]$"Z<<\^YET`Q M$C'?3.F8N>*!V*"Y"CH*2QI)X!!.$6 M]*0;XK*P:R^B+/A5L6Z@+R*2U[XGXO<397PZQDE\7WCM+JTR"Z`LP,)KNIX. MLN-#).CY&'])#E5N$!;PLZ.3].:1\7[B_,T$WYMC#(T%RFBM3`:BAQNM*&,F MD19^GW/^E31$?W[/_FRKU>Y/1-**LU]=HUIM%L910\_DRM0KG[[1N83,)*PY MD_8?U5>I>'^GQ%%//MS8#7:%^`F\GS`'ER$&0A*(2H'A#9 M`@%:?S&!5DP@RT\M/X-A?KK"3RT?.W[R:'%P13A(;B$)WD$(0[#*A^VQCWHP M@U?,8-\,"IIQD)V%P`U,PB+9BDCFBZ1!$0?)YJ:Z+RRT71':^D(X*+3UA!#> MIRC=!\NN?&"RQ[O=+L%A1_F*H]QWE`4=Y?_K*/^W(^#=IY%"_>(N$#Q\?XD+N]R^0=02P,$%``` M``@`1((&1T#\5"-F!```=A(``!@```!X;"]W;W)K>N^UH>TN=0VW_=&99%20F1:YJ?S8K7L[WVK5\OJVA:GL_U6)\VU+//Z M[[4MJMOK`A;W&]]/AV/;W4A7R_1AMS^5]MR==,Z_5]6/[LMO^]<%Z7RPA=VUW1"Y^_BTF2V*;B0W\U_CH%]S=H;^]7WT M7WJYSOWWO+%95?QYVK='YRU9)'O[D5^+]GMU^]6.&D0WX*XJFOY_LKLV;57> M319)F?\%J%MU/_8)TQ&KYN1)RF7YVXP3( M>D#H@"@,V?@(/(C4S?]P@L:=6%//G&(39#XA-.K#?PZRC0P2N,EF8L5Z>S;8 M&]R>S]CSWI[W]I*$+IZ'2`R(&A`.B@J&<9G/<0H<#,IM?`Z`22VDP<"M#RHF M*.<1@6)&H/`%`BIP0,3@$&%&HOF!>)=V0D?VM9O0I;W]+ MAMOK&7OMQX>C\=&>GUP#I7@<,QW$1W"#QW'C\%!!? MGT3UC2TTA&VX8D$$%=>H_HG*FI;T!]G>C^6H_,,-<3 M!>$R$;YA)R0U+K6A)WP3DEP::?##SC)S;3/O&L488099[$#/E>EP2_3"B_3((/LQ'1$85!6 M=601@[$X4RBV#;`GEU-B*7JN0H/RM:'':CTR7V%4DD0V:DARYSN-+*$*-ZHT M0"+I*R2E<5F%1)3.]1+@-Q/X05N/C+IO5$,T'I-L0KJVC..;?Q.24DG7+432 M5T`JHUVH8^EKKJL`OZU0>%L!?H6GW%`=:06R@`3%)3"&MT[AF&[IC<#;D.UT M3-=FQQH,.M=@4+_!4'B#,3)ZB"IY!GQ!IQC%5_-?&/[P,\7X=!U3[Z&ZM/6A M?YW1)+OJ>FZ'RO.X^WAE\D:[A_+)_36\9(#MZ>"TR?&FKR_TMS^-5 MT^H?4$L#!!0````(`$2"!D?GWZ$Z+00``$$2```8````>&PO=V]R:W-H965T M&UL?9A-;]LX$(;_BN![:\Z0(L7`,1!K470/"Q0][)X5FXF- M2I974N+NOU_JP\XP&/)B??@=SCLD]8C4YMIVO_JC/J.`R7A_6Z MWQ]=4_5?VXL[^W]>VJZI!G_9O:[[2^>JPQ34U&L40J^;ZG1>;3?3O1_==M.^ M#?7I['YT6?_6-%7WW\[5[?5Q!:O;C9^GU^,PWEAO-^M[W.'4N'-_:L]9YUX> M5T_P4$H<)9/B[Y.[]N0\&\T_M^VO\>+/P^-*C!Y<[?;#V$3E#^^N='4]MN0S M_[LT^I%S#*3GM]:_3>5Z^\]5[\JV_N=T&([>K5AE!_=2O=7#S_;ZW2TUY&.# M^[;NI]]L_]8/;7,+665-]7L^GL[3\3K_8\P2Q@?@$H#W@'L>/D`N`?(C0$V5 MSLZFNOZHAFJ[Z=IKULV#<:G&,8<'Z7MNG_EB^M7XU]1=HV*[>=\:LUF_C^T$ MDMTLP4D"=\7:-W[/@/$,.R3AR"4HJ2(O^`PR48.)>+5%*_F>!M: M/,]%S!(S2;YHH[4PDA.6@=#8`H34O*,\X2@G%16"C]>)>$TJ*H"M:);DL\1H M$&PY5*5-41C>BTEX,=0+LEX,R8)H(EY"E;"6]U(DO!34"SN`NX)6K&QN6"]4 MY8=82>3-V(092\THUHRE9JS6F+-NJ$P9!4KQ;D:LQ4D@J!\^T:)9#`D@?L)$ M2>0`3:39PA?-G$@J41A^3@0Z*/P,M;':$XQZ`J0/7&220XI!(&E1!5^4)&:_ M6)T;B'1S(-128AZK*L4UH&!#'FR+9DDET2?C9WPH!+\:B%E*@0UR8DFR8[I; M-+=,$HQDO9>!$'(PT7F?8B506/+%[X!RT!IMD1WA,M!!G@/(B*,4,2%`9F3< M3-!)PE@6\V6H,Z!BAE+8!,I-&QFU(IBS`H3-([,[4/J'P-H8RR'%3[#DH;6Q ME4D*>4B19_EW$XIP-J+BA64HQ$(J$WGS8XJ.2.EH^7<40M"#2AB^IT.=%%)$ M>(TI.")21_R+:M'<>JG0N>8Q$@HE2%/$1BZ%6Z1K/ANK*@5'I'"T_%L(*?/` M=S/_C(4ROQC0D=4`IM"(%(V6YQ`&Q)/&^&5HA'F88AY2YEG^;84Z'%(!*E96 M"F9(869YF*$)RM)":"*7[8C7>L5"'D,_(%PW+M;DT=V$C+%2"D"5SPD)64?Y!K12IZ2H5*! M$3*V=I8I3$H@`/`K\$@3*:Y)#"KCP;:(Y@T=^`U!P>^GRD"HMO(D_31Y%/]W?P4,[?-CZ:V6XNU:O[J^I>3^<^ M>VZ'H6VFG?]+VP[.&Q1?/3N.KCK<+VKW,HRGQI]W\Q>.^6)H+[O1MO_ M`5!+`P04````"`!$@@9'XT&'IJ$!``"Q`P``&````'AL+W=OV;ZP$\>=?*N"WMO1\VC+FZ!RW<#0Y@PDZ+ M5@L?0MLQ-U@032)IQ7A1W#(MI*%5F7(OMBIQ]$H:>+'$C5H+^V<'"J&JVM(@6 M0$'MHX((TP'N0:DH%`K_/FI^E(S$\_5)_2%U&]SOA8-[5+]DX_M@MJ"D@5:, MRK_B]`C'%M91L$;ETDCJT7G4)PHE6KSG69HT3WF'\R/M:P(_$OA,^%XDX[E0 MLOE#>%&5%B=B\]$.(M[@8L/#0=0D>',T;J7N(Z(J#]6B6)?L$(4N,+N,X1DS M(UA0GTOP_Y?8\3,Z_YJ^O.)PF>C+?QQ>"*RN"*R2P.IJBY>8VT]%V-F9:K!= M>CJ.U#@:GP]OSLZO\RY=(ON`5^4@.G@6MI/&D3WZ<+/I;EI$#\%$<;.FI`__ M9PX4M#XNOX6US4\J!QZ'TP>9?VGU%U!+`P04````"`!$@@9'VJOUQJ$!``"Q M`P``&````'AL+W=OD M%T6.I::KJGVH5/5A]YG88QL5&"_@N/OWRR5QDVXW+\`,YYPYPZ6^V'-F*M[T,)=X0`F[+1HM?`AM!US@P71)))6C!?%#=-"&EJ5*?=J MJQ)'KZ2!5TO$!E(I"H?#O@^9GR4@\71_5 M'U.WP?U..'A`]4LVO@]F"TH::,6H_!M.3W!HX3H*UJA<&DD].H_Z2*%$BX\\ M2Y/F*>_PFP/M>P(_$/A,N"N2\5PHV?PAO*A*BQ.Q^6@'$6]PL>;A(&H2O#D: MMU+W$5&5^VI1W)9L'X7.,-N,X1DS(UA0GTOP_Y?8\A,Z_YZ^O.!PF>C+?QR> M":PN"*R2P.IBB^>8NR]%V,F9:K!=>CJ.U#@:GP]OSLZO\YZG._F$5^4@.G@1 MMI/&D1WZ<+/I;EI$#\%$<75-21_^SQPH:'U9?VGU%U!+ M`P04````"`!$@@9'43>(O:(!``"Q`P``&````'AL+W=O@!/7K4R;D-[[X$.E(I"H?#+0?.M9"2>KH_J#ZG;X'XG'-RA^BL;WP>S&24-M&)4_@FG MGW!HX3H*UJA<&DD].H_Z2*%$B]=YEB;-T[Q3K`ZTSPG\0.`+X7N6C,^%DLU[ MX4556IR(G8]V$/$&\S4/!U&3X,W1N)6ZCXBJW%=Y]J-D^RATAMG.&#YC%@0+ MZDL)_G6)+3^A\\_IJPL.5XF^^N#P3*"X(%`D@>)BBV>8/'M7A)V_A>VD<62'/MQLNIL6T4,PD5U=4]*'_[,$ M"EH?E]_"VLY/:@X\#L);#)[:+2VB!5#0^*@@PG2`!U`J"H7"OXZ:'R4C\7Q]4O^> MN@WN]\+!`ZJ?LO5#,%M0TD(G)N5?<7Z$8PNW4;!!Y=)(FLEYU"<*)5J\YUF: M-,]YAZ^.M,\)_$C@"^%KD8SG0LGF-^%%75FCJ.-#@9GP]OR2ZO\YZG._F`U]4H>G@6MI?& MD3WZ<+/I;CI$#\%$<7-+R1#^SQ(HZ'Q+X^J7]+W0;W!^'@`=5OV?@^F,TH::`5H_+/.'V' MI87;*%BC@\ZA.%$BW>YEF:-$_+SMU"^YS`%P)?"7=9,CX72C8?A1=5 M:7$B=C[:0<0;S+<\'$1-@C='XU;J/B*J\ECE^:9DQRAT@=G/&#YC5@0+ZFL) M_O\2>WY&YY_3-U<<;A)]\X_#"X'BBD"1!(JK+5YBB@]%V-F9:K!=>CJ.U#@: M/Q_>FEU?YSU/=_(.K\I!=/!3V$X:1P[HP\VFNVD1/003V)ZB`0``L0,``!D` M``!X;"]W;W)K&UL?5/+;MLP$/P5@A\02K2=!H8L M($Y1M(<"00[MF996$A&2JY*4E?Y]^;`5NTU](;G+F=E9/JH9[:L;`#QYT\JX M'1V\'[>,N68`+=P=CF#"3H=6"Q]"VS,W6A!M(FG%>%'<,RVDH765P\*YQTMZ3GQ(OO!QP2K*[;P6JG!.(F&6.AV]+'<[M<1D0`_ M),SN8DVB]P/B:PR^M3M:1`N@H/%1083I"$^@5!0*A7^=--]+1N+E^JS^)74; MW!^$@R=4/V7KAV"VH*2%3DS*O^#\%4XM;*)@@\JED323\ZC/%$JT>,NS-&F> M\\[JX43[F,!/!+X0'HID/!=*-C\++^K*XDQL/MI1Q!LLMSP<1$."-T?C5NH^ M(NKJ6)?EIF+'*'2%V6<,SY@%P8+Z4H+_O\2>7]#YQ_35#8>K1%_]X_!*8'U# M8)T$UC=;O,;<_U6$79RI!MNGI^-(@Y/Q^?"6[/(Z'WFZDW=X78VBA^_"]M(X M+X^J3^E;H/[@W#PB.J7;'P?S&:4--"*4?D7G+[! MTL)M%*Q1N322>G0>]8E"B1;O\RQ-FJ=EIUAHGQ/X0N`KX3Y+QN="R>97X455 M6IR(G8]V$/$&\RT/!U&3X,W1N)6ZCXBJ/%9Y?E>R8Q2ZP.QG#)\Q*X(%];4$ M_W^)/3^C\\_IFRL.-XF^^DX4N-H M_'QX:W9]G0\\W;[J9%]!!,9#>WE/3A_ZR!@M;' MY5U8V_E)S8''X?1!UE]:_0%02P,$%`````@`1((&1T_K4*>A`0``L0,``!D` M``!X;"]W;W)K&UL?5/;;MP@$/T5Q`<$FW5Z67DM M91-5[4.E*`_M,VN/;11@',#K].\+V.OLINF^`#.<<^8,EW)"^^QZ`$]>M3)N M1WOOARUCKNY!"W>#`YBPTZ+5PH?0=LP-%D232%HQGF6?F!;2T*I,N4=;E3AZ M)0T\6N)&K87]LP>%TX[F])1XDEWO8X)5)5MYC=1@G$1#++0[>I=O]T5$),`O M"9,[6Y/H_8#X'(,?S8YFT0(HJ'U4$&$ZPCTH%85"X9=%\ZUD))ZO3^K?4K?! M_4$XN$?U6S:^#V8S2AIHQ:C\$T[?86GA-@K6J%P:23TZC_I$H42+UWF6)LW3 MLE,LM(\)?"'PE?`E2\;G0LGF@_"B*BU.Q,Y'.XAX@_F6AX.H2?#F:-Q*W4=$ M51ZK//]:LF,4NL#L9PR?,2N"!?6U!/]_B3T_H_./Z9LK#C>)OOG'X85`<46@ M2`+%U18O,#Q[5X2=G:D&VZ6GXTB-H_'SX:W9]77>\70G;_"J'$0'/X7MI''D M@#[<;+J;%M%#,)'=W%+2A_^S!@I:'Y>?P]K.3VH./`ZG#[+^TNHO4$L#!!0` M```(`$2"!D<=4(K:H`$``+$#```9````>&PO=V]R:W-H965TV;&P`\>=?*N"T=O!\WC+EF`"W<#8Y@PDZ'5@L?0MLS M-UH0;2)IQ7A1W#$MI*%UE7(OMJYP\DH:>+'$35H+^WL'"NDI\2K[P<<$ MJRNV\%JIP3B)AECHMO2^W.S6$9$`/R3,[FQ-HO<]XEL,GMHM+:(%4-#XJ"#" M=(`'4"H*A<*_CIH?)2/Q?'U2_YZZ#>[WPL$#JI^R]4,P6U#20B8WX45= M69R)S4<[BGB#Y8:'@VA(\.9HW$K=1T1='>J2EQ4[1*$+S"YC>,8L"!;4EQ+\ M_R5V_(S./Z>OKCA<)?KJ'X<7`NLK`NLDL+[:XB7F;Y?L[$PUV#X]'4<:G(S/ MA[=DE]=YGRZ1?<#K:A0]/`O;2^/('GVXV70W':*'8**XN:5D"/]G"11T/BZ_ MA+7-3RH''L?3!UE^:?T'4$L#!!0````(`$2"!D=SX#:ZH0$``+$#```9```` M>&PO=V]R:W-H965T3%WIR0FN MX,D@.TG)S/\]"#WO<(Y/B6?>#RXD2%V1E==R"]VA[-@`00T+B@P/QWA'H0(0K[PZZ+Y43(0S]8JSG/: M*?*%=IE`%P)=";=9-)X*19L/S+&Z,GI&)AWMR,(-YEOJ#Z)!WIO%82MV'Q!U M=:QS6E3D&(0^8?8)0Q-F11"OOI:@WY?8TS,ZO4POKC@L(KU8'):7!#_SQH(Z%Q8_O1KDYY4"IP>3Q]D_:7U.U!+`P04```` M"`!$@@9'=9T:+J$!``"Q`P``&0```'AL+W=O<.<,E']"^NQ;`DT^MC-O3UOMNQY@K6]#"W6$')NS4:+7P(;0-$V^R:7U,L")G M,Z^2&HR3:(B%>D\?%KO#*B(2X)>$P5VL2?1^1'R/P7.UIUFT``I*'Q5$F$[P M"$I%H5#X8]+\*AF)E^NS^H_4;7!_%`X>4?V6E6^#V8R2"FK1*_^&PT^86EA' MP1*52R,I>^=1GRF4:/$YSM*D>9AVMA/M.H%/!#X3MEDR/A9*-I^$%T5N<2!V M/-I.Q!M<['@XB)($;X[&K=1]1!3YJ5CP3@;YC!B^(B9$2RHSR7X_TL< M^`6=7Z/A MS=GY=3[P="=?\"+O1`,OPC;2.')$'VXVW4V-Z"&8R.[6E+3A_\R!@MK'Y7U8 MV_%)C8''[OQ!YE]:_`502P,$%`````@`1((&1[N2E@H2`@``XP8``!D```!X M;"]W;W)K&UL?579CML@%/T5Y`\8;.*LSG>7"-9>B%_)#U0`:?7+6JFU2:]UM M,%95#9RJ%]%!:U9.0G*JS5">L>HDT*,C<89)FBXPITV;E(6;>Y-E(2Z:-2V\ M2:0NG%/Y;P],]-LD2^X3[\VYUG8"EP4>>,>&0ZL:T2()IVVRRS;[C%B(0_QN MH%^4!''ZZ=NF M=6WO5^;YC18GD!N!#(15Z@+W1B[,;U33LI"B1]*?;4=M"K,-,0=1(1.;2NR2 MV[U%E,6US,BZP%1>8)9&MQAB1C8YGS"9!P(D:A)B9G&3Q83)(A#(HR8A9AXW64Z8+`.! M1=0DQ"SC)JL)DU4@L(J:A)B1Q*\G3-:/`GD\\2%F)/'V=H_?H#20B*?^"322 M^VSRIF:!1#S[3Z"1]&<3UW67D4`B_@,\@9[_`/Q0A#C(LZNU"E7BTFI?;8;9 MH9[O7#G'7_"RZ.@9?E%Y;EJ%#D*;4NB*V4D(#2:*],7M_`]02P,$%`````@`1((&1RD0K]^Q`0``%@0``!D```!X M;"]W;W)K&UL?53);J,P&'X5RP]0@Y-TVH@@-1V- MVL-(50\S9P=^P*H7QC:A??MZ(32IF%SP]FV_%XI1FS?;`3CT+H6R.]PYUV\) ML54'DMD;W8/R*XTVDCD_-"VQO0%61Y(4A&;9+9&,*UP6<>[%E(4>G.`*7@RR M@Y3,?.Q!Z'&'.5MY\($*0LR\VHN05FN%3+0[/!#OMUO`B("_G`8[5D? MA>P'K=_"X+G>X2Q$``&5"PK,-T=X!"&"D#?^-VE^60;B>?^D_BM6Z],?F(5' M+?[RVG4^;(91#0T;A'O5XQ-,)<2$E18V?E$U6*?EB8*19.^IY2JV8UJYS2?: M,H%.!#H3[K(8/!G%F#^98V5A](A,VMJ>A1/,M]1O1(5\-HO#4JP^(,KB6.;K MNX(<@]`%9I\P-&%F!/'JLP7]O\6>GM'I,GUU)>$JTE?)/;M?%EA?$5A'@?54 MXOUBB1>83;9LLKEBLKD0R!=-+C'?MX*<'9P$T\;[:5&E!^72"(%:+1VX$-D-SY%YQ_I/!#0N-#]X?LFW=LT<+H_ MO<+Y5U!^`E!+`P04````"`!$@@9'K9F/\*,!``"Q`P``&0```'AL+W=OL%C3/=@!PY$6KT1[HX-RT9\PV`VAA M[W""T=]T:+1P?FMZ9B<#HHTDK1C/LD],"SG2NHIGCZ:N<'9*CO!HB)VU%N;O M$10N!YK3]>!)]H,+!ZRNV,9KI8;12AR)@>Y`[_/]L0R("/@E8;%7:Q*\GQ"? MP^9'>Z!9L``*&A<4A)_.\`!*!2$?^,]%\S5D(%ZO5_5O,5OO_B0L/*#Z+5LW M>+,9)2UT8E;N"9?O<$EA%P0;5#:.I)FM0[U2*-'B)?0O!WP]QY%=T?IM>?."PB/0B1<_?B5]^(%!&@?*28GDSQ;>8 MW7]!V%5--9@^/AU+&IQ'EXJWG6ZO\Y['GKS"ZVH2/?P4II>C)2=TOK.Q-QVB M`V\BN]M1,OC_LVT4="XL/_NU24\J;1Q.ZP?9?FG]#U!+`P04````"`!$@@9' M0LGOC:0!``"Q`P``&0```'AL+W=O5=2VST=G!MWC-EF`,7M#8Z@_4V'1G'G3=,S.QK@;20IR8HL MNV6*"TWK*OJ>35WAY*30\&R(G93BYL\!),Y[FM.SXT7T@PL.5E=LY;5"@;8" M-3'0[>E#OCML`B("?@F8[<69A-R/B*_!^-'N:192``F-"PK<;R=X!"F#D`_\ MMFA^A`S$R_-9_5NLUF=_Y!8>4?X6K1M\LADE+71\DNX%Y^^PE+`-@@U*&U?2 M3-:A.E,H4?P][4+'?4XW9;;0KA.*A5"LA/M(8"E03/.).UY7!F=B4FM''B:8 M[PK?B(;XW"P-5['Z@*BK4YUO;RMV"D*?,(>$*1)F13"OOH8H_A_B4%S0B^OT M\HL,RT@O4_2\O"ZP^4)@$P4V2XEW5TO\C+G_)PB[Z*D"T\>G8TF#DW:I>:MW M?9T/19S)![RN1M[#3VYZH2TYHO.3C;/I$!WX)+*;+26#_S^K(:%SX7CGSR8] MJ60X',\?9/VE]5]02P,$%`````@`1((&1QL[LB.D`0``L0,``!D```!X;"]W M;W)K&UL?5/;3N,P$/T5RQ^`D[1A=ZLT$@4A>%@) M\;#[[":3Q,+V!-MIV+]?7]I04.'%]HS/.7.SJQG-BQT`''E34MLM'9P;-XS9 M9@#%[16.H/U-AT9QYTW3,SL:X&TD*2DT/!DB)V4 MXN;?#B3.6YK3D^-9](,+#E97;.&U0H&V`C4QT&WI3;[9K0,B`OX(F.W9F83< M]X@OP7ALMS0+*8"$Q@4%[K<#W(*40<@'?CUJOH<,Q//S2?T^5NNSWW,+MRC_ MBM8-/MF,DA8Z/DGWC/,#'$LH@V"#TL:5-)-UJ$X42A1_2[O0<9_339D=:9<) MQ9%0+(2?D\K@S.Q*36CCQ,,-\4OA$-\;E9&JYB]0%15X

"(&4WI`$``+$#```9````>&PO=V]R:W-H965TV=&W>,V;H')>P-CJ#]38M&">>WIF-V-"": M2%*2\2S;,B4&3:LRGCV9JL3)R4'#DR%V4DJ8OP>0..]I3L\'ST/7NW#`JI*M MO&90H.V`FAAH]_0^WQV*@(B`WP/,]F)-@O M0,H@Y`._+IKO(0/QO='8>$!Y9^A<;TWFU'20"LFZ9YQ_@%+"K=! ML$9IXTCJR3I49PHE2KRE>=!QGM,-WRZTZP2^$/A*^)9%XRE0M/E=.%&5!F=B M4FE'$3J8[[@O1$V\-TO#5;2-^DZ/G==8'B"X$B"A1+BINK*7[$%)^"L(N:*C!=?#J6U#AI MEXJWGJZO\Y['GKS#JW(4'?P2IANT)4=TOK.Q-RVB`V\BN[FEI/?_9]U(:%U8 MWOFU24\J;1R.YP^R_M+J'U!+`P04````"`!$@@9'TOS[\GX"```?"@``&0`` M`'AL+W=OLI1B<5U#8!#,,D:%'=^46NUMYI MD9,K;^H.OU./7=L6T7][W)!AZP/_L?!17RHN%X(B#\:X4]WBCM6D\R@^;_T= MV!Q@)"$*\;O&`YN,/9G\D9!/.?EYVOJAS`$WN.22`HG'#1]PTT@FH?SW3OK4 ME('3\8/]NRI7I']$#!](\Z<^\4ID&_K>"9_1M>$?9/B![S6L)&%)&J9^O?+* M.&D?(;[7HB_]K#OU'/2;)+J'V0/@/0".`:../2"Z!T3/@%A5JC-3=7U#'!4Y M)8-']6'T2)XYV$1BYTI/%,-\^4IMET04^:T`R2H/;I+(P.PU!FK,B`@$^R@! MYR7VZ"B4GM(BN'R,H@ MR$R13HMH3*HQ<1:&H0UVF,+6\11E9),XLDF,;-9V@M1!D"[9],Q!D$TS2$/K MIIN8F8]O[1!9&P303B#M/N^0<$FAP&DR8&01V5UF@N9T'$[;`6A0S#@)N*P$ M%GD)N,P$X@4'^P)*9G17?`O1"]UQ[PCX:(K4/?Z MF1".11;AFS!#);JU<=+@,Y?#5(RI[E_TA)/^T8Z-/6'Q'U!+`P04````"`!$ M@@9'ADQ&0@H"``#U!0``&0```'AL+W=O@&DQM)W1O/W\D*50>-_'7 M.<>_OXE=3D*^J98Q'7WT?%"[N-5ZW`*@FI;U5#V)D0UFY21D3[49RC-0HV3T MZ$P]!PC"#/2T&^*J=',OLBK%1?-N8"\R4I>^I_+OGG$Q[>(DOD^\=N=6VPE0 ME>#A.W8]&U0GADBRTR[^EFSKW"JAB1=->";`7\Q M`$_FZGJFFE:E%%,D_;<8J?WDR1:;DVLB4XR*[9([+JNHRFN59*0$5QNTT.R] M!CD-"BGJA>(S!!B`!P5:H4#.CST%+,(!>"4`NX#4!VR^0`Z^#*_)/60*<5XD M(5V]T,$<(?R?BM(5H'0!A(-`7D/N0)"D09ZY#.-D,\->X)`5'++`">ZS)[-] M-D66),%CK!18ZE.`,P3!0O@*4+X"R M(%`^^U]D!$,(@SQS60K3NF9_:+RW`TJ.@AM+KN[KBX,>`LY.VW=STI7^6_$"+\?[(/E[ZZA]02P,$%`````@`1((&1QC5"$#H M`0``4P4``!D```!X;"]W;W)K&UL?53;CILP$/T5 MBP]8$R[9)")(FU15^U!IM0_MLP/#16MC:INP_?OZ0@BLO'G!MW/.G!D\SD8N MWF4#H-`'HYT\!HU2_0%C633`B'SB/73ZI.*"$:67HL:R%T!*2V(41V&XQ8RT M79!G=N]5Y!D?%&T[>!5(#HP1\>\$E(_'8!/<-M[:NE%F`^<9GGEERZ"3+>^0 M@.H8O&P.YZU!6,#O%D:YF"/C_<+YNUG\+(]!:"P`A4(9!:*'*YR!4B.D`_^= M-.\A#7$YOZE_M]EJ]Q(4+>B1+\!YB4AW_@CQ@R1BRX^=P7#O%T@>""16()FJL/-688W9>Q/Y"K,R MDCXPDBX%]J'7R!JS\1I98R*_D>T#(]N50.PULL8D7B-K3/K)"%Y<5@:BMDTL M4<&'3KD+,>_.[\1+9"[[I_V3?C]]H_A]02P,$%`````@`1((&1SUM MEE`\`@``B@<``!D```!X;"]W;W)K&ULC57+CILP M%/T5Q+X#MGE&!*E#5;6+2J-9M&N'.`$-8&H[8?KWM0UA\,BQLHE?YQS.O^V[@>[\18MP%`:\;TF/^1$R^L+.A%=.U`7IC'+WV/V;]GTM%I[P/_MO':GANA-H*R"%;> ML>W)P%LZ>(R<]OY7L*L`4A"-^-V2B6_FGC)_H/1-+7X>]WZH/)".U$))8#E< M246Z3BG)+_]=1#^^J8C;^4W]NPY7VC]@3BK:_6F/HI%N0]\[DA.^=.*53C_( M$D.L!&O:Q'?0XS2=1MM#L!+@0X$H`D9.`%@+Z1`AF M9SJN;UC@LF!T\MA\&2-6=PYV2&:N]F0PW%='.ET*41;7$N1)$5R5D(%YGC%0 M8Z`-41F(>(4$TL#J`CI<0,U'BXO4+H`<`D@+1(M`9IHW$#CNQ82>W"R0. M@>21.TH=`NG&@6PFUH2DFTCS.$XC9$W(%I:E*(.1W4[FL),9=H!=('<(Y(\D M1'62^\47/I"2!30'BV03MO^7*@,'LSBY:\G9#X!A"=Z1*B:@:N<`7HD M,=LZ!1#)LK#7LPD$>92"SW$%FZXYXC/YA=FY';AWH$(V8-U"3Y0*(N7")UE* MC7P8UT5'3D)-4SEG\U,Q+P0=;R_?^OR6_P%02P,$%`````@`1((&1U6)S1X` M`P``@@P``!D```!X;"]W;W)K&ULC5?!;J,P$/T5 MQ'T+-F`@(DA-*-H]K%3UL#V[B9.@`LZ"TW3_?FU#B%T9ETO`YLV;-X-G,F17 MVKWW)T*8\]G4;;]V3XR=5Y[7[TZDP?T#/9.6/SG0KL&,+[NCUY\[@O?2J*D] MZ/O(:W#5NGDF]YZ[/*,75E>Z<_M(TN/NW(36]KEW@WC9>JN.)B0TOS[S) M;E\UI.TKVCH=.:S=1[`JH2\@$O&G(M=>N7>$^#=*W\7BUW[M^D(#J9]R&(-,QFP$")B6(3I%`AP(0H503TPPGC<9&3 M4CBO=`-5`I.+K8J($J/.;TF>OBV0K@$32\R/($9!"DRX8B&NU'%1@!)@%AY9A$>:\-@H?,!$$H/\)`I2H^YE ML%*%17$,XIF3ARRJD:8Z,:I&BA\`?-\WH;9(2>(LJE"Y((R!$?6D">-*,![Y(E7S,PTJ-+>('9R9L M\:\TWS5]3?=,)0!KXP5+<@*&XHC3-)T+WE;2(%WRGG10;/8#;34(]1HTMN5R!!DC'UQYRKS4D.XH1]O> MV=%+RX97..U.X_,C%//6E_T-6&V!8;\`JZ=A.+[3Y]D9'\EOW!VKMG?>*.-3 MGIS3#I0RPH7[#_P@G_@'P;2HR8&)VYC?=\.(/"P8/=\F_NFS(_\/4$L#!!0` M```(`$2"!D&PO=V]R:W-H965TT$+G(\UIT:#JUJ1(LD5/O@*=H=,JMP@M\-]&K21S;[48@/._AYV@>AC0`, M2FT=J&FN\`R,62,#_AP\_R-MX;1_HZ(7I M=]'_@&$+L34L!5/NB%SGI?9QL MA9/-.),_<D/N1]HT=VNK/'>+/X!4$L#!!0````(`$2"!D<9\0LWH0(``!P* M```9````>&PO=V]R:W-H965T,#C'ZH MU3;69-K.9O=BD\E<[%XS+6W-J'2`3F???@&ME09(;^3'<\[W`Q]07BC[X$=" M1/#=-AU?ADSJ,5U M%U:EGGME54G/HJD[\LH"?FY;S/ZM2$,ORQ#"Z\1;?3@*-1%5933R=G5+.E[3 M+F!DOPR?8?$"A8)HQ)^:7/BD'RCGWRG]4(-?NV48*Q](0[9"26#9?)$U:1JE M)"U_#J(WFXHX[5_5?^API?OOF),U;?[6.W&4WL9AL"-[?&[$&[W\)$,,F1+< MTH;K;[`]*A^Z051B*K\JA#, MR^A+"1F858]!&I/E-LAF"H$1$4D'1B^0VXL5FM`1BFTFUB8FL;IA8E(;YL6E M8SB;>%*6:(%T$,CL`JE'(-4"B19('`YD'GYF.#`SH^SZC/:8O%\0!'$#)NIH6;$-O/$-IO&%L_M`KE'('\@N86'7QC)M>_V*09R MQWZ?>XS,#2.%->ES8P4S5S+58>BN[M@P-+<:&D"#)?>R@?<<@:FEQ+Z/!E"F M02XKGG/B&=#4"C@R#[[JA>2!#0*^\H74"!7L!Z()0@X[OC('H\XA=4CXJ@EF MCP3K*R?('PG6!+GL^,H.C+I+K$?WY@YT?_1&DZNO)>R@'QT\V-)S)_HDC+/C MP^89J:OS;GX%BS58YC?J(:2OVIM\59[P@?S&[%!W/'BG0E[8^LK=4RJ(]#I^ MDNMXE$^U<="0O5#=7/99_WCI!X*>KF^Q\4%8_0=02P,$%`````@`1((&1ZCK MAIWV`0``:`4``!D```!X;"]W;W)K&UL?93=;ILP M',5?!?$`M8TQ(1%!6IBJ[6)2U8OMVDF<@&HPM9W0O?W\01A4+C?XZYSCW]\6 M+@8AWU3-F(X^6MZI?5QKW>\`4*>:M50]B9YU9N4B9$NU&'F7F19B)OF3<=>9*1N;4OEWP/C8MC'*'Y,O#;76ML)4!9@\IV; MEG6J$5TDV64??T.[*K,*)_C=L$'-^I%E/PKQ9@<_S_L86@3&V4G;!&J:.ZL8 MYS;(;/P^9O[?TAKG_4?ZLZO6T!^I8I7@?YJSK@TLC*,SN]`;UZ]B^,'&$H@- M/`FNW##?B3`7@R5]=W MJFE92#%$TM]%3^V5HQTV)W>*3#$JMDONN*RB+.YE@K,"W&W00G/PFL1K0HIJ MH2"3!!B`B2)9H4B<'X\4FW``7@G`+B`=`_(E9.?+\)J-TZ``TD.0S*JKD,08+1%P=,5G#('">%01PRWP=G.,^# MYU@M="@C,(%AH&P%*)L!(12\B$,VNPBES+ M?U!+`P04````"`!$@@9';1PXW>(!``#C!0``&0```'AL+W=OJ:A\JK?:A?79@"&@-IK83 MMG]?7P@-*^3-"YZQSSD^,\;.)\;?1`L@T7M/!W'T6BG'`\:B:J$GXHF-,*B5 MAO&>2)7R,Q8C!U(;4D]QZ/LI[DDW>$5NYEYXD;.+I-T`+QR)2]\3_O<9*)N. M7N#=)EZ[KRT`A4IJ!:*&*Y1`J192&_^9-?]OJ8GW\4W]FZE6N3\1`26CO[M:MLJL M[Z$:&G*A\I5-WV$N(=&"%:/"?%%U$9+U-XJ'>O)NQVXPXV17$G^F;1/"F1`N MA"!V$J*9$'T@8.O,U/652%+DG$V(V[,8B3[RX!"ISE5(%2,\O63:I1%%?BW" M.,CQ50NM,,\6$UK,%J)<(9(%@I6!Q47H=-60-=3RS)HSM9-5 M]\M&U676=J?U6]#L:IFM!U)9!(R0."BSO/(7L^&[IWHQ4Q]MD5?RJ?::C[+, MZG]+6:C]W*?^X8OG_&W;]E\$BUEPY*WS4E9-KBJOEINY_XN>/_*HAPR(W[G< M-Y-CKT_^1:GW_N1V/?=)GX,LY&O;2V3=QZ=.#T^J%\- MY7;IOV2-7*GB3[YNMUVVQ/?6]8G;C7W;^-W_\V.*2'+&:?"Q;26?#9*P',`5!,7&&7IE!<%L4%?1"&A0TPA8 M:M`X`SCAI/^S1$,=2(&]8N/`N=:@,9IQ%MY;(#`3U*74R:84]2EU,.H*@F)N M"81:E0*OQJ$IT"4`T<2R[-I`<+%#7<\(R"8R=6BE07H92DD$;ID)\@(BA15X M!8",),A=R-"1P\`TB2W#D^%+OM.:S]!IPCC(0YBJOF5P/<>*1L<.@\/",D(9 M.BR8TQK,T!'`8I>BI_YF$58TZG(F0##+S&>HRUGB5#1J8`8,;-[@+34(%&VI MFJ,&Y<"@POSD<0*R;5I1(W%@)&%>NT]`YN'E`KJQ@F#*J&\YV`4(\^8*@KCM MVN`[>F!N$9L"/9Z`+)LPCAJ;ARXK&4>-S<$NP++EA"!Q.D&"R>/Q+GN3CUG] MEE>-]Z+:[EE[>%;>*-7*3HJ<=5);F:V/)X7-*JW>&EUO'- MVN(_4$L#!!0````(`$2"!D<_\DGCV@,``#T4```9````>&PO=V]R:W-H965T M68 M&D`^0.(Y;W]89(>FI#8W8?'7K=;R_U)8GTW]ISEJW09_RZ)J'E;'MCW=AV&S M.^HR:^[,25?=+P=3EUG;/=;O87.J=;8?@LHBI%$4AV665ZO->GCWH]ZLS4=; MY)7^40?-1UEF]7^I+LSY8456EQ<_\_=CV[\(-^OP&K?/2UTUN:F"6A\>5O^0 M^U<^(`/Q*]?G9G(?],6_&?.G?WC=/ZRBO@9=Z%W;I\BZRZ?>ZJ+H,W4M_VN3 M?K79!T[O+]F?ANYVY;]EC=Z:XG>^;X]=M=$JV.M#]E&T/\WY1=L^B#[ASA3- M\#?8?32M*2\AJZ#,_H[7O!JNY_&7)+)A[@!J`^@U@'`T@-D`MC2`VP"^-$#8 M`+$T(+8!\=(`:0/DTH#$!B1+`Y0-4+.`<)R_8?8?LS;;K&MS#NIQR9ZR7AGD M7G7K:Q=T4]ZL^I^&1=43F_7GAG*R#C_[1(!)1X9:1KJ8+602%_,(&.%"OD$D MF61D[J1P02]>")02(Z7$H!1/`HDDD$N658(D M2&XOJS29+(*8,S;!0#L*:4?=7@.IFJX!*:+(M]CZK"%:/'`0I2N*<; M0LPW#9@[4.`.,G:U\SJ#I*<=S!DH=`;EGNZI,TATMC%GH,`9E//`ELX@WXD- M,P8*C&%^0+JT`R'/<81B[D$E2.%<<^D,\AP5*&8Q%+B'4S(!(W<:]A5#LZRUZ_@=4$;Z9M33E\SS@8T^HN7W37K;JCSO;7AT(?VOY6=O?U^'5K?&C- MZ?*Q[OK%&PO=V]R M:W-H965T*)=:15.R?&*99JR<^1Z#C!1T.B303B&$44UVU8Y";VRHN<7613M^25 M!^)"*>9_-Z1A_3I,PEO@K3Y74@>B(H]&WK&FI!4U:P-.3NOP)5GMD488P*^: M],*9!]K[@;%WO?AQ7(>QMD`:4DJM@-5P)5O2-%I()?XS:-Y3:J([OZE_,]4J M]PZ M-6-O=]#S0/,3P$``(V',XR>D`R&]$[)90C80LO_-``<"?,@0V=K-R>VPQ$7. M61]P>]L=UA]5LH+J;LI`'9<(]9:Y$(TH\FN1QG$>7;70!+.Q&&`P<.&#[%Q( M,B(B96!T`3YWL0$.'?@2;%T$?/9Z^%)D_XG(Q&8ZVRF3I%\AF!#(C MD`VGG4Q-MK8,BX&VC"6$SJ5,\L"9/'"2!_CR;"QF83'@.5T@'VSKPD""D%]M MY\+0$B$`?;"]"\L669)E_N+03'%H4ESJ+0XY>9+E$L6/G_9@>PYG#47.>Z*$ MGTTG$T')+JVTW\(8'9OE"]#O\2&^25;;Q!/?J>9J>^%=OL@[?"8_,3_7K0@. M3*HN8-[QB3%)E/'X29UDI=K_N&C(2>KI0LVY[8AV(5EWZ^_CGTSQ#U!+`P04 M````"`!$@@9'*9VZRDX"``"D!P``&0```'AL+W=O=_'*AK,5" M+MDUX#TC^*Q);1-``-9!B^O.+W*]]\**G-Y$4W?DA7G\UK:8_=N1A@Y;/_0? M&Z_UM1)J(RCR8.*=ZY9TO*:=Q\AEZW\+-\<0*(A&_*[)P&=S3YD_4?JF%C_/ M6Q\H#Z0AI5`AL!SN9$^:1D62RG_'H!^:BCB?/Z)_U^E*^R?,R9XV?^JSJ*1; MX'MG_H49%E)%JPD5D,3YY_$QJ1ND71!)+4" M9,Y4TEEE$Y#!9Z8*DXC_=N!&5&9O7Y MC`2SVZ['5_(+LVO=<>]$A;PX]=5WH500&0JLY)FKY),Y+1IR$6J:R#DSCXA9 M"-H_WL3I82[^`U!+`P04````"`!$@@9'F(@J&[D!``!L!```&0```'AL+W=O M42*"%(S5=4N*HUF MT:X=N`1K;$QM)TS_OGX0"AJ&3>QKG]=U;,I1JC?=`1CT+GBO3U%GS'#$6-<= M"*J?Y`"]W6FE$M384EVQ'A30QI,$QR2."RPHZZ.J]&LOJBKES7#6PXM"^B8$ M57_/P.5XBI+HL?#*KIUQ"[@J\,]DC!>TI^I(,`O!J->S)'+ M?I'RS14_FE,4NPC`H39.@=KA#L_`N1.RQG\FS?^6CKBC'S,K]30JE1R1"H<[4#=/Y@D6)D<-EL)F(/' M%''\H1>\N$D#O<)/JJZLU^@BC;V4_EJU4AJP6O&33=S9IS\7'%KCI@<[5^$U MA,+(X?&VYP],]0]02P,$%`````@`1((&1Y-J/X[I`0``O04``!D```!X;"]W M;W)K&ULC91=CYP@%(;_"O$'+(A?,Q/'I+/-IKUH MLMF+]II1',VBN,",VW]?0,=*RIC>R-=[WN<`'O*1BW?94*K`9\=Z>0P:I88# MA+)L:$?D$Q]HKU=J+CJB]%!Q5%SJ^*M3U] M%4!>NXZ(WR?*^'@,PN`^\=9>&F4F8)'#):YJ.]K+EO=`T/H8?`D/IQ`9B57\ M;.DH5WU@DC]S_FX&WZMC@$P.E-%2&0NBFQM]IHP9)TW^F$W_,DW@NG]W?['; MU>F?B:3/G/UJ*]7H;%$`*EJ3*U-O?/Q&YSTDQK#D3-HO**]2\>X>$H".?$YM MV]MVG%9V:`[S!^`Y`"\!(;:)3R";YE>B2)$+/@(QG>U`S!6&!ZP/H@0Z-QF8 M);M[HRCR6Q&%NQS>C)&C.4T:/&OVBP9J_P6"-R#8&D36(,2IWR#:,(BL03QG MD'JS=#08^2'Q!B1V#$(7TD^029-,FB1!Z`$GV>`D#@=[.F*@OV(;`.1.8C8>RNN)O%#=AN0G6/PX-_9;QCL_^?G,_7[N$:0DT/F/EVF@^'!_+)<7N_@#4$L#!!0````(`$2"!D>.[Q?W73D``)SW```4```` M>&PON'%?,)L+C"SF0^8Q6QF[T_QE\QYQ2LC MLEAL=6-L#V'8%BLC(R-.G#COQ^^:IDVZ,O]3ITZKKFQ__VQ_[]6SY'Y>E,WO MG\W:=O'ZQ8MF,E/SM!E7"U7"DVE5S],6_JQO7C2+6J59,U.JG1E]%^ M][L7^`Z_=Y1\J,IVUL`[F M=G5-+^3-!+;T'RJM![^^O;V[M[V_.P05F>FS6E1UFY%OCN M;5I`%WA]\`Q<4)S!C\%R^R/ET*)C_[`70+P"M"D;E<$*RZ8J\@PVG"5OTB(M M)PH6"M>O@;OTX^7;9//Y5O!Q-0$4V*4;<3!TFFG3P"2O@\=I,Z/+,L%_J#]U M^6U:P/A@U2>3"1*0)JG51,&@ZT*-DE*U235-X!2J.UHJW+0DJ[KK=MH52:I? MP2&+15W=YW`-5;%,GN_N[(YV=G;HR\^/#_#?(YBY6:A)F]_"D/[GS\M;6%4$ M!RYJM4CS+%'W"P1A0U-6[4S5_9%750LG,_'@$<* M9*RK)[.T4`Z4+#=.'Y>&<78%DGC*S"Q)NW96U?F?5?9MLG

C5[M'NC!>=/@01!:#I.:DRS+D4/!OA"=M_,2;N0B MAWU&CKN;=P51"-E1'#[-2B#$WWEO84HKC@'REU&OS8L446BFVAP(Y-8P-5MK MNK6HTP-D:3467&@$6#TLP(BUAC-.K#5T!RO M+8V%[.5Q:^B_+A<\9Y2;(DLK$!8AJL M+J2$L+5I78JV9290M)FZ*^,>.CY=K8FUXI_/[[C:JVQ M'T&8P)WW?_^CRF]FB%0GMP",&V7$N.""`(9?ITT^X1/+BZX-L9E@>X%"I=PV MG"7V8K()-#BKBB*M`<_@!1JY+KGR+P!)66=`C59<0AHSI3'NT<.N4I2)XKP? M859$8':2_=0U+7^_K9`J5G"6P)E+>0%_Q7^3V-?A\I%&KO7-MPJ4PDD>5:A. MYBB(_YF5/]AX_I"0U']A7?2CP]^&0X.A@%:(4=$%D:R?W*!N%\QA<#_-@.P1 M1*I0Q3F=P0X4[$1V0#BRECQF>=&@:%C'!9R/:YW,0QB4@\SVHS%AU6;J:N)4IF\HNY5/*PY/`0KUL[.(JE9NL`V=LQZ&=U)[$6@E[6"DWD!,AO_:RLAL7!- MC6U0M1LEU^HF+TM<`NQQ"5SN$>\J%&2G2!%!PPVN6[=8%$3W@.QGH`L#K>F( M2D]Y*CQ1O>]E7!LE=8[1A.]G?]0;(-4T(^A^#7XJ=O%WQTETW,;53)$(2(8" MIB^:@D]<"B['A(*TI>5P)D67J:252;1ZZYJ(DDU\^K>__'8H+]9*(XI9[TE9=O`!ME0EL(JS"A3= MW9WM?Y/#=`]JU4?X,.AJY/-''00NJROUI@D!>6W5`F16)N;SM`0)BVT>M9H6 M:M*B&@4VL1 M`&CS;=()JT<64561@QB?"KI9R,*PP`#\J;Y)2RW`X)QONB8O52"2H.!F<8$/_([GLYJ"E+#<\*@.D+4T*P&^\,W.%L"F25DUF M9554-\M$;SBC1RT+.`C?Q8S4E1)7D)#UK&:DTF^`.)`@P]%H4N03QK%47`DX M\AH!)(>]@*%XIMZ<=BUH3(!O3UB0PL,B@3VM,V8+-2OH,$M."$87-%AI#C>X MAJG&B2:C0(CP-DWA<"I&":87A"($$0`?LMZLFR#M!H#=IGE!%JH8&1F!G%ZF MF=`0=4L?9]V%<*;65A&YW`UH)$C!_OJ_DH^TQ._K=`H7)T6@3+?AQ>UFI@J6 M(E`484IFUK!`L:-!P,XZN'BR3[1:W.!$!)3K.L]N\(1I/1K$#"/0?&@3,'U5 M7^>9F&V:ID+I',8R92U1OM7&)>#&-X0I(,"I$8&R@X,P6P`E!NY<6]6P#80N M@1#XTKP#`2<%D0JNS$0510=J$5`+@,D],:9WIQ^(,TVJ="%40+-QP(T&_BX0 MDP4U4"#S]A-9"0AE[8J5P`?UT;)@"1AV5Z<+.J`%O\LX`\_ZR,3'6*L<74,3 MQDF-NWC=V[H37C'+Z:!03"?FU%1P,"W9;Y*T;=/)3(@K4A.D\_?55=5-9G_[ MK_\SN;JKMB^J'*VL(`G53%-X/VU5%;ALM$#*TX^359`NZJNLCN0'X'_(>; MWY"'HK]DX!OH&FWAOPV)=F96I`9`0E%Z!-X$*-.E([0&P-5F6@/@H<,D"RGI M5'W)T*I_5D8<183$<1)*Y,0[<-9+AR>>6'GK`NCG)-1!X@QK?YRL/^.&]@)\ MAEL%(TG^UK_EI"#CSW]&$,]00`1L[%($+R`J@%N4,*1@=8W,@UQLZAZ.!B@& MXS\`%J>:YO?"K3(%UP:O&MF`,^#E0&B8J543H;M"#WB/]"2B90J328@3U7`%?`:=2#$ MX4TW.$?77_M)"!W[H)++3^0/]M#,\L6"B2!Q!&=R,RE1GE9DU#:?`]G+6Z1N MJ+8W#[R:@*""4$EC7QUYHC)"NJQ`(*N)=<*ADO^=8'I=Y#=LSP0\DK>="=$Y M@>B>-N;7:T58+V/9,M;5('1.T/ZR3&[S%+DS\.:Z!]BBF@BEJX&J`C1OK,"B M/UGR*Q5Z[R?D47&/0,\`%[QE*HA@P]WF=H&`_"BI@K)A#A>`(&*#K&6``OHT\E*E(B4$V5[LW!3=<:]LZ M6^;Z'Q>ZS=H`ZVI6JA'[.2M9=)_'&\9>0?]X9^T5_&,%R%>V3"(WSE#6[(!D M-LJH>49-\@P5C8_8=$KH"2.5:);?S(`^%R`0YTAUT!A$D@,+!`NQJVDI#(4E MP-)VR9]$37S.3A=8#LE&`,MK%1A8DL3>'-4IFHVO`F43!4@O#[5_V[C9(;^0O@TL$T&2$\&I45 MXDRA=0T`'>"Z^1;1YDHU"=^6(E&C%[K,QNX:'3\9XGO(S3+D1L=425$$I@`J)'D#1NIKG$SLI,$U9^!ZG)'Y4#+SDLLH+HZ=M9 MVNJ+<[239.E2Z%I+MAG&$33%T/[MR;,/H6D,I1'("-!`S@36@BK_R*(4$4)T MDB!T)JI%J)#<(O9+6 MHZ^NBP$9"&IP*Y'C@IA`3!"E>,0N2P#82$(?9*_($IC[0DWP#O=@1I)UY"#E M.$C(I%NWN[/SC>P2]47GBLB>>6.U0OKG_.S[`W%SYH#(OD,J#](#="2FBT61 MLU$^)25[(H%FR69R^`WKWWK:H]UD.SF6J=@RVAM!'S,C@-ENC=Q+SS>"F+-5 MPA@H!;DY.K:2I,6$HCO89$O^4P$,_#\0O%H?JOY5(\%=Z@D+N"G8WY(OKK-K MP[,IBB1W9KA6[1W:OXXX,,O=;4K\CL6YWD3Z;7?_(/"4HG`B:C%^HOHT2[N& M38J.<*VF`$CAU8@==%$8;WPT&>$D=V3<13T(P`&SR\4F-0#(7FJ<4, M,1EVD*&@VBA'JIRG7U32+5S1B9T&FL4@9%&R`H3G^&)MG8#%`_MTENT+'VG1 M5"RK5T7C[0[DJ:J[F>G?],$VAAVQ+,/Q'A4HHE7-G@81DD%\T`&&J+8Z_V9I M``T<.:$#Z.;S!9QF2Q!C0]!(["!DM4-3%IE`DKY94!LNDIBQ+7SHVK_0'MD1 ML7+H*$4G&1$%,)'/!\7C9'.:UTV[G0/+X'\!5=Q*",$QVL5R=@ZS(0.Z-BR] MWM#8M^$BW0:B(O[/P<89QKC,X-L4GK/Q'/[SQZK^@GQ`+MG&Y_0.)5[@$'`, M-,(%ZAVJWA(\JB])&"1Z=+AO[\;!SM=4DDK%Z,*^(,'U!I`#L M+^G`^!I$=N_)04!=2#O&+Y*'*/99Q`'V^S1XK1FUA?!'YD^;!]_<&K7,M"'BB)8A2`7\!OQ;1 M$GAT+^E9T91"B.\"39%BU!=FV. M3,LJ?%8CXA('*&#> M5$!)M!A@.+1JWP;"PI<9:6(T3,"Y8P`8A@,L)^\%'K*=5`&6$L5"S#-HKN,D MPT`$*_]C\A)]!'W`#8J'/XFHH^[3N796RN$&%^(26!!9DIWX#IXH[H;?-2(' M&J)Y;"]*&R/C"Q?B:XTYO M]6OZ9*MR6Y!DFSF';P72%BF'NV:B5Y'KGN9K7.[6`*:WVZA))&5*-(GO3Z/< M">DT&C7P-0U)--2,8N*F\^.JQ`4^<[O07F`&84%1E3>\7#+#.1L53XP/.I;L MNP7:DX3;US36DED!A'QDO,'AAF]2CO.TX88;%%\8B4-D,@%^`[+MR(ASDO81,6@0LB/R(;)$2/.3!6+D M*S(A(%/D&R/MA_(MP&C:DNM)VAW)$"#_5DNEY/YQ+"#@C-P@MMGZ=$K;,IK( M$A1*.`P67HI.F+"@H0UJ?LS^--D@BTYI\J9(X10N)[,*>,+V![@7R#MITFUT M$5&(!/"\@MESUVC#&7QJ+D>"L9_&\LSB_;4"$6'55D"13%O#8=CI9P,&M6CN MK]D[#G\""L"HV6JE*.H`/TH"LPDL6G3`'R8H<:"RE(TB$3:HR`H"?P(%`LD6 MD2S0O6Y81WBO)E=J(H$D#GXYGL21;[H*E#EWGQ2](9^W>CEA/;)*_JX/QYX% MTPBF13Y5]JN.S<0Q-Y$NVX"$@S$(A#,@7MSDMQ+,1^9*,:^(J4/\.QU%R-1S M&*X#4#'W->NTL1/X8[NM'\&NIBIO23WTUF[0!W7/[2F:\@TW8W]OJ<4:,B\M M&_R`-I[L8SB)7"L`)W$+1OEG2#:": M^8HHB"8<^;^=2N2_>U\Y*MHGITZD@PEQ[,4VOMZX''CB:KCO-`P)V)@)0-+` MEGU@;^[&-_`?]"8DA`J(`?23&6I`L?&WO_PW>,#_&Z([Y,[.BN(HD?`+@WSP MCGY$EG&B!&:?X^34JACZU\R;N.<2U/)6ZAHN)VD[F6UW"R<^40=A^KS,=R@: M#4?"/="N)#H(W15V[I`ZDG)^0I^[:^"SP.]_2-0X(8@]L@<7C2X.6F8Q=M)L MF/31B2%;>.\Z"I.GZ`^QZ3FF[350O1?&BPP=AB]9XA>-)2\=;]MXXT?V3K_3 MYT18RG&[1B$="(Q&*HN.?N1EOVY(K[%\.-99`!'9&>W-H9-TZ`,;"``#Y539 M7H%RS=QF)< M+O4VW7A]A`ME6ISK3`O*[GL&GSNY_%%/`E_E:Z\M%QPEX4^3A0D;=%]CQX2Q MLOPZ4RX).F@H2J=&G(*+)D&"QO.GQ7WZD-7#X>K,B.R2_T][`4&7=S;`]J%K M199"15B+!(XD*Y+X'&%0$$+'3!/B._A$ MO*8^KNT97.OH>XT6,:W<29(3<&\Z=A3CN/R$I"4X`#`J?*%N4,;%<;D6-WEZ M%/RJ6VTH*RE""MDV&R8Q0'F:H(T@9Y-BDYX8H(Y[1#F8SL_\Y5 MN4N7XM26)1B+GC$E`@MHQ13([T\QKHA$1Q3TM13!]MO:B'U>]+P-SI.P*@O5 MO^,+D'JF'2=^PK==KKX9C\+^'])R!?+K(]:B#@*F4*P(Z,P%CE&JE3'B4VR- M@QZ8$*KJ4F^#_ERT$FY)8=Y5#8(&K@*.?\Y$[ON3DPL7.9WY4`#U3FWP1#B" MWL_W0(&!$*8BB9;>?.0)8@!@]`R3ZXZ!JQ+]`;:_ M!LTCL8V]5_TC#\`=6)9<\52\TZ;TCQ&@Q&GBAF2VZ-YM76FI,P"',)[CR2)!*G MYU-DH@*Z1D'FF31!(UNAP_QGF,V!^35L3JM0;]<)?<*1\=CTQ&F=DXU.A[F2 M'48,'#9D0!S<&$B`P4ESM)T:TVQDB98"LIE9@ME@OGJYW>C0(SU*9S?5RBHB MFF#KV7D[N;XB?9YM'1[Z!=1O%<@2K8Y<*)LI&]>`!RRW/U0+QT&FT,O*^7,+FD>O(^,?N>PF"-:(?.7*8_/=(R M8F)$J$G$J*"T:DU9R*0DM(RTCM:-88TO4B]L;8EG2/!?GU;UG7F.>C_C\'/V MR+IAJ/AGH;/R:E9E/4.#J\JR"5M"C=E%QXZY4KE\;5&AE8NS\X8)<&@!CV[0 M"8752CE`V-9Q&4EBA<7QE37(W@U583@8)_&!&_$:9E\1[K-ILH:W-LXZD!G9 M7N7.3A$^[[%&`1:+0JB!'B#VA`MV>A*#-./?PR^O\>2<6E:VK`C3!Z?9EL`^5CT@D81RL28PB9$:-3<7J# MO',2J54@R5N\/YX(HW.6=J*18RC3C@\]'J9[OHMUU_8.^%T0?#,[P"FPQ'%F M2"`%8!0S[M6WO>E]8T M[O8"WF)0-P%&::_F3A%BB?YZ"9H@$+=;'0W!R1K&P@]BQ_.]0V^]?%P9BT)F MB<\ES!5'(8MUPB<`N\8&44_L#>B[JA2YV#+.V8*+T)(8%UF[+K\1SDD9RJ;\ MPX\EA:Z*[U7G8YJJ7V?`1[35"&;[\>SSF:GY3,@"?=*@W\?"K$QP] MAJ':C4V>1TTIPL7Y<3;IA$.];<:IDX4JFVXDP@<^P&'>3O9_)YFVG`^LE3F; M(0\_<"8TRQXFQ=]+VG>C86ITQ9&L*@;^8RM/R3?8#"J M+,&*)>1S&X03.Z6RQJ"0AJT5Z9E(N@LDQ MU^2ZIB@)%E?[Z[B*0PEUK516]44M!?N*O.'H;F!3KS?^^G^DI`1Z;X'R5\NT M0/$>#7L^&_@&5[/_C1.4$?FD<1UBD"(G,EKJ8I-@,9/4^J4=SJ3#NRF#&F0P MH/KS;FZ6Q61_=`AD!,NQ_:E+ZQ9E=-:+$+H:7U,=]FV]<3+:F"6;=([NPT*A M^,I2N*9@1B-3P1(XY4><_PZTL.9(4XW88QN"5`I@4+PHR>,H@&K$X"Q,#2VS M-H$6%@O07P+9&0T]6..`8\%'^`B/D:$*/]\5ZS'3C7%1M@3M9"8+=^E@F:I86.KAFO/%6Z`=A#H-5E=108H" MZ-.H26>$:=0IR_CG'S[\;W$*7*1S)`R:RM[D&$?S4(1`!%>8Y85Y#AC?XOM3 M!/2BT@EX'-%U037ISL\3JO%M:N*`D%Y6M\R5#:>&70\-O[(<\4J;:#@,B[.` MM$X;\K_E8*@MX[#*207ER0)4X)(9_B:![M$KWH\2/HSU$,PME5JC-DEO,4OK M.2@L'=7.I30.J?<#0\7KPKG9JQ!VG'R4@"POE=OJ^?RR4^ETO/'990D<*=R3 MD?<<(?D5'ZWCL/XZ.9D^^'QO]Z4CAQ\:"T5%77\.=CN]G<(IO(6ZC2M\GQ&+-Y%XJ].?-D473,WK1Y&4-2 MS]]\^HRD;7<,8R7<;.TRAVQJ4U(%8Q=FP#`\)N$KSB1O!,`V,`Q%:[%<:.)G M050K+XU?GDN-'Y:XO#@>S(*LR)QX3W(D'M@^\;Z"W$NE'9JSV79WSRO,.&8S MCHEOET1P^M6MN+_QJ32QOFS%WC/B+M^^Q M@M(%L29=^!+>@-]QT`@+8&"D3>N[+C0_U;52' M.BG)_\BO_H+QI<2P16QSR\YI!AHO M`/>+*U@)PO:6"U<:KZ;6<2DH5N.H-2_TWQH1;(V\4O>1>04BKP7HD9MCHR45 M4NCM0?XD3$`1SRQ4.3/FJ(*Z)8YK@%CL1X2@[-I4QHQ3FQ&H%6JY)%[SH6IU!0COZ1CQ,K=2?=QV+ MB"0ZB,>S@``,GN_MC%X)<]$4X:PC,>N$.!#?=`FXU:+4\]WCT0XWS1BJ0'N>"Y.P#5ZD'BYK<;V!@N!KX\2%NCZ7].0 M,)^)T$BXF`N1&='1@R=HJ@+SWT1)L38QTLO_M/6"C!'`'+:EA)G",H+7J*=> M5[/"N-WQ&%N#)SJ7FN`,F=((O#7H7W0O-9$AF8;$*)NQ5>Z-W*"##3D MZ+SPX(#+^7>6S?OJ'J7J+F]F:]RI7ATQIW:8H^8$4VP\O$KB/4<'^R/,?-5M M-OQ:WY[<188GX.WN?G"3PN[(]09+P)82;"&F&!NJ3$<2VOCEGFT@X",K)N%B M52@\W1AV+L6%.8BD/8-&*:91#LMH9\K4JK-&E]Z2::L2E>W4+-05LL:.A&L7 MMEK6'3@#?0.H:B#<"&PHQA1$%[;%1.RJKK&4`=.#DU/Z\0;H-./( MQ('P$EFX[P%`ZQ_:!,4`A0YB"9-[K)Q.15^QG!*%!G/IQNV@J#=@PR<`2<&% MRGC6?U6`OS,J@OLA;9`)(85-WE_09_1P^4;3:S`BKO$"#=[4@H0BU+5N+-MS MA80(2$;>9DE[8"8.H,`9\/]%DG3!S;J'N1*6*.;H2;V5IES%)6I MO.><&A#$U"8_2R9]CBU3O6P5: MZ=RDD7%XC;GT"X5?LL>V86:SM!=-A%N)9C!*#L41VL(4<45RE\,"5NG7>'+# MCRTQ=I;^%6JWHZ#]BAIXOY*5BN(IQ<_!A90[XZU1-_)H.,2KUE[#V.(.QJ^` M)OP"1.,0-_ND"VG^>.,!1A`G-10/N92*L15G@RW]2>?M'DQ::""C*,`NZL%VL,")F:Z^\&K[-BFNI2])+8 M55>%19\1F0+TA9RG/U6Z:*>#7OJ^U&ZH6)I))2RI'",-P09'&2,Q(34MA@1[1>.^W.!,N;H2%_I#TC5S7 M>J;+?V?=Q#'!,06T%66H<+81]VP93TE7YTA0G3YI#%V.;CC(>6AM5O"@HLS: M5XF!K!2*P"Y=5[S:MV"28%J*R;WEP&7'$R`U`LD&H$D/7'J';O5\HQ1V.J#L M^B_&"'M2/;AA9.@3MD+FE=,#)\H'Q'+AZFF]Z*1R9?>B$58SZ4D+EUKV"(W, MX:.H9!`S*7/UD&FP./B^5);N02^-"T&6LUI=JO$,;@R1 M`"YQ\5I;;X7F@"D_N;70S^/A0Z29:'6F">^?78:[1P>EZ-))U#Y:82JX)D5E M'9J+0F4WRM4=1_'2C)ON=UY(@:)4VO=(/8765$X'G30ZPERJS`C"&&,0B6<7)&UEQ1 MR;@KA2O`P#B=O\V>`(G9MJT-Q*RPE-(IJ\_SK:1M:[UL"';&DO=3E]V8\W,A MZM;V=ZMU./FLMJ2'EG;G3L@(X];^Q:W0*:C5\Z"!8DW1O$ MA:E-J;KJJ;\VSA+"5FM"GDC?*Y;.`<,^DAR' MW:/1T<[>5Z=3T&1'QS#9GLXS>'DPVCTX^-KT">Y;+2@6)EB;K3EH6U:Z7`^7 M)(OD2O3=VJ-C6'JLJ'$D*8QK('Q"A),+H-M@1WK3QA'K&`65E=.@X\94WCC4 M:2,Q\Q_"EJQ)&(Z.,_7(K?<CEWN< M3F)QW!$/O?IT-&"$]B@I.?A\9[RSZ\@[3K-6VU1H=NB*@ M>TE)?=0WM0\LZO2TOY-L9T!\K37?W%\Q"J)#BWL6$;M]N7,\VD-,L=JHWP:= MI'%,OL+_V<:$T%8B+;CP+G-Z<_!X)ZE9R:(GNKI`M&2>^QC"'KUYMN4K\-"]<-N[X02F;42\8UI(WO8=MRH<;K^D,%4>ZB5)UM:M/!B/9_=^_#Z"YT%CSNSA_ M)#G8@["NS.%L5%L7#T<'^R_I2+US#*(IF'W;1M9T:;PC3G1.,.!K#RW%W20I M.3>4EVTH8FE%>+I%G*[]^,*VO_ZH[GB0"60U M_>6ITAV;5=YT=:$:7#FET?$)FE?=JA#L*@:UAKI)&7-#$:QC,.G.3&M`1R]G M/3/?WF@7>0N*YQ2C3Q89X.EJ5F%4!?'5Q+; M0E6,D=T=<5`64A9NLGS%:D5*0I5>MFW+Q_4`"%ZUTPH"92FNY%G:QG]^VT.V MZU9W/#MU&F7PI(UI@$-0D"-T(NS=5',;C,+(@.K3G$5`#EXA_I5)!.85=W2- MO6_P.7F?3Q5&0$;,E/H11W,8]-)-3W66Y.1+BA6WHCU2K:YMC`B]#'Y]:^"$ M^M_[][R^`?4L3=Z@1=3^38G`;F5_8YQSHS$IRL&;47/0''N\"KS=+L)T(&0H M%K__D0C4+1:8Q-1$,IL*&.BNF!X(8N8AZYYTL>@,&OH;L?C$[C-A.[8XW$LQ M?,ER:WZ>V[@US>*#LW.$FV`ZS]/O4T`WSHA.'BEB5^(2WQ15!52;V8OK M%ZGS5#!,"LTW6T1^3Z\NV;SH'!+5U7!4V(!W..[G=V@=#%A1?T#`?)+=9)P$ MT]AJ`0!,O4X_J$M"(8^280[DLY6M/@-9_0USUR)7#&`U1NS,Q&S"[.-MNFR1 M7'Z:Y16L"@9Q;PC0QN#R8>,-C!Z'`P!6ULYT:TPJ4T.6@:C&)2'4^K6(!DAK")LY/"5UCS[L?L'[$JELD:^702@!>-+ZI M_>,8PN`[DK+(T8Z43XHMOKATL_4YWU4\:\3M[.OX2+5E!@JKV'W%^?*@.IKD M="N(V7?=_&@$16J!@:F@M#"0R\JDKJKY"_3NKHF MB4?>H\_]1[_K7N/AV:C]7N1KT7(GGJ;J__/>YL/5PYX1*_S MM7#MJ8GZ4Q/UIR;J3TW4GYJH/S51?VJB3M3EJ8GZVDW4`SG%Z?F]EOCQU(3] MG[@)>P0[;%/V-='CJ8N[&\WYU,7]J8O[4Q?WIR[N3UW<_Y]T<0\8VAI=W=?B M+7.ORG5O-/K>:?6LT_M9I_:C7O>56>6LT_M9I_:C7? M^]`_<*OY0&CJMYY?2UAZZE?_S]ZO/L"3A_K7KQD20:46$ M/F3-&'`?9[KN$HO[A)AN#_#]O^,>X&OT\8WTPOS*3KXV,2':!WP]W-H#W/+[ MVF]>50N`Y:O=G:W7G!3CM/@AAX@S^$2\WCZN[1EC=!M$HDE:WVLY84J@>"A2F4RJ&\J.SG"VRMF6LVS4G)QY'U'C: MZ<**[E6YH[)V&)0@2S`&46.)U4'^LWS![U-C%%VFVL@WDF%@!-*)!]+,K5#@ M7H"]O^,+L$Y+6*T`#-Z,1V'_#VFY`OEM"VBA>3;,7N%IEC/12MQOR"1UFE5@PB$JX#CGS.1^_[DY.*I>[D^VU^[>SE7C(VV M+P_`'=B\7,%9H@LT>;-2F?BEZX*@<>F)T[KG*R'.MZ:+$1B>K$A'Q)@H-.= MYVC5-1;HR!(M!;158*7I^G*[T:%C>A2CV@2=G4:[T01;S\[;R?45Z?-LZR_2 M+U"Y59`E6AUYPAW6.,I]3L$:0=]Y/PP\YX`^W7(QQ:U."VYKWY9=H>%PF76!3"US;3*U?+H)^%'*. MG:^HV(*W61<\[FQ!@%#FE0YXUJ27H-P7.(P;9C"4%B`-+=_D"#( MN(<(P=&WR:RZ0Y,=9?G^T,&=/A[U>7$&2):)!09HL:2R1?O+XZ6SM9H$WM=+ M2EJD?#/>)U5(;E1F13OTA3/]Z9&6$1,C4Y>0L\8-92%CETZ$T]7N3`QR?)%Z M86M+/$."__JTJN\+=6P&,\Z#8(>V&T:LN/0IYWG4K,IZU@M7E67CNL2DLX>3 M_9JEU&B;`H6T^ND$GE%EK^I7;"V\D&3X6Q[\F=>R*PFR#Q+%+ ML;>3OV0P$.V[WR+.:M52'FMI#N;ZN[`I!_6I=&D/JMYC$@;7.1OO59-K^-AC MVNS*M*/TZ*V-LPYD>K9TNE-R+S4LI#'#;"G`:JRVR/8>I_*#'?\>?GF--XO- MP$25%I@FGMI2%4XO]8WX3F((<5ZVV%\9'10G;)];#XO-6VS5^QH@F4Q\VW(= MX7.1MEP,(-B[M]7S_E(P_C*ZU;6Z/*ZU_;4B`AX+DK^3+I9K`8#?6$3[7CZX M4:<\=?G4J/*I4:5GP/\M&U5^#6M_J]HT+YJM9#OY\?)MLOD\DA[.DC\M.Z+_^@7L@!K-R\XE@NJ#9+R>"Q%X_VJ66 MF#M8`248X`(E7/-J0!Q&P=#_8O)S,K`W&+;6FG$&QK;^T./A77^2])C8IO?B M!]A[:WCAOJ#7?]J3^0*(NR+@4!K$?.F'-@E:1TCZ/OSO].3SAL/_P M@&G*X#M.%-%J-'IY--X["$[CY3'VMPF`YTF?#UW4\=YN,`/\&$X[)),^3%36 M$TD?*1X&^.9)J9^X,LB[H8_%ES1*OD<[0[@R+>2>.T)N9,I`YEU#4'T8?,`; M/K"&\@XUE!5SBG/:9L&\?AC(JV`:%TL#FN#,@%3GP6T1CZ/^_'1W^L MRFU]@AQ]R$$FY%M^!/9%Q-^Q$;X&\/*,PV72WO$73DVR!6W&48I"UHK!<9FI MSG2X:B$'`PN)+59J7`04/]41@URF%&$E6D6P-!'SR"=I"LAB]2,SQ]S,H>)S MA%HA1V;A3(QQ`R*.$3)141N$WH<<5M*BZ0FK'5&0-<=\EV5UR^?U6:IW!'AEVTBCP?<&]-BX[AV9)5#%'U"P']X2OJ#']Y]Q17@,P@F> MV/X,,<4Z;.L;W#FC-7DK#K[CJ.0_VZX0X29NQZ:_1__A)VRRO",MMP.8=C=C MT^8Z.!8L^BIJ;$#S^)O[\6^NTX;[9]?@,'1GG*QY(`280R=*Z1!)TLY/,0U( MY%KL_$)M,,Z]'KV7879Z$)6$UYK_XNW[0&<:'X=W_<*V'G,Z;VM"K1V1`8Z8 M0EE"`Q]ZX54<5B8]J]^DOJ3X&Q-*&'+I%0_7!M"P%'7AH<-7?2!^LI8@K$1K MIBA9A**<>R'^4JAXM59T'&,V;RB!E\L#$-BI4%U-J3KB)=L-B!&:MW[!1`'! M>#?0(^8A,TQL(T=Q##M3UX;L!#2)'@JI"QY*^2)3R$\?V6;235T-^V!+0UH=J,Q=S\6Z MW.\*JUD!^=F^OB-KJ/A&T?CZV^VL`K?VHK?$?$EH#_68= M<#VVF6L`KCUSJZR.6*)-[AW%SD(-SS*#YA)'TX+I9\5>NK`6XW MU'4J!H[D>?)"MW>"/6&N#9SC<_SW!W9*!5_YM**5E,.3>4X&9+R#52@P.DG$ M+FL?MD%0R2\JGF"[/E&`.!;`LXCHK2E0WP?<((_M`-6?X'N_#1`%);H-+E?M M\,=HFY_1XWO\!`+9JF8X'H*<+$`1U3UPX&]I^A*LE/%HVO[U?Z^`H/1_Z;=A M'`\9=T!``!?&UL4$L!`A0#%`````@`1((&1\#E_K\^`0`` M:0,``!$``````````````(`!?P<``&1O8U!R;W!S+V-O&UL4$L!`A0# M%`````@`1((&1YE&PO&PO=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1WZ^)(R= M`P``(0\``!@``````````````(`!X1<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1^??H3HM!```01(``!@````````` M`````(`!=R(``'AL+W=OFH0$``+$#```8``````````````"``=HF``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0# M%`````@`1((&1U$WB+VB`0``L0,``!@``````````````(`!B"H``'AL+W=O M&PO=V]R:W-H965T MH@$``+$#```9``````````````"``0XP``!X;"]W;W)K&UL4$L!`A0#%`````@`1((&1\N="H:A`0``L0,``!D````````````` M`(`!YS$``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`1((&1W/@-KJA`0``L0,``!D``````````````(`!;C<``'AL+W=O M&PO=V]R:W-H965T[DI8*$@(``.,&```9``````````````"``1X[ M``!X;"]W;W)K&UL4$L!`A0#%`````@`1((&1RD0 MK]^Q`0``%@0``!D``````````````(`!9ST``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1QL[LB.D`0``L0,``!D` M`````````````(`!!$,``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1X9,1D(*`@``]04``!D``````````````(`! M;TD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`1((&1U6)S1X``P``@@P``!D``````````````(`!0E```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1ZCKAIWV M`0``:`4``!D``````````````(`!6U@``'AL+W=O(!``#C!0``&0`````````````` M@`&(6@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`1((&1S_R2>/:`P``/10``!D````` M`````````(`!A&```'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`1((&1YB(*ANY`0``;`0``!D``````````````(`!@FD` M`'AL+W=O&PO=V]R:W-H965T.[Q?W73D``)SW```4```````````` M``"``9)M``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````+@`N`'0,```A %IP`````` ` end XML 12 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable (Details) - USD ($)
1 Months Ended 3 Months Ended

Nov. 12, 2014

Oct. 05, 2012

Dec. 31, 2014

Mar. 31, 2015

Jun. 30, 2015

Feb. 13, 2015

Feb. 05, 2015

Nov. 13, 2014

Credit facility disclosures

Shares of common stock sold 19,488,814 24,932,392 5,437,200

Value of common stock sold $ 194,888 $ 249,323

Public offering price (in dollars per share) $ 2.75 $ 2.75

PDL

Credit facility disclosures

Shares of common stock sold 643,382

Value of common stock sold $ 1,750,000

Public offering price (in dollars per share) $ 2.72

Three Peaks

Credit facility disclosures

Shares of common stock sold 1,375,969

Value of common stock sold $ 3,550,000

Public offering price (in dollars per share) $ 2.58

Term Loan | Three Peaks

Credit facility disclosures

Term 6 years

Interest payable 9.00%

Face amount $ 25,000,000

Basis spread on fixed rate, option 1 LIBOR LIBOR LIBOR

Basis spread on fixed rate, option 2 1.00%

Effective interest rate (as a percent) 10.00%

Optional future additional borrowing $ 7,000,000

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date 120.00%

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date 135.00%

Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date 150.00%

Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date 16.25%

Upon certain events, the additional percentage of the originally advanced Term Loan amount owed 3.00%

Revenue Interest Purchase Agreement | PDL

Credit facility disclosures

Term 8 years

Royalty percentage on net revenue 9.95%

Revenue Interest Purchase Agreement | Three Peaks

Credit facility disclosures

Term 10 years

Royalty percentage on net revenue 3.75%

Revenue Interest Purchase Agreement | Three Peaks | Maximum

Credit facility disclosures

Royalty percentage on net revenue 4.80%

Royalty revenue per year $ 30,000,000

X

- Definition
Percentage points added to the fixed to compute the total rate on the debt instrument.
+ References
No definition available.
+ Details

Name: axgn_DebtInstrumentBasisSpreadOnFixedRateOption2

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents potential future additional borrowings on existing debt instruments if certain covenants are maintained.
+ References
No definition available.
+ Details

Name: axgn_DebtInstrumentOptionalAdditionalBorrowings

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the royalty as a percentage of net revenue.
+ References
No definition available.
+ Details

Name: axgn_RoyaltyPercentageOfNetRevenue

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the additional percentage of the originally advanced Term Loan amounts the lender has a right to demand upon a change of control, sale of the majority of the Company's assets or a material adverse change
+ References
No definition available.
+ Details

Name: axgn_UponCertainEventsAdditionalPercentageOfOriginallyAdvancedTermLoanOwed

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.
+ References
No definition available.
+ Details

Name: axgn_UponCertainEventsInternalRateOfReturnOfOutstandingTermLoanLenderHasRightToDemandAfterThirdAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.
+ References
No definition available.
+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterFirstAnniversaryButBeforeSecondAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.
+ References
No definition available.
+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterSecondAnniversaryButBeforeThirdAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date upon a change of control, sale of the majority of the Company's assets or a material adverse change to the Company.
+ References
No definition available.
+ Details

Name: axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandOnOrPriorToFirstAnniversaryOfApplicableClosingDate

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of any adjustments made to the stated rate to determine the effective rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=axgn_PDLEquitySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=axgn_ThreePeaksCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_RevenueInterestPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies (Details)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Summary of Significant Accounting Policies

Expected term 4 years 4 years

Expected volatility (as a percent) 76.24% 79.80%

Risk free rate (as a percent) 1.21% 1.20%

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 15 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events (Details) - Aug. 05, 2015 - License and Services Agreement - Subsequent Events

USD ($)

item

Subsequent Events

Term of agreement 5 years

Number of tissue grafts 355,000

Number of hospitals 5,000

Number of anniversary after which the agreement could be terminated 2

Notice period for termination of contract 180 days

Forecast

Subsequent Events

Capital expenditures | $ $ 400,000

X

- Definition
Represents the notice period for termination of the agreement by either parties.
+ References
No definition available.
+ Details

Name: axgn_NoticePeriodForTerminationOfAgreement

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of anniversary after which either of the parties has an option for earlier termination of the agreement.
+ References
No definition available.
+ Details

Name: axgn_NumberOfAnniversaryAfterWhichAgreementCouldBeTerminated

Namespace Prefix: axgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of hospitals.
+ References
No definition available.
+ Details

Name: axgn_NumberOfHospitals

Namespace Prefix: axgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of tissue grafts.
+ References
No definition available.
+ Details

Name: axgn_NumberOfTissueGrafts

Namespace Prefix: axgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The period of time covered by the agreement.
+ References
No definition available.
+ Details

Name: axgn_TermOfAgreement

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for acquisition of or capital improvements on other tangible or intangible assets not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireOtherProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=axgn_LicenseAndServicesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 16 0001558370-15-001476-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-15-001476-xbrl.zip M4$L#!!0````(`/>`!D=$'3H5%8P``.!7!P`1`!P`87AG;BTR,#$U,#8S,"YX M;6Q55`D``Y&^PU61OL-5=7@+``$$)0X```0Y`0``[%UM=^(XLOZ\>\[^!R]S M=\[>R2>;>.Y]R%%N`9HSED>TD[*^_)?D%&VPP8,`0 MSYSNQK8L53U5*E65).O\'^\C2WK%S"74_M10CN6&A&V#FL0>?&KX;A.Y!B&- M?WS^RY_/_]IL_M_EPU?)I(8_PK8G&0PC#YO2&_&&TC?,&+$LZ9(1GI\>RU&R&;U\B%TI36Q+5J,=*_.0JK(G:/:ESTCY19:4E:3U9Z[5:TOVW MH-S["[,D(-=V/S6&GN?T3D[>WMZ.^>UCR@;PDJR=$-OUD&W@1E"R9Q'[]SG% M^>,7("LJ_CY3_DT3I95NMWLBGL9%H2*3Q&63];9/@H=14?0^L%.5HGP-.HH(FG,'&Q<3R@KR?P(%DO2%22SCF@/=<8XA%ZP'U)`-SS MQ@[^U'#)R+$XR>+>D.'^IP8'LAG!=?SNF@WI)*B(*Q&U/?SN28_8\$";A=+` M$R.\3%?69D_/\1)-70.7S5SQ`UHWM$6]\\4[<9][J\Q-0 M@.\Q^MV]0@[QD/4-CUXP>PXA>_Y*[8&'V>@:OWA/P,#DS0?\BFT??P$R&':] M>Y\90U"YBP%4R/O15$4/R!X$;T=WOJ%W,O)'0;D`..`+"P+#*[@F)K_3)YA) M`E"2U254N'G#"XAMP*U#H'GYW+&*0D&;) M)%`N,!T`7&\*N,9GSG\O![GSD\PZEVHT1*B7!7[8>C'TRR0F%F#C\:[.=GT;T4I:FH4$=\-RZ(;7.F6'0O:BI1 M^?E)V'7F]"/]6>']IL5[4?M9DX.+2'&_P$@RPH\>-,#Y^4H-\59*N1^Q!1U\ M<&&;WQ#['7OP^^;=`4QQM?4]$NT<'B?R7\3D1E6BU92YT5VD$E"LW=3DM55" MJ55B'U1"V:)*A%9"3ZJ$7JM$I51"+V8E]'*M1*T2U5:)(E9B396X<)_O^ADC MQ3VC4($WOK>0[0$`-W_XQ.&L7(YC_SIVOC&X=$-JF5]&#J.O`E!W/]2@`)L3 M=9C#9]F:$,2,7FH8B.YM7\#QLP,4ZA1OARE($0G?^LPFGL\P%+KK]XF!#U&N M(NQ6OYN15&:>C[U-B]^U[]@C$\H<1(F M:O\5!B_;Y0/9(V:O<.'NB<;'B:TL6!-YKTQU1,6LWFIQ7H! M_6N_'8@EI%B8UZH+.A'MUB;CHYJ,3>5-:IM1-9M15N9D_KJ46V(3#W\EK]@$ M5L$C(R\6OG!=[+F7XV_H-\JN+.2Z*>_]'GR>OL M@`W'4B6CZ,'UC[1%8W;R,,ASK_9//"M'!KF43 M[UVLDF702\VQ:E5B32LI]93YX8*=,[K+??N9F[2KA4@5]BA7#I&M;=&-EL;N M'(&T#Q0L0=S$XH"=,[JS&?+-IN+K$*NZ(=8N?-?ZTUK[J8F'_VFM0^P-M9;O MP\11Z9I7SU36,Y4%%2Z>@*S0C#R<[6,T:K6JH9$)?72/V*/Q-@;K+?>0N5]Y^I((?D:F_ M`Y.C&O5G6';]&9;,Z>YZ@UT5-MBM-M6_UGK'781?!ZD86]N7M]-01UYR7?8F MW:Y]SP$?KGNV-WEF7+V\7K-6G77K.TL M@:8_J\K4)P?Y<0")6#*M1/]"5[3JNS-2!QMDE,M8[F_.@EG M:K%M)1`)!+:('*\IIYJHKR@4YI#(ZZ;[' M^EOIS'L3=F\[:U6:6D[WR0^IELL:IEHMJZ26^Y#:V0NU/-CE3',G@O;4T'U$ M^Z(F5BA49NG/[`K30A/>:GGGCNP<@LU]'+=*K*VP4OJOS>8O-O&D1VQP!6XV M@]L^O\?9Y0^5TYA)D[P"@9/&>;GO_@B#^M.4F1]AY/H,?R8NU57EM/?+X_7Y M271STK.SWQ?57F.;CHB=5S&W&:3G#A'#;E[-LU6 MPZCI&UZZN?Q:6MFU$`^/BE:ASU3A>ZSG_M$O3(0V4T.`G`,_B]:AYM21A7Y^ M+3.5Y.I&L@Y0T"??L?"TAL+]&TNDWZ:?1)X,\[%Y14?\)'=AG*]\QGCQ4/\? M<#^C-TN\9?$HH%DRL4%&R'(_-;Y\OVU\5I1V2U;!>BQH9552)B9S(25:6^MT M.DM18IJ$/T$6E!M1^U'([XE>48AZ>>1[85G4$^LH4J3-']ZF"%5G*#V5NZH< M0U:R:^B]>W[N>_62!75*>5#(;5ZQG%G.G6/F0&V"0WP/.-=3F9]RK!J2<,*0[)\S/WS ME6BO$MLS:=?4O>L?D`%=PY_#4UQQ;M;GG*/#45H$#_5$)0EN`S%YW@.;(F0%Y2 MQN@;L00!O<2?!'%AD0*4UP609OE)P""D\T#&RO/%=/]HA%!%2>0AX M_XLAF,]+BFW7P):%;$Q]5\3S4&$Y20NYI2FMF*+\9E:GIGC>0I5;';F['#'? M81@84>:1_P0.G6V"5()M05?4S93Y M1'^Q3&,BRE]K96A` MDM\$''_`%X.&) M+@X\D'W73QH/44=L:)*JFH%0\6D;_53M3"2U)B4)GL)@X(G>O/,B/G&'\P1; MU6_^+!"U)J?"P\5,)Q&*,Y8`+W(<>"$H3+`+;L0W'WXY%@XK"*N&P2;HG93M MW@M:-9.1RJ+I(H>FG4:1R]JP)"%FU,#8=&\9'44J'>NR1XW??V+4S74!,C\D MMRA=T$HEO8H1D*38#U-C#V"Y"<-!(@'\")$\[#]@SV?VW#S]KA,O2V3VEV0V M`=,#=F%DXC,"LS,!UYP:\Q?;H);%UPP4GMA8G.R-,KTK-Y]D(5#@6XS=R7-A M5:L7[I32T8/)+"V"L#C[!PC:O`QD!FA*&:`E#>MW[(6].F=)Q'B^86%>KL2ML??:KR&%4RTO M2U-5`\C/]ZW%'/+Y@RO,/$1L08`[2:LD)7;'R(#`/6M\8;YR#\N,YBGOWJ;2 M93LXE*=0%PZA*(7A>0!F.5A0G^_QE<0\61U5]!7S4>6?R'T@@R$$--=X!`5$ M0NYI2)B9R-*![!R^I)\[/U<6Y4,A7TN^![@K;;65A_P6D9HGL"C<6;;I6\)< M+]'TI>]=XCYE^!`Y!?,JQEBN\G:&V"5'.M!U3=2@]43DN79)K@U:R)._L M.W;/"&5/=%K)]E=J:HE26QZ@0$+\0ST7X#>8W'>XM=!@B;BO\;D/[.#SDYE* M)G6'T]2WQ#60]2M&[";8*K54,\UHR\Z\&B=M7E-#K"\)BD03BX:_3$S;^/QO M-6@OM[:\!CE-RS?'_\YJ,*YMMKF`EE4`3>[PRJUQMD&N\$NUH\C-?Z=;X%5, M*@YZWQ7FR5WK"^CU^\]XO%0+R5UAN37.-#A)(`8I^40WR[`;G<*S`:K>U52M MJZ9HF=/8#&&!;C]@AZ^"L`>/'O*6U*-?^5ZC135.MWM++,RN0.8#RI;#_Q&X MAW>EN`&)[ZY!]CA)1*KZZ;8?\("X'E_=]!V-EE.OBW?Z$[:/I"^V<9QL+UUE MN,TJW%4;91SOT5@LM(91+M@5])6@%V(1GB=?=SV1S#5!4Y2N?GZR0KME$EQH MR1'0J^ER1U'5+=%[#:8-1B(?W`D@]]*"OK&4X'^TO#.3O/XX\,ZD\+?D>F,+ M?VJ,$(/@KFGAOM>3'>\LO&9\L!0W&ORMO_SY3W_B+SKIUW@!*?JC=*`T)ZE) M;+[?M"/>34G_!&_+*7.']'(.;-?7&?1 MK]);CA1%"C5%`ILHA;HBA2OZW52SD=1.G`4R+"PC=1D93>.U6=*65Y\\?)T$ MOBC$%X?X\F[G$KXZD/8E;XBE/N7[1<"0]_8;^H1)>".F-P1@Y+\U(N7U@IU; MV+(<9/*1F!M!<>TZR(BND44&]J<&3QQQCSZL[H4R<,";?((*.2[N13_.@G:D MCGP,39U-&Z(TLQZ++X-K4WH-FWNAGD='C33UI_JQK/_M+&S;HTY/`1-E4QM+ M/UQW^?]2]%"TF/LTJ#W_>6`H9Q\/@]ZL`&_`3(C:%&.K*46Z9K[#M0\:V!L2 M$ZQN0F6FVUI+:=(*$RJ09RXG%%DY;M="F1)*&N\2();5&N*-0MP]UFN(-ZW% MI^T:XMI0[#?$M:'8@A;7'L7*$`?7+'6]=X[V"S)^'S"(W$P>8E#6DWY`OD=+ ME45N'%9[U25*0.2.!*>]((0L*I/.DB*9DV[IK)WG*2)/@`GB9INOMUL@6WG' MH_1!RO9?/K"HR4?21CKC;CW7@Q18W1D/5[;7V!`K`"92U)2C>I3<#^%MI&/6 M;FGMEE9(`BMWN%F9+!W\[G1L'>A'WCT^>UDUAWC;IK9'4- MO1XU*M4U#M5QNKJZN;F]W9CK)*_2.Q8L'OD8/6/#@EE_D%AA"BS;M!\*I&7H M^G]M0+DSI\JJ(8J"V"J)":"P%>U82X\$XO99`YI^8\CYU`C^C5=9)=9@]2V* MO!YG-7YZ$J[@5(XZ6N=(5UL'YH'6QF3?(*V-R0$8$Z4M'W5:W=HSV8XQ.0@? MO[2MNNUY-5K6A2Y5;1QUYS8%KMU[P MOJKBH7;A,L:?C^=QS,K69;ROZER&`YX]71_-Y.L0*]D4I]+OJC]KI1^[^%DZ@J0 M5VU@U(YTN7.DJ.H^N]NU":A-0&T"5IY\.M(U\(^[>NT%;-`##B[%>MHI_*.G M%?ZBFA/1'%0+;7YJ***:.?N.DSQ*R8OEOC29\<'(N5^=+.=$8*4M=UK=7$J+ M?/ZRC,.`E8[6T?FG]E>A8W*RTG?LE?%AT\ZIJLF=66*R&EJ+I,*?+@5X9%5; MD2)_Y%O\(-1K[#"H54-WJXJB_ ME5HNE^@EC+'>*8WHA&[?]6^)#=6`^U+PL/:(Y(7V1=9T+?EAYSFMED3?U.>: MY]/7UKNMT[+)`^O`788@%[83*),4E$FWO@+=+555"D*\*;)7U8QV)=!>BFQ- M416Y7+*G3U,L3Z555>YV\XB=;G9]$I?6WM`13YO<#1.YBJZJZFF^T#>&8W$2 MU\:18<3/\4+6C>N!PQ;Y8AECZ5I']TVQH,_PT-)3+.20-47\+)++.NEM:/:T MD^PI62#EM5-8BUJZJBDMK4@S)<1RBJZ#2G0ZT\UE>RL+6BW,HZ;JJJS*A1J] M1"YQ[_JA0S5]/$M]3$1FRE0Y+OH9(P$O__+_/<,N/QZ1HRD5R055.$U55L)Z ME6SUTQ#S+3K!$3BANII\TE607F`2Q<=BH=$690X->)OT]5>=5JKXL[4*"^OCCA+Q/BF:C+Z1) MFB+NZN)N'XCFO'G\!#9QQR7O$L2HWE!RQ+E4KL2//C,S:N259"H]E\<,0-TS M=RFY#-$KEEXPH.$P["`&Y8@M),1,'OE);P1H1!,;Y3`0)3_`S94&V,:,'S7* MGV/'"][E?'+;"%?\0"8,$0N!G!'$$:@#,8`7AB-MC.F]L&T?&@@.>I*`"@AX1]!E MFC]+@:"30IS72*Z@"/^L"!DM)1M.J6]'.`BE#LBE#K$Y5D`8]'(4.!Y'`&>? M'RLO@4@D9/[FNUY0CPU4NORT/,$"DOJ(,"[NB56$BN#2MZ!PQ&6DEF$Y;&:R M]I!X*V(Q>I.3;U,O;AX,%)0Q00T\`DJ7T6;?!\HYO,?2!?QRR<`F?2@/=DI4 M'MJ>B0'AF/"SL%PDE">ISM@B(P`U5,H)V%#L>,\'@0W-5%&./#P?\@*_N$\,ACTQ8Y3[+<[IZV$LY3H2;+H;)PFD17 M3F4MF2C9(I&%G=^.JK1.N\I.D5R8,6^U5;6[$22#HQ[!I6`\.`,C+?XM+['0 M;'6Z75WI+"(]FXX-<;!42'^JRZ>@RAMD`*RM,:[>"7AGP<+2<"G#E@*9C#8G MOK4(KT`XH2?:\_D1N).A@>,JQCGQ(X%P<)/:AC@/=&;S4?%A;35$#B72F2L; M40WX@I+C0ZC@XMCQC+TT?L/@DN$'/KA'*:]4'#\'PG2%1S8$?0`/R"(@0A-Z MXPMW:ER/^8&3!BT80\0=P\#C!L_.\QGQQD&3/&X0\8++`R#POEW)H]R'%HWC MB5H<2['&3#\2'MD(@2L%?[A'Z27\3DX+\?S`C8*WC_ACCZ-\)+T@B\<"+KP\ MEO"[@;G'BLW0^8+MY^(2\`?X^[G*WC(_%`^1C!4PUU9P(&Z'$^& MQ10I9P:@`Q,7M\4Y,"G\X#[D"[AS4`U$=1($]5`7=8.7>%5)/Q$L%+C+$B/N M[]R/-_*P*.0#;LC1*F0QIXPL'0&X0E/XFU3X9P!FQ<\;32[EXO$(Z8^#6^%% M3[CU3>@D=,"0,]QE8DG.#'`2P$<&=P+]BG9L4Z`)*]%(R:(#&+%_V_O M39O\WXOX'/D]/A#M"I1&URY[IB&HO?7R>NUW/Y3X3YY,#14(2QQ2I M(<@J:W[]RTP`7"2J2@M5(F7,1'>7)!)()')#(A<4:N2ZLY:+5*^GPZ9[0"^CRK)8&FRR M*?[WW?-NR^YTCA[%$O].4*=/.2=#Y`$^S,,$D;($',"*0(<_>&!\H*$0+NY( M[1,BT#VJ\7,T'(-6_Y2K^5LX!>VN%U5"$8]?!!3)Q1/*"W8TO&24';]J2T8Q%&E)+MAA0K MW9I.*.B)HV']:=AI=:K8:>!8Z>?;ME^`"D8>5KW5UI0Y&"^[DO0LJ3QB#V@F M@UU)CE,0E3/I703=D54K6T1C1),<7>!WDJ08VJ%@B:%@0^)0 MK(^BB(0OR)R&NPP;HKIOHA!]Q<0#FK9KM[PU8I::!+CM>B$O!9#./G,Z(;HP M:03'EB^>$`FWRI:WJ1Z/9J^/WA2C@H_G]VP/"HJ:%(B>Y+\X\^-YJBZ7%-;U/1[JU##7[UXKO/P6@2RS$L((:B2^6/KABJNW>1J7JZT!$&OK M\_Z/AUON,>M7SIS< M"+]^Q&[QZ90[=$>UL:`G3`UE61\+RH&4\+0KZV0#HY^G>#0(0,VI/BY>-/_YLMM\:J_6B#1 MLD@%3CS/TW\8'&Q4--5_<"IWVEZ^L4V_FLH4N&'1IX@B%ERZ:+KAT>T1C!UKK[P-7=C(24 M3-4IA6U]JB=@^H`"H`P>V\8;5;K\<[GW]2.?,?\=4$^\R@(X;]Y^1!]MO+IE MV^(X-Z$?]GN]Z/NHP1Y'"A[,$>W/^EU>Y.C">Q3$L,I)7#70T]/ MLE&YR8X"JUH\[0+5UFB,:L1''NRK/N9,#K9*OK((B&H`W5%>K`/;&U0.[,X! MWD1S%B[U06AV(/QQ.X6M'=AI@/`."3_:CP> MC;N=*J$X*$6ET^V.NMT3(&,O,.Q.;S+N[[,G:++JVE45TH;=P;RX?A&0_%R' M0')0>MZPV[?S"7I5`'((A=C]3K^[0:D5H62_V*M!KU/(8GX#B?0E.*]C8"!>B)7+B=Z9Y$0O+RBZZ(&PMXJ()U:V*U*D M&^-)C)Q+M,LP,./O-[ M'B1<@W^CPAU3K[OFDYOQ_VY;.B[AP"4^HSK8>:%VI^$K71=Q-\.]%C3E4<1= M632`DPWT1QBHF!2\T3FFD,VDUY\46.B)R8Z';>S$O.18_!6#!F_8 MBFZEZA>77>,$__'."?ZRG-BGI4Q9,`%:1R7VZX2-6<0PV1>CZ0"YH4)N'*;Y M*17$ODX&K4$E\:+DPJ<,''+!*J`!4I%@+@A`C4%%P$X=2Q++!\J6PL@.K+.7 MYAVGR?BE6?BE!$GC7=TQL=8`BO)<`@PW9J*"@,M>=]SJC8;'XPH#<8X'IVL/ M6\-.]WAPB@41MN,^K8"`0;!B*4^`6'"@DN4,)["<[J`NV.V/^BV[WZ\.NX_3 M]1;'(+%[G^/-%LQQI8A3ME7G9/3%P!E#M=1I1`F;\Q.SV4.UFI95!.SH#+O:&T M>X="J>)\551>1L]YBO]#RY1K$BDDE?*_(RO\$<;_RP%()YP%^T8=;=PG3X:% MZXJ3`;F&"RE-%7]_"=_F\VU74FE,"^[FU@"7 MPD7^@*['BI2$0U@!Z<8 MMG(H/O#X8FS&ZR'%6D!-M(R,UP>(2)]E887*FD]BLQQ]RV8M*] M+@"0LX]TM@$5:J+QA.7"H#))'@MH1?$5I8P%C(PT&:2/V6W9@)0G"5^5SZ;K ML6%>?"LKJ!2E59US7RYS_;:8ZK>E;$"5C9D!NE:9JUB8S`^#F82;RA_D5BQD M0F(1A_)TE2S1!:3\:1$]R^Z9Y\M\N#`_VSGMMIWDW)IH]+!,VD>@'G>]0&FN M>OQ65]C>).=4!`DR"U"H?Y..A1Q5V/6%4I,,>L[MS;5,4.T1AA`AW7L%O42@>KP>=7NT^,LJOJ]_9O\+H MC<^$H!O?]#H8CD(!)FRF%]IBQX"P\:#8<>BI-=1EQ3>@1G9?Y6@"Y\AG7&1* M@^?:53PT-V_!^VVJW>U/NOT3+/+(.(?!:&2/=H-K(Y)@;ZAV;FT!;-[;C<_W M`4I:"4BB^;9)5*#0WL-_4"'5_'+3^]^=EOD8Z(U:_U8QD3[Q&?L@%-[YG<$1 M+UFD..MV#-*>1AK,DT>:/:H::;_)XMT8[N`NX!5!123ON;(ZJHL1Z8$\Z.93 M,YZ8N0(P#TE4L$=VK]\?/2>8AX2P],:3SK!S#FSNEVTQ&1?[8.P')NK0FRB< M>G%U=#@8#7N];B[*+#?+GM,?0E\P][`WZE4Q_2%T,^GU!^,">1^[^KVF'_1& MH[[=W6'Z#X$3+O@7]MU4$*[HBD!BU`*4'ERQLC%W`<^P-[O=#!0*X(8Q.M:Q MO[.;>K(]N2LQ^Y[&4^1<_+*UAN[-$&!!/%F,+)BIRKEM2T>$YH;BLL:O\MRK M4D6RO!*.JJXA+'D-0>YW+.8C^V*H&DAT!X`7E7IR5T^#H#+9!0IO`ORL@W$: M<)*&?*C@$:R`#,-R*NB+-P-\@04MHY7E>E,85OYPQ^,'SF5KB^RV(J)F'`CZ M'77R4:6$"(P[W=NG')ZV=4U7"!*!3'>QQ*`46/*]A_OP,(<993GA!=8F\KUO M&)<2SUE`&T:UD5C)ZE6U)"I*C!U,?+S2Q1FI>T79M$@#LB>%P/[8'J#?Q<)) MN)J2\9EX$BZ%7D(%4,K4VP;5AZQL94N_E<2`IO^DQ$6]5M(+E4U2D[XY<61R'B@$U1VS50%!Y&/Z+U<%4[35)R/`I"?1%)I+;,I2U MP43+\K`MSJJEJJZJX`9!].3!F`YM\):W26)(N4/EP9#O9,\ODH+7JH!@2:17I/EG/N*MR-^[_$'H-&[%3T:<1\6A6&A<""% M9YFL'Q.OVM9M`G!DL*$(=?&DID/7DB#*(DQR3"=1Q4#,17@3',J:%5H0K2@( M;I/E"U*XI%RZTA9J.I8;CZ1Y.4*!U:<*E0_X+\#A-JB+1>H?J!E3^J1LM`-0 MIS>]N2B_[7@`<-(7M3JC`H`4,4J>B=0@,R.5!Y"R<;8U+#9#:GT,C7"J=*:V/D*74U MRD]-:U-U#\]Y`[W-BT'+5BI!NIW.HZ2:F[4J`/?S MT76!G48507B#;1D]5R->!X($[B?43%6WS+ZR!_:H_RAV=P'HY(O:SQG9LT?Y M"ZEJUE1TO->Y"TN-L_W*DZO*_LH0;BGZ,!E_563\%:UN+\,R2[E0>"*M`ST- MT:T!9OFK9J,_QU\/GAO/`3F=O[[09G*&'NT,_7W0%IV^?+05_I?]X+>>QQITV3/5ZG:N+BXVC]*/\[*)GB::[ M"^,X7+PH0C\:M'O#O[Y6<\?A\I4-_!Z$`;?^\G:"_[?TCS3CUE_EZ-M_EU)G M\^>Y9'0;U@:+45A;6]AA1%$<.;SG$;9:>S7W7!!A.9)9G^LHHBD2C"*@V-UO M4SIV>]@WFU+[%UG.8L:HKW('-^^H=]V2\ MYY8\XHD9EW0&>ORO0_83T`3GY@#+!CRQMW`V[IJ]K7AOT]HF)V'&\UJN%[EA MAADO=V\+\09&.S9CTT["D,8<->9HC7;@8(;;W).]#[UGU4DB]#W74G&2]4?W M*>0;WD$;X]"PAF&-,M;8K,AIM,8Y6<,83L9PNH0=>&Y=4"[-ZXW<6NF"ETG` M$A<3GWXVUE(-^.&`&]^&\P!-51L,EU[X&@Q?T'UO_?^_NU>F6)]`5,_1&SYCQ?ROVG(?2X@?^J'+'Z%2TU_U=FNXV&GU>D,+\S, M-H*D81@U@J3Q@F30:8T'$V.1&.M\9X3769JHRJ07:'C7CYB;H17K3*TGO5N<7:`0WZ:QW-M5X=+1:`RB_:5JSJCW91Z%6K3Q?]D;#5F]B_]QD M$]I($"-!C`0YFP09]%K#\;$2Q-@@/Y1M7BLI\E0EOP_KE>-:6$O^`DWQ^A'[ M><(A`5[+#1/<\%V%U3BCC0`P`J"9`F`P M&K7LT9&W4<8">-3];"R)NAS-3P0W:743YF[.1RSR-K M26TUA16AW0L_3Z-PL5G18U\([-'10UP=/4*W<_00LLE*VY*!*983"L`EM:8I M1>;1\\78YKTRJ*^IN]C1PZ65ETH3[/<=33;N6US M]/-5K.1K!%="OV`A)7^N`*(--R=WQI%V&'K"C&':R M^^XM8!C`1@6KM%N@6H]?)"ZE/M#H)GW$*=8"'IGK)D@%.B6P,>V]A8W:L*&? M=P]X/9Y\JT%HU9M]O+#L'8^:&I%;MULMN0GO^_[$IB5PX=FT@V'^LA>?\I]. M0#H8_`#L7VL*0$G54JV+-!M7LFM0?8P)5HC4J4WR/7%OL. M!217)W!^ZH^KV[TJ-FM8)^RH;GQU`@D[FQ\]R*%=3G_(4]HCEP]/-+_6![KK ME.V+>FO;U__;#UX M,76&M?X,0/5&0K5\?>^'D>KR.E'?`R/_Z?[S^_+XZ(=D9Q ML"_\.YX=8NLZ$;&W/L"7Z\+[;7@9]2$9T#Q:"-T0:7,EQ?ZJS*&VVBXH?<=/ M!!H2#V'DNP^>FZ)*J,ZN2+DK:M;-G7D0^N%L926"$&Q1A[*(3L[4;U=W"(AF0\CFJUGS4_)J"30]/"&PP:L^(%*_5O6W/IEY@=X%-%=N8^H( MC`]ZLL\J8I[Y%A#C-QXK$/AT*LTX0M1V/`%&8#)7I`U7-6[U*[KS;!Y`ZE:= M#:':4>-;V(TUZ_:;MK=%0CI:6`\KT,XN6V'[<0\;'T=>#$O"$RY@!6Q=U:*; MP6&^I7&.'19CU8"=`6^UU-Z&D5QVNF;L]9NB!+LRY]<_99Y/F^V0X6S=11Q; MOK,IO+X!QY?R?<(^=DQ!]8VO%/W[GB!\A\NT/QFYX8M#6_98]EFP2I&7 MHCF%:`\5\SJWOSEW]OJN;:&"V]4"M/PZ!RD64A+YU]'FII;L:A$SQ2N$1]". MOV5_[8G_`LKSFW$BM.XIB8HMX6F8Z^_A;R`"EBB=HG#%?.PSSGF%;NV22>V_ M5CP@2KB*A^Q5#F.26A`E0O:."=DB/N`P!_.YR'DV7.PO[B8.J-A,L'T*N-:4 M^>L*7X1:8L,G"W2$MT@6Z=X>>:`O6==/=K#JWPF+0-NTK(>Y M!UH+U9XV99CE@%7EQ:@NE5M(/2VT!A5LP2T'4`DF8D3NF]3!P1;8')K^7$<0 MV&F1^F1US)"3)Q MG9/Y;Y(H@E'Q@*;F=$,8#B\I'@9_!"@9T$KH3S(K[=U)3'BV8AG(YXO5#PK MF19Q;W&71"2:"M8@&4'5.SN.#K4H M^Z'2Y'JH>6<10OF<%`S#B@D M6/B"N_0G/`I+2)UFCUK.[:I)Y(^P:NH@_*6+0(EBV! MZ*C8V6U[<0K"_*EKCYI".W;_),1S5."KC.!'$:\N.BCX0]X8X"\RT@*)4P?` MA_*R@SF.5,[XFQ/"A*3!T9N$^684&R$P?F.ALP'")96-7U/:^%M/.'XHDHA_X=_C7_W0^?;+ M__T_EO7WW`M`MR)^I]:/=UWPY&<^_<>+MXE@ M+#WY(`:TV"]`;3H@0WV!!Z)?NH-QKV\/"J#E9SH`C/X!8-B]2;X(DY=W\+0U?\P>-/4SP@8)Q8`:YK\?73]*O=_=JS MG\3$AS_>(UF,NMU>@4F>G+$*$'?"E82PW^F-)G85$,(SQV&KU[5[PVZG!!88 M>J])=U]_;]";3`:CO>:\`17AK%*!NP_I_J)\5*F(S_FKI"$NLW`S+X'*JRWX M"K;9[T7]>CIK/A]@7#+GSN'&&J,>/S3.^+`5GR'J^!FVYM&=6,>W/!>##11Y M%$DSM;P%C!9(#VE,P:XM&2N+?HHI^8ON6>#LES6Z#:9A>U!(-?C+]^MW^T50 M/+U:P"E"_QM"+YU="8OVRV6I`?AOPB``,FKN$FRB,U1+0*!>)#-'!>)^8 MZ/">^1A:S62(D1\^R%0JS'"U7DZ]2,177M"RY%]A$O],WBNR[6E$N@06L?9U M3D,?QL":`YJ3]#X71XA=]V3<74UE+,PNVS''O_KD/T$-,&Y&3:T^^*) MO86S<=?L;<5[F][]&F9LQH899KS/Q9==+137Z:+]]*JR0:UC"L85@#8ZT,:]2*-2[5<&I``S\=QFC- M,([QQ^"+VC::.^*&_(@^,`U`:164?HJ6/*4WZ?78BH.BM)ZM<4^WU>_T6J.) M;41+O41+R9UZ/>CY1Q,MI7?O]=B*^@F3SJC;ZO8&1I@\CS"Y"'N]S@+EGV'T M#5,UEU'H<'&)9GG]B+H9X:EUIMJ3>N7/';1:#P9MFR[:P1$G:CY!+9RW07$CVA&5R9AZB93.I-6?]+H M4W:39,I%V-XF;O;B,%WS>`Z`UW+#!`N>["J"ZZS\FA"W<0#*ZVT]]UJ#WJ0U M&8R,0*B)E6P$0I.B+0X1"+43`5V[UQIV.T8$G-"HE1_W+9E?RPILSU8R?[]* MCE28'/N@AE,LCDTE]^#/(XK>/SW_3\-!;^]JX#L4#-R[4 M*->YLAE=8=+L9N'R\]80+Z]CNZ7:[6?V\+N^I*BP-/*X,^E/^B50;9VO`OAV MKPL\G@QMNUL!>/_#_(2*WQZ-MLZ+7X"4@1Y+H-J8Y0AH=BVT#2+@.&`P".Q# M<"-#P"HDK5[/'I>6M-X^8140[E5TNS,HH_V=`10BP5J\GZ:W,7#N=>#^DT78 M34B\#Z-;>,&#`3Y%;WSF+42%I=T[=C=?S'P?*(H+^.BQ.\_W8N\X?NB.AGWX M_R2#*3?P/C/N7.=_/!GT^J/A?A,"9@A#\]`'6TZ\^W?BQ:MCUFT/@8)&X_)U ME\YV-&P[8VC0[_;L0:\"T%0_LZ,(I-\?]/)R?'/X`Z;?%1>]?K<+O+['[&$P M^\*CQ5M^%_\1!LX."/BJWOV*[\;JW2^K);_^[HFO[/LL^(HC?@Q9`-C_S$'2 M)#QMB9!$#G8_2_M[_4[6R],";-`9#T:C7-G\T"4G8]&N9:%C__U1Q@#7#=L14Z"TQ[#+\5#4(;Q M`AYU37Q165'\FJ#XTLK@=TT9_(WZJ#_\36\=-Z7R.Z#SENJ[?!3;G7;?E,$W MU:T;CV(C*(R@:#B*C:`X>QG\-.=K<@L:UT$FFUKO'AN4=B617%;E@K< MLF[;K!VU_;;UDDCB+]^!!=^\SCV9??WV]<_6-(PL9L4AOHH17I9/DR\`M93+ MLL&\>^?1=0>8^+%W\D=INL?#W'/FUIP)@/GHT83W_7B(5IQ%$G&X81'_=^+! M3L$K:L?"P%]92[;"31/T#+.F7@#87D9>X'A+_$O^;+FPU2RF0"$.#ZJ8(1R\ MG9&`)_!YBK#Y=\(B^!8F@+>.7LH$`VN.1\@2#N+6'1.`ZA!1':G?<;&5 M`-]KCP85()_2_0CKPDJ6($@!U@7[[BV``2H1G[T*Q":H+M\#-`+1IL`B`0=[ MIB26DG"W`OC@R[FBS/;&M#J=X>M8;_1)4>,/#'RQ,B3FLB3SGC0&HV,/&E2N;YSNZ]J)5*>2B+# M[+LK`%VM9$"1@H8*?"C M6\/UDP)K-J_\N&\UOX/`?(K;ZIZ=_XAM2\3O4E2->P>F'1]FB,)'?U$/8 M'^-KHO=38'URXA`OT09TA]9M6=??P]]X8%'``UVET:W)^N65L'0]E=PUUDN\ M3\Q?;.M[HS*#P6LM:)A%6 MU8KQ/D=>$>*\;\+%$N],!%`3_H(#X_<+R1@F#FSY]3W6,E,_7K][#3!A M)$D+'(W?@>(`@YD%M&U[=;';B)@:GRLM"S*EY(E6G.&-_9T^JWB M.H_$4667IG^BR"K=FA81IZ)'-[T]36]73WFS^LR4VK)$8_6)6@FBJM;,S:D!/("QT_PF0JDS*35&52TDFTX#U.[+MNWU,#; MNX!T^3):HV=8Q74R2X"=L#8T`E\P_5@@K5%OL1E:56*870N:'Q4;ONOX(0F"C8'>R!^*]C"P?<'8)=M++T1)B4R< M9&:LRX4#!AU\Q^[">YYJ349E7'7I0;*V28I]YTZBY4RY>8+?;ELKC8LFEQ<@ MTMH6'"+^@&DI%`_I2Y;RSJ.9-A=W^7BRZW4J4-*I'@(JFB8^&`]PVH3M2#PQ M+]<;VP2A7N&\"B$7A,>O;(K*$Y7BG>_-2#`+*]EJB.Y48]V=G9\@>SJ) M'KVEPWZOU1M7$,:5Q$3:[5&%IJ(ZR:^[!"Q5 MA?D6CK1%*:\Q(8OJ,*D(\6+VU`4859MR"+(UERNTQG217UB.IZ M4C*AU1FX`F?#(SX.L<3BZ1R^FT;A0MJ>180234CO`5IYT3(DDQ4@7X:""R,U MJO%QKN649-O^>':)P7[%,GO#.KOU9@&:;6^!ZM>.`](_UL+#YET81>$#CZ1% M??V&OIS!H91AHX+6N@HU3'=)(K)NP>GR9`@.3[O M"%<$8+M>A(Z;AWD()M)5^(#.1I'LG0*2/<^IY_HN#?3%W4,[] MS@2>SO%L97V\*4ZLWUN?55C,18>0B/%0><]I/51D-B99Q&:(-91..13D/6TE M^&L5$$+92=+]!.C"$?"_RN>=WZ2*LJNJ4X0EAQ'0&X"4=,UKE&*RL9J=C77T M^)3.58&KMY;Y8)D<[ZGLKX*$D2=8R2#JL+TISNN8,%:A`UFFGDGAJ%WO3@AB MG8Z%Z4T?B@A$5RB=CR`.W8@]H`K`JW;\#G!XO"P<52@*"\H:-!*($A0*OY)& M7O.KH""!R%:96E)W"4P(+GL%R"6:4]#A=OB'3+9L"SBH0!A79+$\DK=;X,Q'3FR; M)GR.$!N=7EL6+]#HE%N[6TQXA>V45B;VGZ._RL0TFIJH-942*6P8"#HPZ@2G MZTD5I,_0Z7P*]/3;XRHLK3*OT@&2/9Z'@N=^238/:D:,'BY&GSCWEMMWZ!\% M.H\!,-S'9<1![!0':2$SX+&?H_$/?Z.30;HY\K<(FX*NE08EW7$_?&BA`W/! MOFEK*6VPHR5=:\-AH8%-H[9AGDJE%04_: M=EBP?X6DW+=(+JWC(^)*V<(4--4]CY",Y2RIN^"5]=+[V9(Q5&#\A9&^OY0F M!1SL/'Q1N4K(A%@N?<^A\VC1!CM>V55QW:_!#)-8Q(!TPG1Z\LZJSA0)CL*Z M5CK["#9>OL;QTN\UH`APQ*:QHM--U-PE&.%KD8<''F%2VH(5%N+Y_UEQV*LP M,*IB'!:06(*<*@IH0(O[[T[O-HW!\[6>TE%5J)/^DP!#PE?U8& MVN:G`3;-G!VJ%;-:D-'SPA%3[PJIT< MO0HW"C2@)^U$4$`8=^OF-D9B146::&T(ZB>G2E/]_Q`FO@N*]9ZCB"@+$"B^ M6&:E6>&3*#=VW#''84?&2".7I?Z:4J-.11;EKZB*40?(.!C!**]MK/5K&R"+ M-^MG[5OM\W@DE'_SF<=/M65A^L21Q*30RJ]T1";@CE;41Y=.4XG:4R-E%<4Y12"_/3Q,*;H9^ES=\:+EVO*S%[; M&3EH$,84"@*D-!UA=H=1KUS``7`JY:Z>%3!HA0X]YI8&+%A& M>!PL/*Y1EWGE$H3B`:T8Z%TP1WK;J@]0LEN]T:`U&4Y.%J*T)A4JCUCJM0=5 M7M1NN6)_SI"EP;C"D*52EKW)27>28')Q:;PJA>(+,B^4.,ZCHE2U>45/&V#E M`0\[OI\=K]>C-X9@T$9:26`0%:'2Q[`,A=`L\"H]%M4.P=+B!3.YH#]AQ0\8 MUE'4`R181>:")/<&CD%I7`\>H'X!8M>:LOLP0G%-+$^NSLP6!KR2EL@B(18L M5GETQ;>?F)@D#;#L4F7XD)TOF5A3POK"VM;UQC!N""^@BE%Q]C2.)Y#`)$_D M=A@SUI:IW8K;SQ=+/UQQ/(2$TREL>B0PRRVB9#)Z`3,50*N2B9$W2_!MRB+" M@X4>1CO*EB$ZDN0)2.;(I4](L93%9D?I.S[0&/_N"7DT7+NI5A%'QE0^7-MM MYN_D`D@.2]_9$D()!]AT@)A]DX$J(>;ZT!GW+E0Z5E[*!%L--&U6R4PA(4+' MHV2#5$DWXJ9KX])J6]SIMAPI+Y_6Z,1)%LM#?.S2.08X\5_R&G::Q&@UIKX_^%Z27[DN);+K,MM!=]&X;3@*I_)>XL);T\W@4>&D%` MHO0#2DP62HY&W-=IE9KDTS.']K\0=KT%`@&_%+<'*"WB;%%.%!I\EKO$%[PP M/\`X]V9SV#&5+*I#_UP/UDIGB_SC#IU(?,ZTYB(_/;R=/1XF,5B0.X8J%YD& M&.,?+VQU3EOGJ_1-^J#J.ECY#W__6R*N9HPM7V%E+B2RM_PN_L*_Q[_ZH#1^ M^;__Q[+^OOX(EC,0JIP!G:W@\<]\^H\7U^+KI^E7N_NU9W]%U?'"2@)/_O0G M_&&_@`.C`QOFBW^\Z+SXI3OHC`>CT6@3B/P,!\$P_-KK(`B#)T'H=X?#_EX@ M_,&0FCY-/RU5,J$H`/`VD=]^M;\2%@9?OX0Y>'Y!].>W(E<.1:HH68H$A9WZ M+(N+%$J(;-%L:0<">[Q<;T!`7YU.\ST5.=XM9;>ROSY%,Q9X_Y$G!HSBD9E"UM8& MI%[P+S@$\33(;BU3-(SB:>A[H0QXTS=4\!ZA!C":%?)`S-TSSR=9KX[=*,QA M`;@%:/JKB>H1.4G@HG.%`M$]WD>?.D.@(,WK7Y;:!Y2%3 M?T,X2-]YKG)+K-G]Q7LGD0`G(?$*+^:[%%+!J%#8;]I4,)D6B1,*ADFL$7.X M[R<8G@EV4>1]+WJCWKWYO>AY\%R960&4#I]]%%B*CND`GE_I(S"F M55S*800(-!EB/AJQ)-8R4[>!]*XD=/AMG0.$2ASP`@#4D8RD&0Z/^'&4*`?H MW*.M)%<2;50(6Q>C1P'3!F+FS(MG!EC.ES!QYAH[=K?[VOKR$%[=A&!D6V\] MS+`F(U8N+$;?`,`_37Q"VH(S(:."!:!/(91NFEF>>5>M7!"+.L[`X4,()4:8 MPKA&M(R/R<4;J[-&^CA@2&B'+Z(;1D(B+DY)GAN0:/);#)H5JO2/_`:EG@+" MN":.T$V/R!]*14DE2YG$12^9"BRNKI(2.09AHOWAMT=94?@GM.WN'GVLFKGMT;C>TG M%[DC8,^VR+VV$L[BP\%P]*R+_*3%S;/MY&!D3^!_3ZYR1\B>;97[;>6P8WA7C83\8>O:D,]X9AH=K>:,#1`,4%L"?CJP^>`.':6X&H M8M3/Y/09]BO1[='1QK*1%4D4!D, MI(P;.&/GMN96N:>$]6N(7JJ7+]Y?W_[ZXF>ZE,=*:66/_KFDG-8_PC8-?]7I MM:P7M]YBZ7O3E3[!WL!)$[8[/W?^I!7NA:!M)] MIHX!:\-@TF@6,>#@,!33ERY.X%$GO6Y4KZN0"'J:LD%5R0L7(Y=IZ+1$CKXC MHXE\3\?6`:W/=<@]CA#('!(XPV4+D!>%=QPE4.[VCCQ^R1V(%^5WI%IN\JSO MJ>)K3,;YXVUIQ"D,&P.P*3--R+*9="TH70UI0U1;UOH;M*UWC$H>N"H\`4^A M>!D74^&V?V+@!85=R%M+>=^GGZ6;.G@A]532*F382)8<`[N+->'P^43&66!; M=<)4&>X/]2\@>5_-I23"7)?"3L0'#R*_7A%2'T"LP'=.,MYT90 M/"THWO.[*,&TB)RL`"&PGPCH@@AXDU(%A<=]"9=`\F`N_?S*N@:J<%.NE+&) M^8>O`^:OA+478SL*N9T=YRCTURV^`Q( ME9XC'SO>!\CA@?46X;V:!6D.*-N#K^$/'D4R")&"CX'^_@.8F24P,HHAY'`] MO$44^I]4F#%6:U1>4*52M`R:/B'`=A92 MAX8C;T@I(V6>E#+_S8)'A(QF)5W3%`G0YU3OF_O2(8^W`A2'0Z$?CKQI0WI, MV1"+H/(HC9^ACTNB%PK6BR,61BX,!5``FRVDSO_M^OHF+P1RXV%D6($[ME*^ MO)^2+**_0U\],29&XZLW]^04#V5:&:]0'N!#JM:SDNF`+807!N8%3MO5"$C7 M#K@]DPE@>.EI7J)J,VD=TCPC;1!Q+N9+1K,B:^F[*TGX3"OG++2,%!1=.P'= M+R1%`!ZXBM=FQ!;"4DXV=;T&/\B0+4P@<>8>QVC;+`^3!L>;3\4&+7PNUK?O M8FVZM-:,8_)JK^SU19.950&*6^TZ"A+O.2>!9Z^X<9Y<[S#Q\B/T.6^+OV*!4XRFQU90P_,(H\BITGQ40D%YN@H%`<.4&`/ M1I)?1((WSAS#+19P:DY3O\I`S'1W5A`$K&<8+UI=J60])WU*!^!@-H1,"L[* M-NC1Y7(\+8;6K7HU^7^R%ZA^!)PV).-0'M14%M<#(WGAX5WL+$3>#B-M/LM` MG7315!5&YS73M&!H^"3D-LX"!9SQ(ES@8P M$BLI,7A4[!T.N5)PRQ"EM&8@6>>1]DS@J"4LCJ2`F^E$Z'15^Z%C:3"^2+BR MWI:JP(C99:GXY\%<9B(#S:O$/@7B=OD[A4S*U$/A*BJIF2KU17=9%C*0RXZ6FW?'?8T MD$NL&.:MX?A4JD-773D@HJ3??$F*>'3-M@7!Q7^BU-I=)9 MZENPH%>^\QENF\?)Z*]31K,\35^YM)MBU"',RV92L�)!9QX`\J:E(+1RXK M.<@`^0TT;)P#:`*GOMH)2)E1))PJ`EDSI17.U=N\%S^O[4WDW]NX[FO^\PCO1[G#2 MM0>=',C;)CT*MH/N2NU^OS?JCDX-VT%WJ-W.<&)WG@MO>\99='JC8:>_-VR? MBL]4?/L^Z([A?[G;]Y+I#H3G(.KJ=B>C4;]_"G@.HJC^<#*OS,>=?:!12;9?IKB MG;Z^TJ<;_0II:PQ8[.:!VCII.71?PFN'3K.P"#A]8[C\M:SZ6-DN@@3I##9! MW#ISE8#NA@'7\=I-"F?ZN!O][JX]PM'!58Y(77 MWSV1_:J^?(_%A9B(?R>_0/9S6EKB'29_?%DM>?'UXN]K;^/CGZ;7<%`.Y*F& MWF7?9\'7CS('[#IP;Y5S)LT;EX,\@>P^G:X>P78I^IY`.3P.(BM>W?@,8`U< M+#&SI--89=3<'??ZH^$C<&^%X22P[QGAW>U/2J3%WK#+DH=*'\!SM%=RA]XH M%^@1:=MV9]++6T,[3%<%?#NG=/=MNS,^"CS9<`Q+*6@1_6GZADH\W<9[1E4^ MM>.C46?4RZO0IR;?!=9\+O\VB6;W$,"N%&G`8_3!Y=[7CQA9\H[7[J MY*/X]P>T7*6]3?V6]8MFKW&9C?X!]3Z?&G/7PAW5SZRI@]SLF<5UV&U$9;OV M_!R'A'W_2563`AF*"+ILU@R1W^FR.]_O'"HL/$+/=Q=&+D\NJ(:MTO!7^D_ M7LMYK'$'^_B]7I=>Q<7&4?I1?G:M>S7=71C'X>)%$?I1MST:_O6UFCL.EZ_L M92SOK_[R=H+_M_2/-./67^7HVW^7TG7S9QV`"FN#Q2BLK2WLL`O&XLCA/8^P MP-FKN><"6>5(9GVNHXBF2#"*@&)WOTWIV.UAWVQ*<5.*^*X`Q9VN0?$I46QW MVK9!\:FIV`@*(R@:CF(C*(R@J#6*Y>>H\+EQAO8=<[[-HC`)W"L906?]A25Q M6.E>;#V'&:NZPAW(90_+(^2N>S+>\=&,CW8.[;*?@"8X-\.&=E\\L;>= M,VOIB]Q;RM#J=4IBU@TSUG+###->[MZF.24]VS!D4S;M)`QIS%%CCM9H!PYF MN,T]V?O0>U:=1#DYEDI$JC^Z3R'?\*[=L(9A#<,:9:S1-ZQ1*]8PAI,QG"YA M!YY;%Y1+\WHCMU:ZX&42L,3%JG@_&WZH`3\<<./;J"X?(+7X/A"[KO M;8Y,N%2C\,V;=^_>OS\9PCN'J,FU8.+W211XU)JU$$W\8ZC($^_/693D16.T M"HK_J7K:/GOTU/:=V!&U=BXD2,W2:_?*M.L+F!K[[_WCA?QO&G>?B\J?^B&+ M7^%2TU]U.:+)8-`:]7M&D!A!8@2)$22'"Y+QJ-<:=_M&D!@3?6>$UUF:?.1, M\'GHNUB-,`KO2WH<788=7C_:;H:2K#/QGO*NX>PZL6Z:K]?IM(:3D9$!1@88 M&?"#RH#N>&!D@+%Q:W&HJ$)XW,A6]]32Q/B@:\$-S="(S23WB]:5S?$AV:UN MK],"76IDBI$I1J88F5*)3+$G_=;([AJ98JSVLQ^&JO%,"_$*^^\DBT2W-%]& MV+U8M7ERL=U9%'O_H2\NT&RO']&?39'NEU529[)NFK[<#_/[J,6J5>!+NS7N M=EMC>_"SX7K#]8;K?Q2N'_4&K6['<+TQ<.MXHGA"6OR027.U/=4U-TVHV2BM M95[0@2BMH$?O26C62`$C!>J-TDN2`B8_\`*H]B)LX#J?B\N;BER@$5P_VCZ+ M5P?`M=PPP58IE^#6:4`NS@$8K]O=YG#8:TWLCF%_P_Z&_7]`]KQ$11&4#0?Q490 M&$%1:Q1?Q+WYV0L9__!6]45V!#A)8SB]GZ93HVF;:C;,,*/96],VM9&;=A*& M-.:H,4=KM`.F-^0/W1O2M$TUK&%8HY0U3-O4>K&&,9R,X70).V#:IC9,%YBV MJ?7BA^9E0E]44\]:)D9?%(:-3/CAC<(&%-LU;5/K6"6@&6%1S:3X!J185K@3 M=4N]-&U3C2"I`4:-(&FZ(#%M4XV)OB_"ZRQ-3-M4HR0;2[Q-*T:]%^+KIOE, MVU0C`XP,^+%E@&F;:FSIFUJ[;BA&1JQF>1^T;JR.3XDTS;5R)1: M8-3(E`N2*:9MJK':ZW(8JL8S;=JFUHWHSZ9(30/%<^G+1C50-&U3#=<;KO_1 MN-ZT334&;GU/%$](BQ\R::ZVI[KFI@DU&Z6US`LR;5-KB=_Z8-1(`2,%MJ'4 MY`=>`-5>A`UIG+CB+G#D\^I;?N>:O5G]X;CWBC7/O+1 M>8\&L7\`B(/!8#08/Q>$Y8W_GD!BOS/J]P;/C,2]0!SUAKW)Y$`(8P:\Y+YC M40!R1UQG431O^=1SO*-Z35Y-.K8][`[Z>=B>FK`"`'=%W-5D.!YW>]W1,?#= M\R#AG[D3SF`&V,*;T/>[R/C3.-I/H(RJLDF?`NW1/2A@VA-6))']'^Y:#W,>6*#71,*$ M=\\M?N^Y/'"X%4XM%E@LBE@PHS1PBW_W1"Q:5CSGUC+R'!IJZGV'4=!?X_*8 M1PLO0+.A!9]\&"Y:67,FK!#X*XK4<_!Z1*\R@(.)D%ZPF!#`-FIB['C*'0KL M@T\XGV`^X&F)"3K<%6U++0;F#R,+$)=,F8,%I%Q\QDV<6-!!.>UQ"',Z MB0"CC4<6O$BT"-\!,N/(NTMD*.$LXG+!#.!<1Y5`PD&WWB\ M:MY;DXY@U#(E&JK!4 M+Q(Y28VY1;<`&GU2/!XH)<`@&!`.\Z42=$'7M:WW'$9TYF!:<,*=QIA4BT1% M2$YK>HR)#$:I_E.5"0]JVEL3_*V\V$>BX*!>$X&[\[FPX$B=2ZP9J',U9FYR M3RV31UY(M@!J_A##^#F6IQ;J#2^0%D-[%QOK1`?^)ZW^TD."J.YH/^H-NOW^ M9`,BL<_$AQS8^UV[;T]ZQTU\T#D=0=/+SE<,3]>[>_% M^:I&^/HA<("?;F,@>#0R/RHI>0W&=?K,+?=!],S@:/\[B[[Q&/Y6,_Y.K;^> M]&8,0%3EEE(`>O\%E9+0GV*#S+*_"^"8LJ(UL.^SX.N7.9S:;CC[)MZPI1L-6>%Z&C8)OHH2['SUV MA[:AQ\47_.7,/JGR74-Z M>:,N5=`WP):"O])_O);S6.-.&Z9ZO0YNT86R=[A.O]TQ_;+7^F4?X26[C/"= M.FY*O:_Z#8HW43QI]PV*3TW%YPVV_"%0;`2%$11-1[&Q*(Y`\5KT4#,-[;,W M*OKAK>J+[/B7V['J&K_K_3QK:U^SM_^=P!)[G=8CUPR-M5PO2=A3&.6&K.T1CMPCD;WM=!-^U6/.CNZ3R'?\)+-&(F& M-0QKE+%&WVB-6K'&I1I.#:B?KL,\K*6,\_@Q.*.V%5^.N`)K9IVBYZ3U$^3+ MEU^5U6,KZI9(;[?&O7&KWSVR[TCM+%`C3)J&4B-,+D"8V,-.:SR8&,OD+!4[ MFFFCUUF@_.X)C$MF`0\3@8U'HH3YIA5VS16EP5OMH\GJIKJZG4%KW#E2<5UF M34_#PN?3/R>]4S,R8,U\!1G0LQO=@;-^,N`B3-1FGH95;J#EA`O,P+S4EGA- M.K"=32,>?0-=5A=+:J<%6;]AKC<='5E-=*LI3',)6$;:CR'%1\4AOAJ@J*\1W77*,><;-G.AD\ M^V7J!;0RZ+7ZG7'+[G:;;&X;$6!$@!$!!U\^M?H]L(\G?6,%F'XF*:C/4M[T MF-IRVZK4876]#X&(HP0KYPE3BZ[26G3=MMTQ14I,>F+M-Z7^_D^#XC7!V.Z; M0FFFQ%3C46P$A1$4#4>Q$11GKT5W;D/;%/TX-P^]>BLWJV8M$Z\&+YQ:U9K2H-Z.EFC-:MVW6CMI^VWI))/&7[\"";U[GGLR^?OOZ M9VIGS*PXQ%>QBZ/ET^0+#%O!GLL;S+MWN%MWT`+QA_\<.75!9\=# M)KSOQT.TXBR2B,,-B_B_$P]V"CMXRQT+`W^%)0>8=;4"ZC;M!O@K5COIGZ?!`#B;:E M>K7F6"7BUAT3@.H041VIWW&QE0#?:X\&%2`_WY8^66)O=V8M9-O::L1GKP*Q M":K+]P"-0+0IL$C`P:H"$NY6`!]\.5>4V=X8[B+-Q=JFN)TE'N2`>/-F9LZ> M(/B_ZL"12O>B=ED!@U:_.VP-^R,C3XP\,?+$R).CY4EG/&B-1D:>-"D%_]SN MJUJ)E*=2\#^&P$3DXEB&T876NZH?G1^H-Q^1MB;9]D3Z\0PXKZ$>O`"[VD@! M(P6,%/C1K>'Z28$UFU=^-$GWL_*D^VVI\MM2Z]][@1?SC]X]=S\$,0MF'J;J M"\'CM=Q\DVM?1:[]H-TS>6XFU[[^FU*YD68;%)\6Q>/V8&Q0?&(JGIA**490 M-!S%1E"87/LZH[B22XYS&]HFN>GY(89 M9KS^7JQA M#"=C.%W"#CRW+CBB=4WSY,LI=,'+)&")Z\7<_=E82S7@AP-N?!O.`S*@M"X8 M+KWP-1B^H/O>YLB$2S4*&Y`N^]%SL&&LQ71=E$ML'=ND;,YF1$0UD]A/T6CR MW(%3S>UF8T,J!?>C`QHF`P835J3 MR9''9F,&7*!-V\RS\TRS6LE19ZJ9YP5>;,857EK60&/+]`4KQ^QGR<%MMXP_! M/0_B,%J]2:((_C(%C:LO:#P^0?%I43PQLM@(BAJCN));CG,;VF=/,?[AK>J+K-5A:JA>[MZ> MMJ"Q84;#C&9O34'C2]ZT^A8T-N:H,4>;6YJR%CK)5&T]74%CPQJ&-1K/&J:@ M<;U8XU(-IP9D0V`LB)ASUYJ%H7N)Y3.:%+5_Q`WYF:N.-H#23Q'?6'J37H^M M>"T_*S#J%@79;?4[O=9H8AO14B_14G*G7@]Z_M%$2^G=>SVVHG["I#/JMKJ] M@1$F#]7F>!\L\P^@:_6\LH=+BX1+.\?D3=C/#4.E/M2;WRYPY:K;D] MW>^T.@.35507F_D"\%9[B7#NZ-2ZR8!>SVZ-FWVBKI\,N`A3MYFGZL_LP5JP MF$<>\R_1!&[2B>]LQG'=*U*=&J4G,'LK*RA5:XMX/!FV;+MK!$2=J/D$MG+= M!<2/:$:?HV3=L\B4SJ35GS3ZE-TDF7(1MK>)F[TX3-<\GL/4I7KVN(U#ZE+5 MVGKN89&ZUF0P,@*A)E:R$0A-BK:X@$)UO5;7[K6&W8X1`:9470KJ,Y>J>[S2 MW+;Z=+=S%O%?F>#N#5MA0^[K!Q:YMS&\\FF)U>C$_S`_H;ITUT(D"_F=J6)7 M>16[L=WNFBIVIHI=_3>E8A-NT!X;%)\6Q;VV;:K8&2IN.(J[[=Y92W(T&L55 M.(A/8:*<)\OVC#FUM]YW:P%?SX7%`Y>[EJE0]/1^U2HK^J05BIY=RY@T]U-5 M@#BWU761>V68[\(V]$0U)LYM+%[D7M6V%%BY95J/%-`ZWP^]^[[D#O;$!L): M6"^]P%IQ%HF??PQ3M`$;]/P*K1Y,4[<;OJ,"V6IH"-8VD,U0;ITHMX965&TI MMZX>MEH$`51JK-R'/HL]WXM7%VBGU'D'FG:\W@OQ=1/ZLA_-@7^<^Z+M::O__(=(RE.L4GGMJ?JS!T_BM5D&*4! M!E>]&>4(LTI^-)F?L_+,SRIR.-?R0[D/JYU=!^[O+/K&8_@;#;%`\$=S/?OY M7,_^"RL)//G@G_"'_<)RN>,MF"\P]_*78606=<>#CO=T\%T"'4-)\-A=W!R/.T%4Z\[[HV&!\!TM_[,=12Q M8,912OZZRA[)"\[WS(M08/*31:8\FX\Y3E%TI]/5"U^-RH`1= MP^Z30KPIZ,)[P/<1YQ\PL)^+N'+:ZMC=4]%6&>QU0M6^=`6HLIN'*F7?_P8/ MQN)#<,,C+W1_BT(ACD!.-X^<#W^\!SME,AATJJ"D[?#N@A#Y-EB2'P),AO'N M^8W/`G$3^IZS.D\5FJTY.U[@`HBO\&+HD/)U:Z?NG8[<^>R=DCFS$SD!"%L< M2B2]2@#6*#O>$O*O"/M6'OV[''9+T''8\D]]*J\,T+WVZ=%MDLW5K?3Z5HTH"59QT)^ ML5C@6M??P]]X`$_8'?5$RE/R(4]8"\Y$$L&@+);C6RY,WK(D<#`:3C,%@8=^ ML81;X92^8>9=V[R&M_[ M=^()#Z2\X-&]YW!K2<*B;7V!=Y`L6;"R0)IZV/A`E,#"F3-7^)$P`3@B*>"( M5JH6@FO#U^1*$P'G5(M9O_H,MN/6F8<^%U>_\RB&Q^6@5\O(PTI2UB)TN0]C M,'Q-@<(R\6\%(>Z,)Z>1A:GNN!\^/+:4+,898?)BE.>+!(W M(7WYR8G#.Q@)MLL&2HEF\#=,])$[7[C30FIJYPGM31@ME;B1I%$`5N&@2`&% M!2,L&@Z1W`F@#J!6XH,$X)<`%!'JUP1:%BGK(>*&9,(\X#WO%@ M(2N/^R`O9.4WV$)VSP!TW&YX\,_V+8P>$3>O)!,(N4)D1V`S8!E$9L07S`L0 M+DH'9,ME%'XGFH01X3E<6EB"RSS?%Y`O0R07GM.YI@FC=P*JK'O2!_W`PJ3.Y M>\4`2C8K,BX2W;J`=9.(,`2CB"VE/%Y=DJ(T9?8NOXK0$41S&0$8==P44Z"L M:2@^=Z#$#X!B0\4G1_&YHQ@:C>*ZQH.:,GNFS-[3^W7YQ8;.IF5,I2]39J]! M>V68[\(VU)39:\Y>F3)[%Y939LKLU7R#3)F]>J2\-KK>39.*E1G*K1/EUM"* MJBWEUM7#=C&96J;,WKEWH&G'Z[T07S?!;.;?Y8>`GYOXK$6C&I) MS/G176\ZY5'+"B-*%D\S@.$=_=,T"A:()2BJ[]U"P/C:+DB M`?$EKN>>>:U'V\G*) MV=BY!0,4?NBDN>.8_)P$F`^.NZ%RC<,D%C%`C+2P0[YQ"Y/P![1$E+E89P$> M7UD/'*9S.5\0O`)$JC?U'!;$[5TX2,L`2?W5E:W<3Y#6??Q!NV]&+F[P[?8'PD?-VO@])R M0*7(6"\0N/]D=J_:V3+ROG8<9&Q@&Z(?CXNTS&EMB@1IH\VRQVL5@ZPK^JIV M18-HW%Y[U^#DVV0!JZ7B([FML;*]L?3F6`?J\\88'K7;RB?J/WWF]SQ(N/59 MJCM3^NF9+$6-]Z))0]8A&!DB80)M(4X..H?,/RSFE!5=`VO%$[%H21.(!"\, M-?6^8^TEK*FB"N*@A=^"3SX,%\DB+:%#M6-<966BX8#FI(5%8T)Z@0JCP%1R M8JS5`?8?&C&J^HM@6.%F&84.YV@-J<7((BJ`N&2*1B5.`<^XB1.K MG)H._`DY@#6.PEKY.ENR+E,()Y@(>1VE"W#I0C+WG>_-2"T`$U<,Q*U MU4P$>^'R*3Q,I>8J'EUO^!VGFEYJ)73D#9/(`NDFBZW=>R#!X!N/5\U[:](Q M/44"PPL.(G'&M#Q.B3.0KX2R-AE=[^3DJ!ZA;5W'\MR.TJ4EO0QZ#+#:\"`+ MI]]40@,!A40W&I;*">5#Q>-)K>`P0A2];'W'$9TX,@RDZX2C3&I%HF*J*1948\QD<$H MU7^J,N%!37MK@K^5%_M(%!S4:R)P=SX7%HPUTE@$NTTES38<,$47BJIE&#H> M.6ZP"*5\PPNDQ;"3+\&8AL]GO;_!TGAH6M$?[]+R?M+>>A.2@R4R!5V?RZI_ MCY4KDV@9HK&FC>48N(DL6+2E<9^P$HTH*FE=9U*@R]":`W7X*\OW8$/1E+]# M\0[\GBQH;V$&$#/HTI6%'<'D!FM;5?^,T:ND78<`#H@YH5R:-'E6`Q(=MII^ MUG\BML<*D3&3.C:<4`1H,',@]A\>)$^B_A;3)949T(K!?KHVDAX.45G%'P M@&!-.:P,UK7"-^E8X'L++Q;;ZD=FM3EE&4D_).,W5P\74"=X-E>AB.0=R'08 MQO)(;,-8H>"I+LLY1BT'((&'L.HF^L:=;;@X5.IMYID;9CJ1'%2>)H%N#`[[ M1F?8=0F(W/%&[CE&"QN!^`P",=V8*+@$VBY3Y$7X:Z MKB'AQ;+;))`J+I5^!79/[N)IXEM,SY!>N%IUY.%E97XDC6-5W(L61/8`CX)PH7G9(_# M\K9MQ0-HCI@C=TRE`:IND9)`.W[@R38Y".]1+)-B8R6#+1'M82(`!_DQM%JEMHZA/$>9#&,'A$E@(K(*4?^FT@;>O2,$>.C57+6TH*74NX7GP`$1U M&%5TB`13NF+-[\@?R"*T* MJB"^E#7900.P&85S`(G-4!Y7#,#+BL<;5$X;J!K3#:YZ/^V*![RJ>+S):0@. M!6[%`W>KEPJ%G2=VGB@U`BSB_MS*FV:Y%@SWNE&IDI-H9`DKH=,J_.Y@0)#4 M&'$8P_-*5LHPI^@1;:`?U`KE@16\>\BK&*HC+:X<,Z=.MC0628]PQ^,'#I9+ M[<74"0CFA*3-R-,A+R76-D%C_A3:X30K*B7'#RKF[IY"[LBPP7BZ.0,[GZRP MW.4JGP(C*=<=&@QD84E3HF@YM'"0AS#QW5Q[%&5U<[*YZ=`B7]W*)=G3Y,,6 M@FP]_Q[/)=@-!-@3647PP).WNOIP5(@FS$:11ZOM)MH39Z@RIBUV):EXTWZR M^^,6_-@`%OQITC\)I'%)5.%;L(XQ#,WJV?1MOX5;@P&@(!#]E3FS/<>9K>"W MH@-WWEE)7E^U*>38W'*R)R\K*CSN@+Q!R]7'RRDK2&B#L9<4#V<16\Y1'_L8 MR0K25O#-6LGRD<9/V:Z!40)\VZ&^QC#AS=20K=9C*PU]T^U*@+MU: MAKXH+%-'!ZOOM%`2J>M#>I&):A=AX*%=`7.F-W('.VX-K9[(3?LA0#T8HA/) M;,TSB)$U"(UOG+]^MW54?K`$X1^M\0^A;UHDM85$ULS3."#Z(_`+F.@6!-7<)-%,9J M"2B;14).DIP[C-HVILY_L`NE-J*NER^G7B0P0+IER;_")/[9(@LT^L;CS&@"<[-L*'=%T_L+9R-ZU8"L/E[:QIV-FS###->[MX6;H`-0S9CTT[" MD,8<->9HC7;@8(:KH'G:6762Z6E[JH;2AC4,:UP`:YRBW;-AC?,V+JRCX=2` M9@/OO<`3<^Y:LS"\R,KV36K@><0->3U:S]:9TG\Z`7&7WJ378RL.BM)ZMLXR MW5:_TVN-)D>U63*BY5GNU.M!SS^::"F]>Z_'5M1/F'1&W5:W-S#"Y'F$R478 MZW46*/\,HV]81D&E&EZ@65X_HFY&>&J=J?:D7OES!ZW6W)[N=UJ=P5'-VHU$ MJ-!FO@"\U5XBG#LZM6XRH->S6^-FGZCK)P,NPM1MYJGZ,WO`4JT\\IA_B29P MDTY\9S..C[ZP;#A*3V#V5H72>EO$X\FP9=M=(R#J1,TGL)7K+B!^1#.Z,@E3 M-YG2F;3ZDT:?LILD4R["]C9QLQ>'Z9K'"R;'#7E-*)_<[SU\[.:,R4T2Y(85I MG7#!K2_LNZE,^RP2;*/Q7QAG3:)T(R%/[DK,OE,SGD!PW:\'JW[.>,"SQFXD M`9?T13!3'0/;P)!33JW.LZ%4*5Q5,QN[$V+K<:&K5>OR\V+.N:HYS9RY:LBM M.D^D+=OUY*Z>!D'%IDBJ*K7OR7Y!GFJ-3JT`OB^IEY$U3;!%.M4RI0K^CFH9 MR1=+H-((JW%/85CY@VY`0>5.TVY@$:=>2M19![L?J8;N!(;\!C5!*3QMZSK7 M@",KSB^[`6/;>=6L2[917(143_P;*I-XS@+:,%G/M63UA>Y-$6?4.!=GG":^ M7SHMTL`=+I`+M!UD!H]J,5`R/CS]%%P*O80*H)2IMPVJ#P"'JYNJJ;=DLU^6 M[WG/[IGG4]'535*C=G8KV.$'%KG4^?(NJ[XNV]I_P,PS['"G^O,"];O-F&6'08]&-.A[=[R-LD/*86P'3J8YDF8SV@ZFV>+.?<3]OR86\XV2`GIC8Z/BP*^Y:P M[]0K)XGG(;:9;5NWV$`\@RW7XDQVFDV"7)/I'`OJMB\@Z-$>"F4',"V6J`UW MB0`HR.22IK%*=^B&VKGQ2+:7(Q08?ZI0228TX'`;U,56O;+Q2OHD-EZ'][&= MB^-$"?672_O4;L<#@).^J)4;X@;^8CXI#.3W5,JH1XHM42L]>D@.Q`/4"NL-0NRT40,: MNJ\53I4.![&,Q!$4IA:Y2'!C"M?,%'[/O,CZ'RS0CB+C?6IK?,@:4)LM>R95 MDYT9I86!S'VOMT9+M3"X4@+R2AJMQ4;=NFEXSB'@JB:.4]QJ&D_D#6L!4CZ^ MPG9I5L#(')*Z0_#\@"2)!-\RFQ8>V$N[5=:@)O?EDJW2ALU:AA;E70:H5F.E M$M`/@YF$FUJFYU:,YJ)8QZ'L8Y4LL?>W.G%$]&QFZBF,J-F*LNKX+3X3H9Z! MHTCF>`%:3*]Z#12*MW/08E>_$L$@,0!MTG.7OF^UD(2W<>A\NY+-CFST0/=AM!>PFD"4= M]<0':L*%TI<>PN,F9R*)9.L2&I_Z(K>*+?$VI17#CUGYJI=)'PJQ??0;;<>O,0SA]7/T.6@@/R33HU3+RL/<(G$9<[LMS M>")T$W68:J'V!DQV4^Q*:<^BQ#\CQ<+&!NN>VJF4P1 MYL*^%`=`2F*1;%S.8?'T.2"/.IVRT&Q=)G`2<="U@#W,8`>U$TIAK[JYJC:J(3:P<^($QL%IX?%[W%%X7CAPNDM\=7*&(UE\I7^"54VY%U/[ MM@+L*1UA;[BK:<1S)Z^(-CW0)VGJR+SR\&";.X:D2AT>_+-]"Z-'Q,TKR01" MKA#9$=@,6$:V#-=G*C(KBIZ\.BNB,QC9GJVYAI;+>[IC&3 M:&^2YL0T]4 M-OW/8C491FF`P55O1CG"K)(?33'3[;OR%*#[U=3*,KYS><"Z.I7, MFI?YQKDJ`/GJ2?%<5I"B03`+-S\,5LQR_Y4(-.K25/MM2?7%;&P0(RJW6B6' MR[3F_.BR6E_+"B-*'4_S@>$=_=,T"A:;(&E-605 M!5G;"1ES">SI>$LL]B`KMOK(\([#E[D2('\&5"KS-B;9#Q-=+SA6H,@JKL): MV8PF1*FP8-]X3EF0\,I5*9"%24'H*D$FZZ1BO96%+#FUM2RJK+3@"<:(8=C9E'UNHC`(L82EJ;SW?-7UK6N0 M6CY9#;+V9U8&,;AB,4+F.[Z]D\]",PJ MS3U=+3B6PKLP#%7%\_0P6#V+A'>IK`(AJUZ7%JM\FDH3NR"00;""@950]6(M M;'A:BXLFRJJP`JW/R=S&2EM4\8H$*4BP;`&R./,=IS+=G$0W&K94Y(BJ,.4* M-"FI2.5_O(64_D&0%`IBZ\I(=QQHBRKXL"D\GE4OQ:W%N=O6.Q:A2G)582RL M@(U5DN(8JT/_$^1Z2*:JM.BE8:R?)6D/+PBUOW(5)-2!=+5RR_A$DA^;'=^?H6V4."F7"F+ M@^4?O@Z8OQ+>FDCHIB(AH?F$+LJ55>JB6E-PN";NQ,)7`"FPJYB3)9&CT[36 MJ,]G6!4,G_-T@2XY/);*@D.UJF8--`>4C:=J6;P=7@)6P6*FGBR[;LT2&!G% M$'*X'MZC@QX9>=,$JU@A:^-.@Y"6W4[+K8.Y&JLJZ?+]*>="%MO" MTFCZD"]KW$=IH2RG@%)=*(T^Y>54M\9RBA7*+BO$:)62%1A_7(#M+*2LJJ24 MD3)/2IG_9L$C0D:SDO;X(`'Z7):H0ZX(Y!G)1[)+&TH`+R`]IFP(&PY<&&AR MH8]+HAG-/3O%0II7QBG67Q-9#JM9SU?2XC_!BM?4"I^UJ!*1K!]R>R00P MO/0T+Z%/4+9D6F>D#2+>J"V;]WU*PF=:.6>N"M46!0@.?2*2(@`//,[[)41: M#%-Z!>`'>8"_P]XT&25YZ=SL+%"!J-ASEHP MISF%[\FJO[/5%DYE5@`PY(T6Y3\K=&:2ZC!,8I]*WC(+*QAC<4[@XHC/@9&1 M_E6MXA!KH:(UF/-=(FOH@5GD40%D4GRZMJTJ&NO``0KLP4CRBTB`G`5WT6N) M%:K3XO(E(&:Z6U;,E_:B"^-%JRNREZ=@4NJG)#L[V/,H=:MJDTZ/+I?C:3&T M;M5G?4OT"WA!Q>&T(1D'EA6(J:Q<#$;RPL-;L%F(O`W(4.8SF0_9HA%I@;XM MHFG!T/!)R&V<.;([-+I7D[!)QA7J%HF^]*5SF'^7YK^JO(P29P,8B964&&#I M@'HXY$K![9"0M&;TGR@M^YSUAREA<20%W$PGPN9.:C^T=_A?8-4+UW-4ZQM] M;Y:*?Q[,<:_R;F0%XG;Y.X5'`0"J@=!Z6NBJYYX2ML/7UCQ\P&+#)36^CN/. M$!4IB.%):]TH=8%F777O">I3-IG)5IMWDB,/:RI,M^]N96%L`2ZQ8IC;92$S M\I(C7(:"_%;JL(HMO*1.6E,W+:F@B)5(06'5Y$S;T!VVTF_D[L)EAI$'^X3G MYE(LZ)7O?(;;YG$R^JM.^FMKGZ;<3186`T^[;I&O0XE*_`C;&I)G)I*7`H4[ MM?RE@"P>#T<]8"75?4GV7`IXWK!0GKQGY2JF.RO&^DA_(17M-2H M;8J\AF7^"21+K\$R ME-*83/G"[V@XR>B&0#;JS)X)U1ZVL@LULOT96.0O\8%,>KYYK3<\^^[MZY]Q M]_>R<,K6W6^-NN.]^UN71JL*['$D'FVPI7M2T),M=+6KWC)'S_Y3I]VQCU\# MJ!T)W>8>:$8CV`L;T;*DOR;RG+3CE_+E5[%%/W7;H\TJGX]:R7G_//X/5LK]>[ MLB>#P7C\,T9#W'MA(L!ZGGKHG4A5P2V'$UL6/?9.NRR03D`YI/V=UN$&*Y[: M.R;8OVFY]"5$.D@,S7U:ES+X]:,N%T[DW>DS(756TD+[4ZJ4I)F^KA(/OK2K M,3&>*JAA?^+-#WI5FKQ+`U[3=J5;8_?R+I0"M>N+O!RMD7U1A6`'S/'(\D;H\BJ+2TJX54,.UT[;J5"O]LJ!>T2%(K8NY2[)? MV9AI"%3>MB^V"SM^:<#`%6P7$*DO/5DS(-0;I) M_KB^?7O]_UEOV-*+P2SXG47?^&ZI`Z?R;^QZ5E\[XJ?-`]_=H^52PR-]?83\ M4RZ``PXQ9QBRU$^1T8$E":%F&OFB+-U'=NB)&/&/<$S5^6ZW^CXN]6(TV67^ M*;"NDQE02=6W5<.*QUMS,.4ZN5HO\SX'^7O1ZU/P1C'K\=W<=&-D&UT8E0S$ M-U]N2QG[OSAS_PW&II[8>LM6,5H`G^9>6#5J*AX/%T69FWB?`2;#U(LM[+L* MRJUE\7A.;6IU-"<%F>:NJ"/N>$M/GL;=,,"+5B1J#\W4!7?I7;1LT&=.7VI3 M![]8I:&D:GD]@T\>DN'2Q9`(0L0B%T.(^+QTCO+DDC4"AL`9TS4[Q^ MR_PWL+@6.3TE>4>B>=\^+\<9IHUXI M/*_?58T*4)31/;=^0^)4'=-Q];JANTKO`]M\2>*=,IWE@6B;\/X0D_A+`^%4 ML&#%<&<"K&J$9-$,=UQ%%F*8B8?8-QXBLVL\V4I\ MSSN)'>1VU>2+<4CD9&V!D+[[%\67AEF,3Y8E@H3(/7*+H-T@8\L$=$C@L$SE3KM*6?`Y64Q2&B[\U11RW,)`]0J5,7KSI M%.\\L3$]+Q62M'"\5U06MLC,:S`E\=8BC"A)9/VD@U0@1V?V\\)SHO".@NXTMO+8EEC;&HVH M4]20RD!,IG5H*,1?'6/NL-X+U7!N5XV,)RV/W)5;/MWU<'_NTT#]U.]T3F&0 M8W4'Y;TEO[6K2N[(8&-NP7B.NB>LV_1,SEUX'["56^"B<46+_!NT=Q0&&%J_IXT)M6"4-CU,I02GSW M!A,3@S@K2?.&'"<65K:_=,:KA1V?;DR4VQB,6F=1Y,E372'HW0ON0U1G*CW$ ME\Z!K$@;A72@P'7#Y([<:DS/D%-],DJ:+E4Q+CI7_RNMH8./4?4O/&HRX8FV M]7L6:JTSNE4B.<7MI_GG)5.O,&(D\2GX/Q>&[P54#AA3WG3^2PX1HA#$3="E MCQ5MH](`:ND#M$"9@(VVDF.IW"'@DR!<4':Y>ERTK6U;@5>X,4?NF,K:>:K& M61+`]E(:'3S91LY"UYDG@_Y8R6"YF)?\F+HB783W^[HX'[S#W8O7?;5@P7_R M''$JSD"V2+=0EDCXCD$*UK!#YYXL0D$S).6@D"F3LIDLS"*$-GDT]2G"?`"S M=8XL!#9NRK]D)V'6*%*P#'EKZ0/C'?-ESB7"0[8BYLS<84H8T2$2S!8KF*FB M%K@,#"01:9&(&1)MH%)N97YNG@-=F=*&F3!+)JAZ#1X;D+O1Q@-RIPRL0,.@ M4L'*;T1U`EX1LRPK&UA@*<48:,!+05CUD;C3V:QF>KP)##OE1069JO9MZ^9$ M?`$[D7NR6)+Q%`[YX4F\`3H1!N@"K0HZ%],ICO+0V(R*C0*)S5`>5PS`RZI= M7Y73QI1.FFJ#J][/_:(:GA[PJN+Q)JV'FBU`BPB/MS M*V^:27.%[E*5G43Q44PE1PHKD4'2S'>P7*W4&'$8R]*%=%VBW:P/]H%8H M&!V96G225[&0K+2X0J,I"(HT6!05_UT M$"I8#BT<1&85B]3]H*QNRC5*0\*38+OG,'M:W\*BK>=C52YRSP%[(JL('GC` MW[D\U$*MZVP4>;3:;J(]<88J8]K3N@GM_OZY4.=AP9\F_9-`&I?4O$[+`O3L MEJJGH8)80"#ZQE]YHE-:P5-%1VQUC(JP"2,%;*EMH,RG+6=Y7=;NCM-=&PA8 M"O^Q@D2'"HE?X3\$_3=,RY<;]:PJ^UUI&F1+O/V")]Q-)RZ+H*XK%?Y)8X.XUZ";8 MXS](>7V:4F[-I\QS]"L3G@,"]ZWG4VCJ8^*SGQ>?&W4WNFN%+^Q1O]L=C7*% M+PX#Z73+ZA^XK*'=ZW7KNZQR9??$LKJ]41?3;NN[K/Y!R^I/NN-^;U#-LOZ? MJZOW81@'84PIR`C6U17\]/>_?;^+?/CC_P=02P,$%`````@`]X`&1_:]+X@" M"@``JHH``!4`'`!A>&=N+3(P,34P-C,P7V-A;"YX;6Q55`D``Y&^PU61OL-5 M=7@+``$$)0X```0Y`0``[5U;<^*X$G[?JO,?M.S+[@.W0"ZDDK.5D)FIU"8# M%?;V-J78`E1C)%8R"3F__K2,3E(]JM6/4>.\UC@_;J'N_3S=/12L3_,2!I1]/U<_'B%#!`"9/)]* M>ED:AN'XO%I]?GZN/##I@9<5`[:114_(_]4*@4?E&FS.?,*`;_I`\H+ZB]QH'"GUO2$@H2TAE\\?# M[0(:/.4#PBCS*AX?556*JI7.R*Y&C%6WBW7^5G;ZG3$1$7%O!5JGW$GT;2R' MGP/^O`WP*=W_(O8;*KV`RXD@O`8[L4)7<'#"\.6*^9_^F="Q(BT,>` M7$D)8:8X-JVFG>"*'4EV\0M616(^/!$3XG^:CE6UVP"HN6IKY!X.O$D0A;P[ M>!>C5?F_;4N2,BR9A@0D_/E3&JKJ45HWBI4CZW8JP@RH M`^XM%"E0?0$N%LF.U46J^E@^1OJ@$S?`>*RZ2LTJ"4*9/%%NT2S7ZG'C_U/\ M^-O,-1/-`7XDP64I>5C=68':$R'`QDOE6IOFVTGC^+39/*T=-)3BQS%*:I2Q6BEK4S!#1+YON"C5[/%F7";`G/A$P%] M\A*:2"@''ZL\<%!"SX0.AF'T9A=TJ$87*K3ZI0+T$PY48WP5MK$0+]`J_8F# M"='09"3K#GWF9*T27!RJJ\0G0?V!>`3P0%S_2L*<:IDA2K,OO:G#]3!G@OJ-/Q%\>`^K9RQ;: M!_X*('`UX-Z0/H&8X0,D-9)K@U29TFTS1$F^)RE<,E-WSMDYK5R]?TA\"F M'3A7!UJY_7%]0G=(+-+--<3C:E5L\]&(LPA$Y@K04C)W.+/D8TQ`'*4RZ7FZNX`%17!"LJW7V0>W"8,3_A`6C;""AISX9 M*3*(#XT)]:BN'RR^$V6!&(AN7DJQ@^AJ1'T@DH"UU#;7&V@1`A[MS"Z"T]6)]Z^<\<4V*IMC;7KWV"TRF+2#9U)] M=SZDO&4A$43F1.BE5`ZR:<7,*K,F`'.;W%UUIZY&7(3T?Y&-.OW9ACRP0Q*_ MU!&\:/N%;K;>4/SP6-\(N;.]ZVA/NVWDSA8Z/.H+X-V+R?OT\7>3N?M&L;E[ ME0VR/6;OS,'$+H%FUP?&!8%RW9#9[Z6:82>ZD]X9"57INH(_4>#V^N4/J3;5 MSV<5KCSH=\XV#JV/V0@M<;K"\ M1;;6NL0;K"+M9D_<6!"/1FCA[X!$Y,`(-=4!TFZ/RQ=]I_Y0V#2N3NPL]H>7 MCV<9#1^6A=ZI:Q0PBJMS0%F#I`(CR@^',#.)JR?E>D,L2/39OC8?J<%25N.Q M/O$[=0$+8\3D'[M&_JV4$W7:L]./=LY!6_<7%@)#Q_HS%STBGJA'9$>T`TQ' MNN!@I>.=NLKF-HH]Z,0U#YKMD?V-,C^986B3V"5:>^`2\?=[ MDE-M:[_C8^PK)LH^G&A38R538K4]<"^3<^K6;566L@_WVM18B7LY-^6ZBG'I M+*ZQ(RW)??B,A5T2]W!NJE5C,]56R[=>NS-4ZHYC;6GM;A,[N#IE#P$S6I3_ MG5]Y8*K7;Z6O?!]/.\XV5>".?VR1YW7C[XT,Y.RNL15,L&RE"I.XZUI09J$SNXNGP(&#U"?/D9#!=-9G>BDLE/4R(\*HGN MT%VNG#O>L$56UX290G9Q=6-*&LWKHD?^%T9RY3Z\P\(N>W%2(6E?._T;\A@F MX+*V(61(O%?WL+1(;J-27N\9;[X!>H/KKU+D:79!-VN-VA$JH]=,U);H63YJ MLW,J)_2:%4KR0C_'N?WB]E[HC-L<%E_M]*H)]7UP.21^=#8=BM/IJX.3XBEC MYC57TIW:OHZ#M9=/6()QM7V?X_F+B^]J%0&:)VE'JUYR#VFU!./JK-,J5G`/2;7#LL-C1*8W*IHTF[)-XO?):OQ.+:(2LTZVYA@7^[G^\NP%O&E4)9,+?\:5\\'3#%W''MI%&+>%-/OL5H MTD>]UA.7D_I@F"N"<\L+4QKJ[B%8D@!Z^(1/9%1B'&AB2&[ZPZ+/&JG)9)?A M^M%%=6;XN*V!)_\'4$L#!!0````(`/>`!D<&-F;G/Q$````C`0`5`!P`87AG M;BTR,#$U,#8S,%]D968N>&UL550)``.1OL-5D;[#575X"P`!!"4.```$.0$` M`.U=6W/;NA%^[TS_`^OSTC[(\B5.8D_<,_+MG'1DRV,[[7G+P"0DH83F8PL`X?[!WL6 M]FSJ$&]TOA?P#N(V(7N__O.O?_GRMT[GCXN'ON50.YA@S[=LAI&/'>N5^&/K M%C-&7->Z8,098(B];4LT(Q1_N'RU\N(TG4.[,^ M=S]VCPX.3ZSCLX/CLY-3Z_YVV>Y6*#8D60U=XOUY)O][%A>T!$"/G[UQGI]WP5]&4DS,>(NE3 M&_DAI9G*6\H6\J_.HEE'?M4Y/.H<'^Z_<6=/&-JROC#JX@<\M$(%SOS9%)_O M<3*9NE+Q\+LQP\/S/?0V\CJ2K(./QP>R_R]7A-LNY0'#C\%D@MAL,'PD(T_0 M:R//[]DV#3Q?C,)[ZA*;8'Z%?412`P500)#B(B@%4$YY+.ID07]ZQN+A] M7=+P)BV6)#NY`!.AM:!]#)XY_A$(Q:Y?I':[>#F%I-RX0M41LQ?XHH]Q;982 MB.=W'3+I1FVZR'7W,@VB4&6Q1)(KC9/03J&T`K02G[$G5[@=ATX0\0I4,2FZ M"'U#49T)GCQC5J2RZW(+T'0LE&)V\(P[2T,4J&^J]&+'`QZBP/7+&1`+V9'& MXF_B$;DJ[PNYD72I3WE+V1@H_.9CS\'.\EOBRRM_.#@^.+0ZUNH:XH_H,A8= M6K$+6:LK68M+67^/+O:/'#>:T!R20FJOJ>C*30MEJ88/10T1?P[EB8WI"*&I MW/Y]Z&+7YXMOY'WV0^?@,-JE_!)]_5WN[YS`Q8-A!(*''J]/D2<]P@WQQ&9+ M`'O`-B8OT@L^R?\6JKCH&;OA?G@W:=UV:XG+A95>7ZHUP[XWP M#=5S]5RJN1JR/;:NL)A*BRM$LVK+FP5E#F;G>X<+:4-&)P58.M*5YD0><(&# M3B5BY%;&U]6:5\K'V-6:VRFY2CIWS/9\%145+ M'C#'[`7?4+9`L-+U"@L]G&^>35T7V[Y,O=V+98W0"(TV8S^["H,P.[<9";OB MGC)"&?%GX?`L96OBNO15EDH([:YH\.P/`S>II5S*#Y-?IVYB=A-8*=''!1.] M(W8@9.LG<7X9E5+ZH19*RYFR!?EH(P27`6-S7Y+JJ//)J)3QD^+]=DZXV8Q_ MZ:ZGKPI+:>EKE4P26!^2":R%4`MYCK44V[QDU0+'O2L3?3$+F66GLKK7,9F5 M.EW,GL2U-5$MHYX04U=F+,:GKQ%4`'=F-3)QY=2T2:Z>0$)E.8:L$8EQB.^= MQ'@*F-.DUCT`E"T"['P%RN M=@V@`9AR?2R6%F/J.E\G4T9?PFA(>EK-J`>$V$).LHQP`6!*/YN4K2`$`;9D M!.)\44+)BL^:=*PO,FL.*STFF[6PK#X(6S+=OS'*#,`FW)3X; M';1@L4;C6(0\'@G/3ZQ2$(3L00E4*_$VB'QUKB"K$X1L00FD&F8,P!#X@*6] MY*8[GL7"`H!SF)]9O30(M=XE4*X'7?I)C3LA*[IP>+S`DX^4G>_9+RGW4Y]/ MD]VG4JX^%L.5(31HLS,^;`;#3:2JW'Q&ITKY^U3L7,O"!B\AR\U3LL=M2K9- MR;8IV38E"R0H^A.F9-O46[-2;VVZ!P(!;;JG3?>TZ9XVW6-FYZ^>V#WA1U]L MO,/RV^@U*9J[N+9'#?=U12!XM_NZ%B1R86S M].S7`YTAUY_=8,Q73];ZY@G<1K3EZM[$.H3\*$NG+-H41DHEATT:3]E]FEA/ M8`BM=$96@V(PO$33J7S.:*@.P5Q,\ENQ/B-3%TZ%Q5RE*G5@%" MFU@P4!3V"J:AB[E//1Q=?OFR-O_;E'KAL^NF_F#X&T.J*9FG?V/K"?+!++_: M(Y!(PR=2.('M\_`N?H5?L$O3CO(;]FEBM8`A-&C5'M&4VIVKC"S_Y7CXN]4];C+5-;;C]E M.+;W1_1%<$OFVHH/FTJ*K[[W\0BYU^(FZ\]2HL6I+>!43FBL*^=$JO:%W91, M+3R_>&J@,/ESS>%;S8A8&'1=7\C6!!EAS6GARAZX.!`^R46>(];/Q$?N[UAX MD?$E8NG!4+,N=09"56-EN9;)U+X,*S^)7_$]1G_RZ+)JZRJ;UOY:-\.ALK2T M$@F`]6&?>B,?LXGT)!G/:4YO"J<$)L,9ZF$`I$*;6E,U!I+^U`TK'1F`$IX% MT`'2`1=#465^68;\Y1L2-(YBHP6$]*-^\*P\PX;J91JPYSD/^`5[@3Q5@!GF M_GW`[#&*Q7ZS;9Q#"(2<4TX:)H(AV>]V'D/+-`!"_":7Z]J8> M4I>C4@ZY>'Q(XU>232%,K1SDI8.`%BE=:"F!W5'/UKYV2-480LYV"V8V80`+ MFAK'3(_:F"F,Q7(3MI';Q53;;>3/LHU4OGATVT4TR)7S;AN82I;+S=P9%K,E M*7R_\;[R8MN%`MN\&.R\V#M-'F2F9,I)%*BJ\*[Z\L4#_NP1N9HD5VJS.F^D MF59,U1C`P@SVN6*CS61[@+@]0-P>(&X/$+^_`\1M,!W*V:A%E7JLIOT.^]%& M,W5;K>\`83H8D&,"!5K(?!W6#;)Q;R)?16\T:^+-&Q8V5P.!S=`B3/.`_/G1 M6&V3%RR_S$VN0@J$$U*%,*S` M5_IYFG6-0BT>IPPC9^#=D#?L2#4&X26/TEQ=KNX0SD"9.KYH"IF(J>@JGH;SX^7$CH[4Z2(3N5*)->E3)SNALS)GA*IV+P[))1^"2& M\!"D`0U9/:J-#QWLQD$6&&@^:C%)]0=!$ZVJY63WT$8"`#0>XA57\H&W?B"U MZSWSM&ECVJE:EHHK"%3A@4;:1L!,:&Y6CQ4VA!#V-AMUFAAAB*1\]Q[X\T7^ M`_X1$(;G2PLA/US^#Q^PT-M3+J6W$P$A/&A.SW88HT9MC!U^(ZSPE?,` M>;;0.VX%Q?PRZ0@AEIA_OID@@U65N[=F4DU1;N(5%&U1;AZ5WU?!5OL@@QUO M0TTJV&I,B5'>0JWB2XS>ZU,)\A9OM4\E:)]*T,SC).U3"=KC)._O%$.QY]O+ M?S[O^SJMXVSI>().QK>-M0AWO(!+>1YY!Y@8D,TO9E`0?['?$',AK[3_0*3T2#@3=@]U+1)WI# M&/=[GB=F.>.(S0;#WG3J$EMN1B_%IE+(NDHN4FK5I%$UQ749J1'CL#<4SF83 MTD7@7^`A9?@1VU2TJ6UL%J5=4^JMP1FN.6,X@6F)]FE,6-UCN`#MFE*-#LYP MU8_AM,+AO,"+'+65ZE/M.-T^$@G`5-6/S-5N);YZ'C`R(N([=]9S7F2)M+-` M.7A=U1YKA]AV@JL=*]M'0(O$#"T\$^VFTK>.JD;5$K=[J'-3?V@D7-+)A'J/ M/K7_?!PCAKD\K)"8>IFMJZ5E^Z!F)A#`_/P;NW523$&U1K_NT#C&FZUW@N28X"XD]")^4#@^2[UN-R;;$ MBLE:D]Z48TN/]A@[0;B=F6*&)(`^%KHX\U?IZLXQF76MI299JM%C3!8LA545 M&27BRN9P#D#EX6FM5%F)#<`=,$TY??VXI@.02L2LL9=%#J0WW!5'#^PWW15" M665OO/L7NJ2ZXW+KOT.H',T>2,N]Z;KR`"9!ZNTVL?39F`A9G>HK*36#L[:2 M,_(\8!X/VV,8R7@7YX7(#?4+OWY M6LI6$`HQ\]YS4F#4&`%X#)XY_A$(HN>Q[GS;_L/DMG\ET)I+;,Q6?]T2VJU] M:M,ZO(%<*HK)NEH[:O;QBK:`-O$:!N(^0`$$A'->ZB0#:G="D]BR7GSBR);Z M<>WAMMQ2@.SMM8-QW8GG!/BS4@LZ+E`6W95%"OK$EOY7J/2(V8OX@QL<=#?H M!"&FL.5P72Y3#&!"VQF%!\JD@H]"=224T_A"15LXSSTQ]84*(!#HB!3ZYO$I MMLF08$<;'=6T!^+?M`-L/2:DA/*>B`'MG78GJW@_5"Q_-Y1A&_%T7Y75&(*/ MRAR(:31M`H%`R,:]6I].5;:&\V068^>C@@*3%/U=3MT>BOO1#[,,8B`YH**H M@>V`"J`+K`M:5UCO@=+;@G!`60-10Q)<_Y.(/>L)Z4/(NV9!T,V69C_,IYGY M/+-=:YO)*S9=:F+>FG)X=X$$,!@^$5G9_1M#0S_UH0'I[2"D28V-FPZA,@O_ M3GGXO&&M>6.-(.1(<]LVIG]EAHV=Y`J/=_UG3.SQ<@Y=TL!U+K"<6<233Z[2 MF3^W*`@/J39[%DBFNK2I)OG3GIB3S MX@OQS?\!4$L#!!0````(`/>`!D?=T5M;J4````H1!``5`!P`87AG;BTR,#$U M,#8S,%]L86(N>&UL550)``.1OL-5D;[#575X"P`!!"4.```$.0$``.U]ZW/C MN)7O]UMU_P?O@C__QO`[((XL3'H5_^N+MJS=? M$!9ZD<_#U9^^V":G-/$X_^(__OW__I\__K_3T_]^?WM%_,C;KEF8$B]F-&4^ M>>+I`_G(XI@'`7D?D-/3K/=[FHC644@DF:]?O2V^ M.$/Y`^OOW_]]9NWWY%O?GCSS0_?O2,W'XMV'X5@2][6,.#A+S_`?^X% M0R(4#),?GA/^IR\>TG3SP^O73T]/KYZ^>17%*]'_S=O7__WQZK/WP-;TE(=) M2D./?9'U`B*5;L_W<9!W_.9USB-O#M_RAO;[Y)\/Z&=BO7WW[MUK^:UHFO`? M$BG>5>315/Y.K1(18POXUVG>[!0^.GW[]>DW;U\])_X7PGJ$_#&.`G;+ED0* M\$.ZV[`_?9'P]28`P>5G#S%;UDL1Q/%KZ/\Z9"OX28'#.^#P]GO@\"_9QU?T MG@5?$&CYT^VE4:%W%5I9)VD[JU_EM=)'^0-TOA)_5=1BSRD+?>;GB@&[!M)2 M&OFS2,I`._(J!`/XC:*X:BCZO`I/P57??/_-&VD&^.1OYUD@+4+_0YCR='<9 M+J-X+7_CQ7V2QM1+CTM^"^AXODNE<4CUD2;6./=?(-7=^NOUDAN^@) M\,O"TY\^=U#FWW,FA(8^46R(QN>/2KQ.KIMQE1R7-+F7;,6XL*)T`^C[[6L6 MI$G^"3CYMZ=OWF9X\B_9QW_[G(KX!!YPGH9Y?BSZ3-!'K#N7C@@7*U7EBTFH,G'@H[@#<"42*I M'NV2"?->K:+'US[CRAO%'_M.*#[ZFX+A6[;B`/)A^HFN]P&PH1E2!VQ3#-S/ MU`:A\[6*VM?ULC&XI$J`[+2N=R8\/Z;!I4ASG_^+[8RJ'[9#[WP&U:K>M]<( MM?N99#W2_S*R1-(E@O!4'I@GI'>";(W2>U\C]KUKE2Z0>5B]C7\\JJ!$@-Y4_G6WC@B4># M_V$T-H-:0U/$7M:F8.YPIG9(?:]5W+YNF!$FBC(!TI.#7):&*DENV2:*4QZN M8`:]W5\XL6B.V#EM%-V;1]2V1>JD5B(?.ZO(_+4@3Q3]:7WU@@TB/=3Q(E.=6)`3):KZ/PJJ;Z=/U;;SL8C:U2L]TFM MX2R\LD[>H?PR6P(:Q#,'V%N^7E[PD(8>%UI'"6\XO].Q*U(O[F.`VAWIAGX( M?;R7^+U7`Z+09R$KB[(R^/8\@^- MT0FA*69@.6:9!L[H)\`+!1N)*H M-;1'#/=68O=.VS+B)"ZHGY"0I1##-`BB)SEG7T8Q\:/M?;KO'GS1L;%OW[W#OX^$823#?-2_BA:.$H%YV/`MV_>EA9\ M]VV[!:>#E\OP4=@KBG?">`9#[S5!#A]U"NEPH7^/&!YJQ>SKS06Q$R+(N0G7 M<10:1Y_,QXD8R('0FU6V_"' M<&NPSB4LA_6^2<*L;<@<5J4[8$>\RK*MRY$SVK`XW=T(;61!A5^W?`/[L>:< MNJ4+\D"S4;@Z2)K;(PY#*['[CPF*^`F1Y%6)C)R!PSQ]$J6EMJS4-AQ+VS98 MLSC6F@:FHM:U%Y.K`Z9TLFTCM?G6AC9U$B]!3A MKG(^,U[9]$,.6=:JZZC5V@DQ<-G+WOO`;L:!9"R(Y"$PJ^#B$+\F5'^ISH>& M*^(!%]?+#XV31?R!6E7B<*4!<Q!35=<' M/)WI+R\\9JQ^EUOC2S%PTS:WG$>!#'V/62.,Y ML3VBOKF*0,O\0PN8$II.%)"'<@]SU)WJL^B. M.-C[:''TD;6,F1S5,G:D#AK<'MN;U"0;S20T,TF^&>]H\H+%,SX8S##]2M\M M>V3AEC5CI+$Q'JCL7K3U'*\HS`9)#ZIMC# MKD'!2N#5M,,<>DWB]O5/22Q/U?0=*D?S]S%T5#%XSN['4>J1Q?>1`[6`6)%D MG^9#.9R58$*-E-P(11[@-;3%*F;,[6&@O7RF=#.[_*?2'CGZM*K:D'Z7C1'C M4+O,PR7AKO%H/%T!$@A@`LYDO#U#PA^)->H8\F[$T58GY0"9MO,$>Z!1'45& MW7D#?Y+3[B1K!.NMCX7:1IS.^WJ9D22"`!S>`3`]V7151K<4.Y?AF=TPT5*I.ENV@VTZ8@9/:@"X0W\J#.`I+N[B_):EE(?,_T!C MJ(R6+#QON]X&4!`Y.S!HL)=51^1Q;J^\'N?MO1#'>0?A^[IYSH+D/,B7&A=B M.H#L!.L"KA9N!M!9[5^ES0N M!*!8"J^]&="^P&GJACQ@;17O[:](`WG,]S))95[=A0!B-.BG1^\LM%+:->='B@/4 MMUHU6+>GZ*-"^=E#?L/UBZH88.[M(/\PFC6!#1!PH1FK+!M[&4_F& M\TV;L8V0E$9X'.W]C&Y[+:.I7"BYOP6#`N+4Z[6+8KNLW5`U/>8#:29U#5"V MWWP>$&:4>ACHRAX\+ND[AZNQ%,Y@ZF!/&5'DJEU^6Q,5K><6L54U&Z-5-9U3 MI.Y)/&24HCD&,H:FU?#DXRG:+9,85-4,;'&=WCA0]KH\-F-KGVJ7N>%1C<*- MH*2UGQ,RU8D]+#Q=CWS@JCM&C:!S%:@:SIA-^9J1P!-6O(?=+W^,(C_Y+%)%X]BWWPIYG!C4JJ9> ME2:(H\8D:7_83N2KBY(B^5PS0Y@JHQI'KY74R^W,Y\;!:J5Q=)6GH@#AD[>3NOQ"AJ$M/ MUNCG@>MJG64RG?V2OL-)(PM93`.H7.RO><@AE4CY(VN.X/9>R&/84NW*A+.Y M"^(XMI6\]U1.T5<%J2L18DIS.I;(H^T!O7T8*MIACC>FJ3MZYD% M3:*(DB^![$BW^]OB;@P%@0@!YR`1@AWU3U$8597,,*9ET=:F'_*0M%9=#]#6 M3HC#U5[V_E6>2PY%_&9,OG*^QCN^_M?I`XL)SQ3/!E67%0+S^MK-,\_#5LA# MUZ!6]717I0GBL#1)VM<)BYKJH\P3WRF%0K:",V)-X3::7LSE_'=JK2:L-;". MXI3_0V8DU\N+_#GL?.YQSA-U<]=@F`[=D:-+5T-4B@M8]D6,1YU5Z'U#7&,$ MYWT*5J2<=Q?<7*'89-;8!X)3']W+]#*],691ICE46R?D:&"G=&42W]@#<>1; M"GY<=MPX1W`SID^B]_ZL`.&%[K($[;EN/&4U:MAT?8 M`I6EK:OA^VVP!V2=2I4@U!M@#KQ:.7L'&TL)$'*T,#:X+L%HNK1BQ"2_RW08 M\%?&5P]BCK)X%,"W8I^VZWL67R_EU57MYNI[FG!/SD>";6JL#]&;&')4.GE&DX>+('IJ MN^75T@5YR-LH7'TCP-P><;!;B3UJE0E@2R1?I]-N$.,FCAZYS_SWNY^$T)=A M<1AHX:7\458,%XJ(#[;BL[(Z1MO!F:&((X^888VXMT(P`&7$43BP@L?,?64X MYH*0^QWY$F0A//R*%.*04AYX>"N72"L8X_[D#PZ+2FLN`=PJ!P#AEETA@,/# M0@O_[]LDE5!\%]TR"'(>L,J"REUD:<<6%!R)%7),'-/`U9<#A^>#&"]'5;?W MX892*'@/J1"+`*Q6CC;#UQUQUCF@SL'D<6'R,%N1AD_A;P^LO04#P],$R%#X MG&V$Y%P./>+O@,$?<-U*.XAB^%4LNR)'R2X&T%'/IA]B%.LD?M\0T9FMC'7095:Q7*^P[<'HV<2Q0>RA_-GVQ*^+ M8$:B^H1['-F6#_//HC6UY$R;O+$EGR" M!M8(\:*JZ.KF1.:AAEC)6D[PXH;BCW+\/_XJ&?WQLS&*>V(?*0 M-RNGQ_5A*\3!VR!L7T<$DJ<\/`6B)*?J)@)'T*ZX#DE]V!*!E?LH=7@[^C+T M8B8D.V?J_[6MC#.ZX2D-VI_4L2>`/$"[&V/OX1W+WH@#NH<2_4-!L2!?YLR^ M(CS4-@8SALYW!2>TR=F#Z,?`#&KE3V8G`:?W/'"]@7=HA<-'UJT-6-MU=NA@ M-D`S+ASVFQ4B-(@_,!;DG$C)REW9EPG,4.@;&_5U&?"7X2,+!3=NK!7:UF=V M(5ZC?93D1>&R[T9?V& MQHWYWL1F%^9=C-0<_S:49@4,G10:&#$RWGG)-YD-J[(C8QP'.`9&)K%2;HZ\ MK+&TAZSN@`EP\B3FANX@@8IX7;X5%RWE,YR2KA=CL`*>+D>PF$TV49@4X MG10::\*1,5]IL= MKAA4;X:0O4ZS0@N3[`,#0\Z&9'RP`,#0ZA=ZQO5ZSN6ZJL&`1Q-%#@C#&&VX M:ZF(H60@Q=Q?0W56D,JU^=KO.Z%#+U@A2L:Z;-^=^#S1K*<1+5"M(^7YH5M? M!4="N4*<^5ZVG]JB^Y?M>6%"%-<\Q40TNSZ[\'[=\I@)>PDCI+L;H6\*;WV) M3^4[EL8S-QT((,>O[L:H'@2S[8T8AWHHT?_@V*ZX))TQ(SFW$R+YG:A'[W*6 MKI:/IS2*$/\!IK/1DFPR+NII/),1'&*%Y7U1FWYS0P:;6Z.MG>:$`X/?HJP+ M_Y'OCQX1\<-?(@6Z"4=XA_2XQ&F4;`P_0`QCM.&F/(BA92#%W$]Q4"WD3&F^ MZD).W8P&'7H5]X;'6,CI3GR>:-;3B!:HUI'R_-"MKX(CH5SYQMEL%W*FMNC^ M0DY9(0#'0DX<>8SYR8603=X-O-Y(_3\\L]CCB;$,NDT_Y&AEK7IE_^2:XJ!<7=TUS9B0@HNC2WX3*\\RNC!+2Z0AHHWCU])U$Y2WCE7Y=FD2 M"].9^LTHUAM5-\5Z;:>9Q'JS[,.XNW[A/G__`]BX#_8IM.>:]E[V'$*=]M,O MNEXOS]E]FMN@J:!7Y!\:OQ.B.)*:<_]N$&52NP!^\(SHZR]]_<:#EYM,_L%*41S6+MUN M-H%\5(L&^4->E^$RBM<23MN>:K/NC1Q`.IJA4N[4KBMBV.BJ0>]Z>!J?\ODV MHK%ROI'AQ!0^3[P@2K;R!=>E`@?8Q&'^H*'TP71=;RB85;"O'S14KU8 M!^$,&*@&%:_OA$)#R++P4UGZ2X@ MI3C7R^P6OIC6&XQ7UPYYH!A5TYW^H!%B!S;+>K0SEC3)SW?L.27OA<_]XBCU M'%'/8X../J]""*7OWGS_S1L92/!)!5H$FKS?)CQDB6G`LNR"-+RZ*`R19M,> M8=!U$KNO7^KTY7)(SL'AEA!-Q?3K>MF^S5/7$*G/MBM7V8XY:(70/RV$[;UN M)TD"7.H'*YT/"R-HBC#^RE'O1B2HGL6ST$T=D,=CN[*5Y]",K1''IX70_9?. MUFL:[^1K(WP5\B7W:)CJN5S.TN&J>BG8H24`4B2BF-8@;3LC=_-N1J@LJ5OU M1.S^'17H'0K-_H]@])K*$#/`!..%]):1SJ8?)M'QHA,!Q(#13X\C=KZ; MJYE,>M+"H&W;P&G7$WD`=%!_[[A&6S?$SMY%^L%<'-=`Z,0$3N^*0;WW)"\K M3X.VE<[F'LBCVD+=O;MBIN:(H]A&ZJ,?"JA[/>&#\X<";!Y+L!_(^E-#'@9' MFJEF.Z`K*<3A(G26NZ!""Z86L\=C8V1PTBSDCI*U+=$#`(M M`O?>U(]25KBL.^^\BL+5'8O7H&7;(&AJB]PW&U747;.V(6+/;):WKV,"U5,! M]FM5`<#]N#*.FDCBKT0669D$!BMY^N66!5`50=8X^/Q`8P92^WDAA+91Y%BB MR"-Z&*-51J6C*"+&B($4Z[W]K1?_FD&4O=>MT#8>'D_UI<19L]EZ!5H]R9<0 M:2V:]2YD4\X%5?6M0@*2B:"*^)P0*<6I#'A25/QQ/\Z[-B`2K))B/$2!+^P% M.Z+I#E*5MNON;9V0(XV=TI63>(T]$..$I>#]WP"Y#[A'KI=+%L/QLI9*?*[] MVGX)MDO_67J[Y3*K=>?9Q<`8BX,ZI]\1Q8L`,UQKI],9!"T^@!0\5=./T%<% MM%8L]"JKQBW#8%<:R'&BETDJU:.Z$$",%_WTZ%VDH>2FRDCI_%XACY"V8;0S MD9<0(XT#:C<**W/^R4DZ82,IX7+5UD;L.>;FNZJ\85C$G MU-9=>-XR(<"6W3(O6H7R&4IYBW'7%J8V_9"'J[7J>MBV=D('?)"1]"3&.:&E,<8H/=1V,H$>PE8=$<=S-_G[^CEP(9(-I(H%(Z)QPA?U:$SC<$^L M./NLGXY6YY5E31J8`_!'!H6;FG&B'R7DJ'&$>2H[;-W)($:48[3IO4^E72_0 MN9YD9^OEE+7@+`NB)5/CS2.+[Z.6C3QGIGM_8#IWH/-3(A#W0Y+R-4V9J?3\ M02/D4%&OE(X"U1:(`]P@:%\'%.1@Y"L(XDL$1E;8Y=O?3UHAXC@*Q9\>T[(; MN\EZ#S+(H[6O8:HO>G>C@3CB>ZO2^Z8\>ZK4JZZPQ`<0D]L'%N/W2GI7N#J< M,7@/S-\&`C"+]I%T\T]N4=L.P*-*R#J)>VDF2[5I]U MQ(V!F,P&788T:CT&#<%A%D@UJ*)#Q&]-U00B93HAE]2,X&=_H; MK!Z`NM.;!1(=H=80L69=X!P?.#FV',TMM]$L1S/+,>?%SDL[0;5>[=B,/3XU M=)P-"K4I7X\UIEZS0)16X8?P_KW:U!H_A$@QB454&>N-ZS+6A_@H!;N*:`@5 M5[*3=.&JO+@B?RYKM+6E-AN$Z&6FYA3%BM0LL*2?1D,F)BA1!.W[WY_ILW,IC@D[]5=!=J2P%*CHL56SSS_8-8W7HB M#9(>ZD-`=.CFV/G]R)-#@5Q1[_\+#G#181G%:[5#<;\CL-`N7#_9,`^>)R>@ M8`*?I.HF9IYQ0A"$;2FO*?S%'WG#0!5$W2``-5Q_B"PIT?_%C0, M9+8]<%@8P4'QFW@:XM069J`TV.(8J%RQ[]_>1>_>G--=\I&M[UE<:XK:9J@! MT*Q8B76';=##6H/(`R!8^L#ZP11YH(^`=@!UJSC:;J#?]V\!_=Z](;X0=FH@ M&\%0DB8!H@2HDI\572?8-(YZY4\&=(?%F>M'%EO@3$TSY#AC4DS'F?TV,\`9 MH\A8<$;TB(2,[@!F<`M!!"JB&`!F-/6.P9=A%EIOA0)U*T!UWR-%'Z,JE8J9 M^9>(%RP/9>P-,$#IB.6$`7VK=HBK;S$'_SHZ]XR"Y3MC9-&#IT1QYT M70VAQZ-M7\2AVEF%8Q?]K<](`&LB>3N*^,E-,W:!7L-:Y2U+6/S(+J*:$L3G MC*V9_U/H14'`O!3.N=^P&*2BJ_US6$<30XH4PQBI6!WM30G[&NKQB@VTTAHK M0>3=SV)UU9<2D*TNP@F"NX2DG'\MCB]6U3M4Y5!F0.UZ:_%@4G*$5&"FQ5"0W6Y$DIP\T M)31F\J:@EXID)XW(/<.:2T]NUPXH[#1Q=N!P9;Y\@+8#Y,C#+(46U=R@@D#R MP/P?H\A//K'T>IDI8%H%M>N)%)1[J%_[))&Y&^)ESR[2][\P4Y0RS+D0R>:$ M"$:0@>2L'+]6-*(-"L570!M!C/\UBG^Y#&_BR!-#5:<8;^PYEQAO5[\VQLW= MYA#C%M(/$./`A?"09'RP!?F(1L@UWRCB"*+\ECY]I,(VG`;=@KRIXUQBO%7Y MVA`W]II#A+<+/T"`"R:DX((MO,>S`*B]SDDCB.VBNJAM3-=UF$LL&Y6MC>&# MUG.(7;/01\>L5E,729B.J6RYGA,;E)WXU;'[_6>0%G$,AV]A5>S]KFRBUQ$N M7FS3:@=_R):=[EB\?FNP\*@,D:/%^,8^>.IL%&Z(T6H"I7L7HC$\G$8TZ:!@ M1T,E6NB@9'N3A?X203F'@*"+F+'+4/QN+$FG@F\#W]\2>#>9?C3HKF/Z6P'N1MT1PC;(2T!@DDO\ M4E![E%]"FFL)YHH%.3QP710<-;]J8E6EMK4[=O#L:(CZ.K3-?3%#65<5QGSB MQ^$]=J/V[W=W@G=#U1&[GLBCH(/Z5N]:E=T0^WX7Z4=Q^Q,"?)S7/C%'ON!< M6W2U6\^Y^OZA^G9ONA7=YNC[-=(?Z_N9ZR\JB*\\WTF=4!:4Q&QX+K%,V'" MJ9,HI`$R[LK_3:D[ MK='=70ISQ81X#U'@7ZZ%0S[*J7]]Q5*['DAAKH.Z>JK2T!QQBF(C=5\_+F@3 MG;CCXCS3*^PN8)O3$7,KY('9D'`8FB`.P/%2";=Q-K1>V7%T*/V#X)EFXZSF MJJ4:EE5'Y/%GK[S55/YJ!K6O.@@_TMKMU<@UKAY9?!_UG,H/;P0LS[$;5?XQ MCI+.,9YWFFM\5Y2VBFW98XYQ715\I(4IR039LMRPBE?CV*#QI*4LM^MM0%/F MGT.%`X_+11_Q=\#DGG;H+]91G/)_R,^-1C(8=4#RR"%B:$/NE:"$%V2$U+(HIY.UZ0Y(7NP=E+%M6$![9VR9LA6(&03I*$QZI68I_P` MQ2L*T_J:/.I!=4T0#.=3X/)]RJ[X(_,OPWS]>9$D+$WL3JA8$$`.:=V-47]* MI:TW8ECJH43OLW/:F\B*V:GD1DIV1/%S?VREP1CO=Q_IWZ/X+*!)TG!\I1L% MY('2PQQZI'3HCCA4^FAQ3&64AOBXWQ')D$B.S@^Z-%BFM,LGNFX^]-*=RGRC MILDLEI%31V*>T=.HR7$11$P1I(.7"TJEK9A#8U1@P&[3+WGHCEE$E)VO7V\Z3*.EPX%_/>MJ#<;X,\ M$&M5JJR"ZPT0!UR]G+V7>A4UQW$UBDXHD^B#35;[[.%J/GO,70Q@F2,?[E+B M"\U.XH\TGW3_G-(D5M`4IY*TJVUU-]H2$80)3Z`PW0\H<:YIA]VBVWSQS;C+ MWM9GGK@VS(9SVQS6X5;[5+H'4G>^'^@G9.5VT[U!?VW+3M^:ZVY(,Z'YXD"+ M<2R1P4!EGEC1ILQ8Z*%ODR\:MFZGVNIV8*+#36T<>]@-IKAEL$H):RWZMC^+ M>>2;:D/VIS9?G+$QDR78-)&:)^)8:306[!3,*Z!#%'MTRM@[8K_9:RS_` M0UH>W?"4!OP?(M@]($YBID;2-"*;;!6U>$!KHV0Y@5<+B;>-8_%UL"/)]O[O MS$NABS[^O@*$V(8IX8F("2_8^NIZ(1[=]E0') M.!#%@D@>#NX/3Z'VJ:YWYDG*YU`F:A=;>9]:\V")1X/_831.%O=)&E//="1[?*Y(\7QBLULFB$.PG&4;='.*03B06_2JK(,:\`E%L%??M)IP M:$>5YOLLAE/"N>EZK%/84YXOPG8UG^V:GB79>2)E9^VF1<-"%G5T':0A(`XZ M))S,CA6+P#QZ+E`&VM\]18.8MJ3UHN!JST3]`2HC]&(@:5^?:4$(N!/!?@Z@ M,Y2E1,A_/RMD$>Q-%^?Z4WMYZ**;Z4A\`5(O"V$J&KG`&!!@-B@SB+4$`/Q^ M3CAS(4P_F`DS8B\.970C'0'L!H1CH28$3;EP4PND(N`$;TF0W`#&$K$?GOY@(PBZ6PXJ`HLT_Q14%- MK;GZXTV%W(L!G7JMID4>"C*,C#_'72X9W7!?O_GZC3L8N@R]:,T^IS25^VM7 MP`FJ0)FKM#3W0`XC%NKJ,-'0'#$,V$C=_X84T"8%<9)3=UY1Q:!U8_V4MC[S M]&9S;93&#O/SZ($J>S3XM-,*)]BTGK#D'@L"."(=^A]I_`M+Q=_9V-M8*L&B M&_*(ME6\4E2OI0_BN+86O7H#E0?]`)` MRCVF;C!<1/$=B]<\E$!RO5355EA9:F7/%+T((`WA_L;0[@ETZ(W_TD`?9?H? MYP9N^9V79123M&18.558\)S$+\#>]R4]KBKVB-CV5`&:9)3_E/:Y.K`!0A[ M3ED(MT`VM;?%CH#%VVA'@W1WP5ARHY[8IBOV$YS_L@+%;MTQ0V(/0Q2`V*$O M=CCLHTKOHX:*%UD*9OD#[X(;V9`(?P7F<9BSZ8D<]6Y0+NVCI@QSAK^?NZ;\:`_+JEL0BJ M8$?BS*%C>#XE%@-YZH\";R5R7R_/Z&8C_$DIQ5DB,MN/6_'7)F"9 MHC=T)P6XBY3"45R;!`Y!%#-`#F:T`D&/IH@=8H=3L&]$W0D87=-G&55:;BD" M*X^QIP?N/8@V.W(O9N249_-QT2^A00'%"=3(WL21O_72$[+9QLD6'O^"*_M0 M!&"SA\CRGGYMDC(Q5+O_!6XJ5L]D((40TMJY&`7@YX*`@0M1'""^>_/E%DE2 MZOT"KB8-%A?FDQXKK+2.8@:5)D*90`09?]DXD2NK-8X\:,(L>*2"=6:#LRB$ MQ$7\]=,F"F^9Q_@FO5[^*"+$D#QWZH]YG.AC"BVIMN^,'?U[Z3)`419PWBB\3^0ZS3E[9$%4 M]^:E;1_,Z&NK< M!9$\B,;$Q8;4='J;?VMWYVZRU#@[)&`XMW#0""EX-2NEGZ"IMD!\7L8@Z+$S M(<.AD&F.P8RDD]SAT(O$<5IF'5Q&H;U/PTS3,`M/`^RZD3D4U"%#A[?];QX MR_PK3N]YP&%"FI=D:B[AUH\2\M`]PCQ[;V5W)8,8!([1IG=AV8PGR9BJYZX5 M6Z+Q11-)F0'L3%@VGE<\["G9X/)9R_EX];[`0SGN""P0-K3N:!=28FV('&@O) MA]J=R')13V,U,:>NT'0+,!)KJOZ.[2<4YNT\O0S&'DFY^!ZF5(;&K M;XD4@"S4T^<2-M;(/7(!G7`$VN^1NB!35+V MOK,"](@B.-`5>UOW4DQK[\_7?(W8L>H4R;U*_PZI2]6*V->?>(_LQHD#Z),MS1ZK2R.2"T$R*8@2PX.7K:Y>W4P\?QG;)`9M";!P=!7?I=[YKSP@ M:,G*OC>,_I)DK,Q@96Z*&:1:%"S`R=`..RBUB3TJ&$GF1'(O//7SJ\6KVU=7 MKTX(#0E=+GG`:2IG0;B@:RS#U=G$(5)-H*:[M1:85\.T&F;5=X)90PDZ0U.D MR&6CH+[<4M<.X=3$2MS>T][*(LL)`<+.*\SM:]I86L[8>&9>:BXF5]]R1IXZ MT"0T)ZO6`Y6G.JT;-Z*>AS$Y_-0;JL!<131L2%[W6R"-J09URE2U\C7Z#+5> MVE$34^ER@6`Z=5(YK*Y`C@`]IQGD2#J-$/Z+T+]ECRSH![3G*7S3\_"9=NO(IA;(P\$)N5W%\G.6R).`Q;!!YJ M_>##,US.@X0F.SQ(/M)T&]?>(QI$9XN'8$97'2(T.29$3>5F>T^57L3\J.>D MZ&7,A":;_OQS'F,WC\'S@[BWQHXH=L(/=*TM3W8HE,^K5EL-62K2),G53?W^ ML2R0%RRM:"L8Y.N/[DKTCZRQ_ON&^N^+957U@GIL(-"JKE47UDW^I9]Y?803']S3A4#G_PW+)O)0_,OBP MLS5-5&8+DXUFL3LRDYU$;J MN0>861%>B#SQHM:4]MH#S@PH%3MR'1+)4$(E42S)UPX6O::TB`58'I@`0_)5 M#!E'3$[K:2"%V*-,8I=VU1"89=+5I,A:?[B]X?PX#%KUVG6&/8H$TM> MF;T=/VVS2K.4L;F7/8=S$_/0XQL:+$(_U[P=6>V((,6#XXQB2+PL*,PK_>JB M4._*B<7[7.J45?8>[B9C79R%DA.R32Z!O*-2QL[A*[KBMYF$UAF]P$_;<(3,>I%.&[Z,,S'`G<\N0AVPT]R_RNS@!6 MO3`#IKW:Y=FKUB[8(;&#!OT+F3!YBI1$VW091$\2ZUC!3CT[B)1,BI=@YWB6O8&MD4)?GL'4`$:#6=RNKW M'@*DAK_!]WZ77&7;YDOQ#;#+-]#AYJUHI<8<\J5Z_%:N>80[XC-!]-P_UMW*?>!"0>XVYF%#+6[GPEB[T@*L)F@QP;W<3I9!#B2%MN15#&8/# MD!E#A>=L[5HQS+S2;@GGS[/(@20>O\\+:*6TDPH[K;GZ<8(=R(@7VT<6R5@2I.5(M,1*7@ M^IFQRE&SLD@L_.M,;5B2!ZKH9:>WTTCTE\L'<'@*O@BD`60[2F(P`C3RI1F* M]7,XOR%ZJQ-KXK_%C0)A&UAKSXV3RT(+$Y',1@2,I*J"4>(]0$DR:"SWV*+@ MA"14/>LJWZJG?X]@5R#_]UFQ^4J3A`D#"0EJ5CLRJIEL6:>)A^>9.A^(33*Y MB1*K$I'`4[&<#W?IN2>VDOV2"11OMG;ON\X8AY#N-Y$Q#O8S#I\Q M'BW:;R9C',Y2OX&,L09]]_`Y!:/],V-\F9XZ4L98DQ1J*:-4[C>0,2+Y>>>6 M,0X/26-FC'4'^+HZRI`YXK3RS"HK=/!3F?/`"8697>;GPC8#Y7K&0^0*H%PA M;8FN_TSG7I3[U25PU9/OU\7)]_[YW-PRMMG]@G4YVHN#DC'3L/)XH/Z,R+40 MGHO/@MW"?X1CUG[^PU\_,=_*E7H2GE5B=(SQS!E.'ZJS2U6.4G*@G$,[M5J= MU\D@+T2!05?*HL%"=H.Z/>HGR`(QU9\>Z0?3HV"!1C5VGNQZ7E46I?]C.V`CIZ-.LE'[%K=H"\74V@Z#'/E;F MY#&VD77*GEN#."0[1F-W0?7Y@<;L)N:>*:`J#9`'TZ$R>B"5WR(.HAHA^SJ; M)$4D+3?!,Z`N-]M[,8T2@]52I$MJENH'+IYH[*O+5\F/,94S=E5I]<1]TNV%/`-0;HAI6']2:(=HQ]9O&C`/)ZZWZ*PD>6 M")VD(1/Y*J;^_5F4I)^B]'_@?5PO6H7\'P?K6%/P0PZ:HYM:A\[1F"$&T/%U M[EW22;Y\E-WG3B08>!I/PI[A;ZB\%,@G"-.(A+F8HY%(%8Y)6PZM:PCB>)%`^'-%A9=/HX M>MB7^(=2;Z#%_7SV=T)X7L@(UN/S57=/"I4E-UD>M-7DQH?IQ2`V%X*(6`V/&%&&0EYJ5A M?N9I6XH$'R5"*'W3*HNRZ#$[<\%#+HM?T2"(4@>P[L:>BBL`-_"%XTD:9_@G M\-8W3BOX[@#"G9HI]S/A3BW>58'R`=&Z7K^[Z`S\^%K\;Y&[;RU&=^N.&9E[ M&*+`XPY]L:-P'U6&/QQ335P`0;U\OKH7)Y[$6_C/:0&TR<1(.Z7-3,@)T"KY M$6!(2HX.(!6%/4R^,62-_-KJL)G.L/A2MT76K2=FQ.RF?ED(WZH;=ISLJ,4Q M9>]70$D]Y\=#]9H?5$O>ATRZX:F$SC"-^?TV/S`L2]3+4O935Y:?QD)%">F+ M2@EI;>5`+H-*9B[*R$]C!4F%;"KEM+E63CL?4(&CPWTUM?Q\JU:?[Z)SGA2^ M>AVKY718'PE]?97B@AVL#PQ"$"FV#F>LRM97;VJ8][:.5ZIOP&6LR6VYDZ)S MA^/3!7^Y)E=9=P,1'.U=N3-9Q0(^3SQYH/U$8I/`*GE,`"REWDIA26 M+/HA!II.XO<^,),Q@?&Z8$,4'Z(8D9\EJ_]U%P&U^E_QD%VF;&T:IEL[(?=Z M.Z5U?V_N@=C3+07O?W3.X-?`@D@>!\X]S<`XLN*0\7.U`B$'.7@]5S!CH<>' M7<^-&85[M#3XD(C9*Q/S#Z%8NBO726I7;&QZ(0W2CFJ7B[:M7;"O07308/@E M6BJ8JU?OQ!\!I&MP]WF3B4#\K:P5X.I,PP2F`1;JRKY07W$A.1MM@\O%^NL$ MRI>.$"@@%UDZW'E(-M2#O4^2_+J%^QU+QAP^66>RA&$,:&B.%/QL%=5S$U-; MQ%E)J\A'!7%4'\1N\I#15+T:)4X-:0C-A[E/&R"-,::%"JRB;WOL:<. M)G&/V:?8R,LC\L8V7S.U^R8<[G[G](';P36%6^="1Y?'#L?2B8YP''`1AEL: M2/#)UAYK4Y:Z5ICQP*Q6.<$X:((=%1HD/@88RDI',E?4;B%D#T!3R3?894=4 M9<4BX9))7OU!=7,VEQC>*HJD6@,A&5$7$X71-*O\T`[7Z[?W"9./O:=HCS_49Q>Z^O%T15_1[WB^G[:@I^BV=NO%1O;#TS)]U3 ML\E/LZ8S&!H@VA>#6#0Q&M(@\7D%>NST%,INN0IQ[R2WQW<.:9 M_1C39?UU-4,[I-'5JMK!A6"]$?;%QD:9![_.FTHN4(9J.?G]L%$T+6^0*K)$ MT75X@W8D]2J_W`B8\>>AKH`(0ZTID+5/55:W!`TU]\4:_!/($HA'%YQR;;7MW0..4L4>]) MA/EC,_#4'Z-QP&%'-I-5WFQ:.CW/XB2Y$U@J[L0@$@)R'OU MLH^2P2$".[)6@PM6?(AXTEKWK/"T?B\YF'`]2KG'5'';BRB^*[VYY8R:;4?4 MF-U%^1*A;7JAQ^-.2@R%OI)I?AH.4+0)/>%X7(;&&0Q/C:>3V$AQ(8H-$7R( MQDB"JL/C=).:P.P7LG(#]1P>E\\J@R=WT<*31[.NP3%OXLC?>E"B6UV*,BP< M6G=&"I;]C*"O;-OU1+S.W5&!WB4[,C9P02AC1"0G4K+*+@:Z60.?R`YG64S.YU"TV>%FE3P&J#T9T'(:J:$Y\@!O4U0/:5-;Q$'<*O)1%TB(1OD$QYFD M.H4;#R4U=IBA\YJ/)9E;S\R!!SJJ<^#"&$XF3:GOR?&'DPQS[/^D9T+;VD-& M==\C#3.C*L7$6/\2^_RW5M:^OO2?]-03U$ZR&QE)$A4+B#';1+&LZL!DI;G? M)>2)QNPAVB:J('GETF%>S).'Y/TV%I2B4+@E>Z933WT'-@\!:HZ.5(WR=\E@Z(*KE]KX#>CR*0I/ MJ3ZFBS\3ZJF'QUQGIYJPR2+TA:R:J+JDC>=SNU-![OH]S5*M8]")!.)PZ:M) M_ZH')3_YV$J5XUX`.3TC[-0T[>`R?!Y])1*E,)$OR:CGQ9)B"=J<7-MT0@H( MW90NTO#6'MAS-M.M+KZ,K>V*E[?2A>A'%S*-)RZU74^.9!&F]DG416FTY@_`T M"'QT;.9T75]]'4?-G)RNU!]?EP)` M!D=-OUE_$"8``-[=`@`5`!P`87AG;BTR,#$U,#8S,%]P&UL550)``.1 MOL-5D;[#575X"P`!!"4.```$.0$``.U=67/C.))^WXC]#UK/R\R#R_)9Y8KN MG9"O'N^X+(?MFN.I@R8A&5,4H0))'_WK%^`A420!`B0H@C"C8Z;=-@#BR_QP M)3(3O_SU;>&.7@#V(?)^W=G_--X9`<]&#O3FO^Z$_J[EVQ#N_/5___N_?OF? MW=U_G=W?C!QDAPO@!2,;`RL`SN@5!L^C;P!CZ+JC,PR=.1B-CC_M'W[Z_/G3 M>+2[F]0^LWQ2&GFCJ)F#3_NKOYPG+2'OZ^C+WLG>P7C_>'3X=7SX]?AT=/=M M5>X;Z=@,5A5TH??C*_V_)_+!$0'H^5_??/CKSG,0++_N[;V^OGYZ/?R$\)S4 M'^_O_>O;S8/]#!;6+O3\P/)LL)/4HHUL5'M[PFY:\7`O_49:G/X5<`CY"9_.`C%SJ4O&>62W7[\`Q`X`N#E&I3 M3ZQW%B;EGD$`;_"/J`IE2ST(?>L`7 MUYQ`2YW@>@@7"PN_3VH94-0!Z9HPYV@OL.( M3`[!.UTO=HGWQ M'/(;'`+G\FU)I[PZT`3:[`3K+0I`VJD:L#:K=S-_!,C^,5W*K>&LZMW,!>$3 MF8NFLQG`9&(B*R=:+)`7=:S.E,!KK1-\M`MY//JGW]9="Z$/HAA?;% MH--:5)__W-:T6(WJ8V.VI!,NA@)NW))@O3VI+B:(([0^L#_- MT`R#U"#JB/]#N'^V.]Q/7EC^17_T>?_P>S"']IA?<6@N0ZR^KV.\GA\>? MCXX^CP\.OYR0ED^_G&9ZG&7/!&_VWL)V^@WR8X%0F^I*2NPM(Y>'7?L9NBN6 MS#!:2`DTZ0621(6P`_"O._L[H]`G?471ZOO]YW#^-5*))%''8H2+NR&X&$4C. MA17P-+)1SAS55,-*='34@8XFI(<.[>65:\U+=+/Q]_[KI!I.HHOC#G1Q'F(* M^(KL'BWWW\#"["'#*MI_#4DA2Y1UTMU.(.[M/5@B3$\OU"\P]-D;@M+B_5>: M-+I$<9\[4]P5=`$^)[R:(\S>P&V4,D5-U:`2[7SI;EBM[1X/ST0._C0,:&0" MC?I@#RY.)5-T)XTQ4>5IA]N_]51^17Y3-CDR2O9?:3+`TE/MN'-5Q1M6,65E MRIJFKBIHJ<)8=HA?]O(VN\:6/+E@'!&#WOZ8&O16[9*?5TV/LFV/DL9'TJ$^ MMJ=!8_32B_R+NN>\6&YT#1:<6QB_D\WIJR@L1%1?I41^Q(71)74KN@0T(_"<7W((@D25KMN!4,8HD!Q#]0(UC6)$7;S,BYA^$46$$N8J7UC-Q3L>236CP'([G0]B%^\[ MUXKM'*F?-WL-X%71E`320U\280N[@2[(0,[7,``W\`4X>5=K-AWXEDTR*P M/EJ+K0/K\N:100ZJJG.J/JM!]3)@GLZKP#%C&?HU\4O;'WI@<6CIA/DQ31`9 M%W:NDU.NF'9D:*Q^(82&'`@GC@/CGM]9T+GVSJTE)//49LK64FM"947SB%$3 MLR'SPSU-D>$!Y]+"'O3F_L2VPT7H4B=TLFV"-F0M)-45S:-*3\ MQS"/"H(85=U?=FU?J-B*U;SLTHX6[5UJB.-OS235;814_M6>C#(YX5+'=<*E M1G_>^-A?=H;PJ:WM/%T7O5)57"%\@<*G8!:Z18_QBBLMF3:TF4)J!U\U1FO( MH26SX2;#=XHC@3K16>T.X"C^NOKPRJK9>YK4Q6C(,:40B3\)@V>$X1_K58-- MBGP-D\@@A,V0`T@!]K7OA^($B$N;IWP.+D/<)R42E(A4,8\"@GE)U-]I;?U, MP7P'4^0\<2":?F']E1&:C6J]M]E)5"(1(ECUG7%X8);JQOP870:CPC&`5;R/&I;"8L@>^0&XI,TY0?W-PC\`S0B9 MP&?=TC`K:*/R6OHLN:N10VK(VGQ/U$1$3#.Y7)"MB(NBN%P^)[AU3*.%/%A3 M5GC@D0.-2\,EG`7TH@<``O@"^-RHJ&4:.^K`-<;.MBDYP1V#:0P0PF?(!7]B MXO#F\2[K!ODLK9>4-$WQHA`-B6B^11[:1)QF\N&?&"KK:<,+B:-#/5"&Q`Q< M>Z0'P*_8).9*::/E9BHL4D$$9].SPFFL>`_,J=VY2Y?A!7U%X(](3ZO;"&^> MSJ3TC;7()8'ELR%8W5BR-!)`TW.%-BR*$K\Q17I8Z.,-NJ7V5]6`C`D,O&?`,Z?R6HT>2$\GH/;8WWDAT*DS%>?^K5:I,$VJ9NC&&,J:O61&G4@ M,=^6ZK7C#\U,?^6B5U&_G\-Z?C_T,Z/T.QK[_63W*' MT0LDNCM[_^[3U*$K&]S$#N!+G`@@>K(\I$^UKQRRJDQ42AK79K(0471NL]$6 M?$,N2?N[Y]R"CAOL7OO.BXGSG]`/HI7@$=T#&WDVC%ZZ6,-_1()RKWIGJ(5/ M?6R6;DVBAO@#7`#27QM&LB8_NR`BAN=D;9H,\HI4U8Z,6^-'D9JUY67*O+IA M)L]GB!>Z7,A7&NC52%*&S&&\^Y<:=U8#J1K(R9!KBM3(0NT0"VI]YRV$Y84' M&M62D#%).6EH)HWMG\ZB8#VRT/_3PM@BTK]"^`'@%V@#?XK/70LN6-.45!L# MX50*SA"WGCBOV=^AYZ0N+0RJ%0L.?)*6CJK[N\Y]P6P,R&Q]`>)_9R289,BK ML&N(-Z`=R;9JK6@H)T,V6T4I%)/@"!.M6%4[BC74N@B-!*5@C`MC40+I4[7L M'-C<.A^1-%7PC7%5+$)/GK%-L\67/FDZIS'Q1)XQDE[[ M>(U]1.+5EHLA\>%%B>2>Q1!F6*[>1R23B`@,,1XT.PNUXI>C'>.V[8.A6G;F M.)"7289N:?VV7,DD&]>&NHIY*-:T-=1?L]%?`-N;$BHK$!RP_K83&Q!=H88@:E8)IY#_T7M0"^6 M2T?L'<`0.?F+'`8Q99K0AH:R&_S&((WFRX0,+XS?R:CAOIHM4M3Q?Y89R- MB1P,[S)M[6PHAY&=:'],_AGMCM8MD?^(&J,IB'+-:9R$:(KGEI=$B:YS*L71 M[5D4F:?NUMF6&'.DHC:[&/,)'1*O0_8[A85RVHQ^I0K-3@!BD/LY"V2%1N1T M%OK0`[Y8GK+]\4%Q)L@V.+(\9Y1ILI79P'J;>Y34Q^.3PW%$:?J;WQG`&`-7 MK$HGEBPKH&HJ>3LR;YTJ%-1F9,HH9,-H)`:IGR/O(5PL+/P^G3W`N0=GT*:^ M0*LIYH[,7G;&C;YB(!X6!V+2/EV4,U\8K3\QRGQ#XW6Z*!/&&.85[.28Q=/K M(U'EF!0S M71X9@UF@?$?WW>7=6BNH:F3+-*'-^!967^X6NQG2?@YVEE=KQ4`_+@[T=4NC M55,:CW'ZVO`K=.D3='D9K&$QQKMDW8ZL8HQ^50UY@9K:C/1:2LR9RVJ![>=@ M9T9IYM\BK!C])\71GS8]2MJ.EOND]5&F>8UGA*3G?BH6RV5MWKDE.\G/)Q!^ M*SX#U&Q-FUE!0)$;&?@4PNWGO'"+`I#"%YP"/A>G@*B5T;H9C8FSD`V]!,OV<:^[")Q?:TQGI(?55+0MZJ)AZ3DM,>U&CH[35Z%&?J-U1 MVK#&DU'4Q6?D$FWZU-83O-/]2Y4[446E3BSWI7T2W^T+U]=FHI!3X88MOQ'6 M?@Y].B1AG-.5>A-&#NNDM/A]W?ZX./0SC48G_7RS&@]\CCPJCP22=3MQJ!7I M8M6<(->(-A-#+=5NN-PVQ]W/2>(A?/+!SY"TN61JNF-)X- M\L`K_8E9Q;OQC=[L3>52SRJOS0@65X3WUB4G27](T_`335#Z1/UZKQKEE?6T&>URCCCU+3>1#5>7KRW&I>`8TCZZ"L+XB@,.!,F=.T1&86+]3+(4+]0 MW9YRH3XV0]Z7*G\.,+XECISE;"('^`*HMRN?)C5:ZBEI5"%5%%?=_?N*WWTR M?B[]`"ZL@/E&QF:AGJI>`$2BU2\]GQANP6M&-!AYY$<;9&9%L;V#;#,]Y842 MF`ES3DVT.#Y&CI9"]L;#,?FGB;TQ_M9@;6QIQV`_`R=T`7W8/#DZG8>8#J-( M[I57"X+5>SH1-()GB`ER+8."S]3DU<).UI^1;KYC+?I^N(A_)\DC%1_I/=M: M$T)KUL^MAZ9*+4%'Q26H/$"U)\N-Z9&JM>-3]9L"U$:EFGC)G0_&DQK9Q\61 M78A([S*AB$>V"M2@)#H9GQR='!T<'9T>?2&$ZGH>$8G@E)Q0Y)O49F:I MJT/>%*-('/V<:[+AL5+3RN?BM+(1)-N3Z:-WT;)KWD8O2:PO_L3'/ZNB-J-< M/(ZV)JA^CE4QL_4%""SHB@WCHV;YZD9_3CZF^2`WP'"=+E+1''N#+(\N?:M' M.]:^7X_9/`>5.P"AUK29%NH:&INC9O>_@<43P*6Z+Q;KFYHYRLDK6A!L"SI=8H@P#-XC5UE5"IZ^`"R@X'PQ MHQ4L!+:%*[RU@@\ZBGFRO-*5O/!W;=3?[GHMAIO)A,Y46#J42TIHIT:^H!F* MV>XLW(52OT$/+L(%5ZT;9?14+*=O1=56XS%%N=9;M7*S94Q0;B4>0^(#*W8F M-]`#UP%8L!9K:4:+=];B16#H/,&1LQN^)DO`+N$(E\9(7`"R`\]VSD>L" M.Z`WS'<`TX@(:YZWI35K3#LF-=)U;F^O5BJ=KS^L4YWKHE?Z>#?!>8'"IV`6 MND6\])PS*_ZZ]/S7I$&C":5>,IVO>XU(Q9^49-L8J",X!?4]6%Y,%HG+/VNK M)-.&J3BU;%H@A9Y#RA%9%J17R"_"D]@_D MDF9<&)!-6\#THF[_RWUF<@>2,>0,I51\]]#_<84!C3L'A"_!M@A=]MV!SA)R M:>T`N/7D)7*!2$U(:=<_B3"*&4P#22FB;Y?"C*%=E/AJ%]= M43N";&MGR9>`HCFC^W3]3/R_8>1+TR:JI!UE:NI8@BQLW)UO0I5=PX6+T+4" MX%P`TG4;1@HD/[L@>>IBLD`X@']$OV<*BATPI*1Y6TKS>E5 M#6@S*6PQ&;#^QE4.@K/W;]9_$#YW+=_GF-DE6M"&`HHT6:1&4V'TA1MK*+?6 M@F^$EVQ%.XXT5:D4280E8LCYZ`;:P/.A-Y_,,1"QS++*]XDVPDHNL=%*X3>$ M)'?D=%1%C(TR'X0,U9@-,=&;D*A,T09CR$TVY"8;Z%+SZ8VX.XO/3D2X%U[5E73CCJU-2U%&N,O/SG8,]=R MV>LW>0(Q&OJ@E)*1AC&7EQQYL*\O^94^*'VV?HFI#5'N`;6[4+M:UAD`8(@< M5MQPS=8^*+6D1:(J4X5J+_1;THL$0I2PSW-H]%YDB3M'?E#Z*DY5'1,Y41]X M:[DJMNSZE2'Z=)87(\NABUO)1)XT0)X0Y:2$*(60@R[<9<3]90KY!@=_&3W] M93B$OPJC:)L,C9.'BY.\FU$>]!?P$-HV`'0>O"*8+/??P,)5#P2W_%5MII7& MGCE=".H#'-:+0HNWA=L61N&=DDT.4M`$\E^2$I3:3R^(B4D M3MH::*N`MCQ9FG\UPQ((^3S+);=F:P-959&5*4U#PB;E17*%0C6[@[2Q@:R* MR,H49N?VM\ZX2LJJXRHI.W!5%5=9PC3$8B@GD@.O2`X3G?+/P#T!?JTG, MV]R)OZI:7R@B==RJ!=H0G@P!QAT'&&L8*Q-`&\11/E<(TS<`H9=X^,>&";`V M2Y0'SD@TH!U!U$71-)5"YS,,@R#WZ-UR@_62 M[*YBE!#X9&+\%I*?EBY(D"DG% M">W`CY;;"_`"7%3V6H-0'6,I40NX(KIPX^<@H M_4I?O"<3#'XJ)\NMBHWFU*"<.CFBQ#K9/S@]/#X:CSM[!:BJ)/R9,- M5>JJS$=;HR7MYA!9C16G#E52T,IY+@M0$1,2T9RC!5VZ(S5Q>,`N_5%8 M("F!5@U=TAS8^OZB^;[B`_!*E514F;HR>1.W'=IUBP*0XI<-Z_I="4EM%&#K)#7ZA%%Q=F@U[Y( MK*.CN)NE3F_Y/VNC'5$9;VJE$HJN#@/3)X#)AM\YMY:0+(I_`Y8;/)\3Z92Z MHHE4T4J3E7K)[7WK8--5M5':G#M@_?`3-&R5,HIJH\K:NLFI5P9GYVI5%-^' MO#GIPX*N-H_D8QQW\[*BVE"@_JHI#4^K(*Y\K[DNY.6%M=.AL":JE=C#)9>Z M&]X@R^-,QQLEM%>?^/(J`$QWK4T\YQZ\`"^D25H`$7YP%V+[V"&+GBX5:[5.IW2+/YMXLE!S+<167]Q<_@Q)DP^6R_&F*"G6:SV* MXM%JJ?N(F5'KGR2%4J#JD8=M2(&JU=(WI$`54U11M4,*U"$%:O]7R^':N_&U MMW9I7M)L-9G<-K<@2$Q7I68\7@7-E2MZCUD3J"%S^*;,KBR;/B46,F^T6<4- MX4(MF$9.^*DA^]X*XK2PSGIL"'&#UX#1;)$&KLA)BN45<:(;GS M&;`#^`+H+Z4Y5=K*AR&6./H6]B(E<;@--R:;0"-P#Z1_EC/UKN`;<"BZ:=3S M@[)MBD1U0QBB!':K^>:DJ='VM+,:*@T6LI(V#"&4.NRMIJ]K9\*)TTM#.TG< M>(>A9\.EE3QZ&4F@>MH1:,00KB@$WVJ6.U49F!-0C^CRC2;T#*'_G)P7:8K/ M$M='P5HFT:$FVD3_7[2^'IP^N7`>Z2'*WRF@>WZ-#4D<'IST6>\UD"8Z/]5# MYVJV'>DDQT]PFBME"`]DT*56LW$KRN_HJ)N-@*"OW`8A[4Y%-DM^)<.H40-L MRA2S#*Q4"&*1!Z2@=B2HH<:J$P839S\[))N1D?OV3T@ M$O*8Y\TZ39C%"642T.LE%T7YH#&R`7#\*R+O:]\/+<\FXLC*FS&35%Y;;,`,%VU MMM6XTGYKN0%@K?R2MA.AJ(.NY5=8451]CU#L4CNB,M[42B4476=811%M76NL M4OYY4Y(@'EW5UG**Y[ZILPZVSE>][<0,=ZG*VKK)[V`E<'8^8KN,0>WGMD8, MDR$QJ#JHB"]HAF+,'W/-PA2U4:S0O"J.QQ#EJ@]3U$'A]2=;&83,T(#N%=EO M/PD9)>CI(*%=T%"[,6BFD48:>*O^$QWY9+81VFH:42I@MNP:\5D'8G01FF@: MC>JA;S4T47H%TRLTL;\,40*[U=#$COSYN@U-["^AU&%O-3115;39)LQITL>) MX\#XIS.$,7J%WCQ_R)6L;0@[5*#N111BB\E[>JY]>:"MAAT>*U+X]R7RS@$. M+.A=$BB!_RUT`[AT";QI&/B!Y3DP=FVF;D`WU+L7_\WR[^'\.7A$%V!!"DR] M*;ZC/7M$5Q#[P<3SR#2)?0N_3V>3Y=*%-C4NG;O()VU=%'>['?;$)(IJ),%6 MPR]5378JY#69D3[F)746!F=@AC!X`#8B93H;#VIZ-XR1K4FUW=!5[09.058K M*3X^0]SUP&G:'QEDXJO>GK.M:0R^LZ#1M-4&4"29EFU/.[R6&_ MW.Y17L@0MDB`2S6OR=6*&LV?H\4">0\!LG\\/!,9^S3&NS#)5)0VC`LR*%-2 M-+U48=WF2MN]E-/B'Y;+G!+RQRH"F%R":,2!B_AV&-DOWZP*&:;T" M6*KO=BXV5MIN-;%%1.GX1L>72VSQ9;R?3VP1-39*6NM-8HL5@NF,#'.:7,V* MT^6XU+/K'/F!'Q&!=M!)$C'ZK`08#1OK;'R?T?YD>SS!F+I%1_X%[^LB29*J7BXN*29^.#+I M&>*GA@^7BZ6+W@%X`/B%K.#E`KA%W@OPB4BC@>,_HL!RLW^GDKY%P;_I?;>- MYA[\@WDB:NU[!K-RNS)3Y&Y;)':K.[2[\,F%]G1&>@B]>23Y]"@BMV$[+6[8 MXK9':>,C-!O%S2=;N9YLX:+./B.7J->/`]1IBK6*#+%5E=1$G">23?/E33R' MQLZOM!@9%:+4SM'_O9*M/RF]2C]29N%MV*0VLXF<\M9!ZRW`-V0'E)D9[BP\ MQ7%H2F2O('O`2#+5UAM6S1[SIBE*11NB3;/.8.+5@@BB9EVU,3J#&:]M%8N9 M[K1[0O0VI!'ET]F%]4XVNJL5#.!']`#E<,NH4`&27\ M*(?PB,X1F6"FY'\3UT5!=.XJ8X5$];YSH2G4%H)9U*0>*\W"G5G1R@RP$C7[ MKO<&*%N(4^G$\!4_$)-891X1.?$'&#Z%%`W9]$:F%GHD\ISL">D*%!:2Y@WV MF$PM@6\A-&8+-B@Z?&`\61*@]/DI@A%X-@1REX;[XZ(-*M/VR/*.\GQ$_<_<.E:EZ6<4UT;'C555U+H49KW>7RCI.3]M/[."=@J6THJ8 M4GN8JOC_K'/$RU&<_7LO5"B>W[826NOFXI\KXT?I5:@REK:J;^&SO+VH'J@6TT#V-$[ M/2Q1,&8*5G&S2%(+K:[S`HU=FLZX;@2Y(F8I4QAA"RY!#?+OL69YSPLM-Y)# M^0/8C%(&ZE009*NI[[;DF!\^^>!G2-J)PQ;E[&S[)<[YJP9'<8M]L:WE)5'E MU\4H3HER,CXY/OAR=S1\IOK(-=X5E)4NU$M)?`2DYDH1@$364=! ML_182E::]3F58Q\K+:N[3F6.5^(`]55HIO?4$'Q+NI4Q0I"??,)O&F/!??5` MLA7M2""NR;)M='/LG9MG&/NQ&VC3G0?U/(W]UGV!IQ4K*VFG?A4JS&W?Z@FA M5*"VK'4,:K!+B`-M^EK')K6C<]>^>OP0VG$'@ M<.].F.7U4ZRP=LJN0&50FC*V$]!7"`/;\LO7`7YA_4@@I4@V$01@FL*"W'S( MOREGE-:/!PUF>0F('%-5UUZUSG;]B:E8=,E94S2J/"`%N]*Y=V;JY0Z]^0'[UYSM7I MJI"1"N6C:W415JW-3"[H*$'T/Y^A_;R:A,Y1Z#IG@$Y-T*-1.CR=2S9E)#-4 MR*#5)^24\0<%T`9Q`K0KA%-(-'2+OX0+532+&[41M_KL6T=!+VGRJD5+=ED,``#O?P``$0`<`&%X9VXM,C`Q-3`V,S`N M>'-D550)``.1OL-5D;[#575X"P`!!"4.```$.0$``.U=2W/;.!*^;]7^!ZY. MLP=9DAT[8U+]V3O"-?%[@#1&V@PIRXAB\@ M]+M%)]4\`8O)A#I->=J)&A/=L2R4>M[A+`#-<4*-7J9T MA1R]L"FFA+I'+IMK++IG)UU#SK%?*/RL`ZU+=Y-R=[_:W5[[I&?(871.$5HD+#X2$VU5W)## M0O%4C;-RS#59"P:3X^CAA"AE$DD($OJ9>;I8$.JS^!$\5$Z_4"+&X%1'??CZ M<&/QH7[;(PC6WADPZF$*,0(^"!803REQB0*%^N,,8RE:#@'EZS`DNAGM/.P3 M2K0ET+^Z$)Z<1!Y\3D0Z:9E.+-2)I'[HK(M:?TL($H;T-_UYP;$`X=I[:IS& MW#&)C=-%@1L&&S`N-2OFBY\:M/8*8M(JAOYP@;DVJ1*:!9QV6(^KPKJ4[C#? M6$?+;^#-P'M%A!LP$7+\&,[GB+\. M_4H1_(5 MGJDW.,M7..8=SB_Q6_[;P&V!>\09A#WYVJ?>I[]"LE##)7;<.K8V4CN0[[J] M=2"-,`=1STG$-:!5`NT&3*53,@EP7PA(2`H`*R*S@W6:!6LIR(DD-3A5PBD. M2V*$7I%"@7KPA(?8^_2R4/-5$7"5^>Q(GF61-)*=6+0>?K%PQTAOT+6A&R]_ MF+\J&L+,(U]OH!3BZ M&9:05`2U:\U5[K+"\W23PM/Y9>4ES?"T!=]+)`A4%:.4U>MQ-H_$!EP/@,N$ M5"U$):1I,0TR%F2&?(HH^5MK#4'Q,A2$XFPM441F1^@XBU!:D`Z<1E2#TM:% MX&8%8`F&)UD,JQ=^#:@UR[TJ=5X)8)4+O`:<&F5=63U7`DJ50J[!8YORK7;= M5H+8I@5;@Z(%Q7LFL4%D';"5-CLV[[/8:&X#3(.!+9>0S/T^7*2V?0K:[!C\ MFI,7*&XG9F\PL$W]X002I*'O8P[ITM`?L/F<4>V_3`9@(;4C=)Z3"&AACI&F MMV*TO`B[!C,+9LI11.HM+)A,!DQGNICF)=XV4BMFO6X6LY0P/>&LB&L0LU9- M$X'_"L'B3T_*?=GZ:*W=CDW.>L-2@A.):/#8NHK=KIJM5-4>;[N=:3XUJW[; MXSU6&=N&:,>\-JQ/`.N3;;".WM$@77BLA^2CF4-@!>Y\%;&55 MI`%FYV?NMCIR5WKB;HN-E^;8R!X.6&YYPK(<\*WRU`;PS4_K53VN5WY>+U-6 M-N?U=HM49:C*L:J2IC98U4QF"G'*)[)C5+;1T^"S,3Y5X"E%)Q/M&G1V@DX% M<$JQ*2L&&FQJ;I86Y?PY)'9LRK9.&VRVW40M^M5,.8<=N?I;J@V6VVZN%F!9 M@<.*9>VMU@;)C39="U=*\LGLF%79@OU'X:3^45=3/&#?T?( M%"FQPA9POL+55G+:O>-V[VQ#1;*7NU318YUKEWJD+P&JIPNC][M29^W&HRIZ M:!;U+;F$1ZEQHM2HTTWR;R*JJ(!A4&\^77EGX?NL%^+8!D8N8P<'4I@GF6&B M[]>IZ_D#BE43'MSZH, M46C4=V!="*GJA1N)YVI>!R]`(B.)#)4//G,6+B)"3UYX!'13MX(IXI:#@(XC M5WYL21X"(R5!H-YBOD?B(=(1YHWU"[V0Q[^YV\+D*S9'A-8RVK!$9D>W2"[,I:8^E2\RD^ZXW9>?<*O8H[/)]@WC)^R&U:>^LHB>[M/X:`:4ENX/_18%MQ@2O?AT M2M+[\UIR.W_TVCFC4%3RU\KF6'N[;IM$/R>'!CPA<@>#_0I/Y`VXA.M;"4;Z MU<0=H5?]%28;ERQ0`('ZADH,I9PTSMB$\;!\E1T5MHL@^G%73(V$:N0;3._[ MG.:N0PX5H#H01KVA[Q,7)X"*H0'.S/\@090RQ@[$N>L/O[)&4I6ZSL2 MP$"#D10/PV0I4GY=,*J#[T(._<\VU:BM&+`S0WAXQ"&>UL/V!(*SB.\DB*@@<( M4$/_`4/J0=-51.S4VFSY.ANF_MJ M<;VQZ&`"62KLW6,9(]U:=4LAT5L<^1E+54HR]%.9:&1;]K&EN*Z=JNQU?5&I MKI9]5T=IYNF!C,:,>4-0'S):#Z9A(E'P!4,?G`T0QZOVEI,=J@-&5[=J)4"^ M/J)@S>C\ID,U='4)3%\C^+C@&'E#>DU>L*=3#IV,'.>OFI6Q[#%`[B3Y=,L[9,V2D(M\+)1P_:='0A=QQ)RNL:@UE@+F$;AR=-5K:F9Z9AIQ, MH?0,@M>^]Z14\$Q$'#ZK/?C(<[L2=AA3WPQFMQ%&WT4<)-=FC,+F0PTH&71- MW0:(AE*Y5:W0&"AOL.U,HW\6AAG')"X;SPC_&1CN0J/#Q#!O@:>N][9%[AN=_$<#%[,^I@U9@E MMD!88(\P1)9I?MKNUMH>4%WF@UDRRK=@S`8,@J4ZD:8.'6[58]ME) M=KFT$FW6IM9%8)"O2V!31@/M:@< M3@(RU<)T8"CH+Z54!SX=]3E&*C-#P2>A_M>6Y$JY)$PD@:,*96$*!K$"O8D) M!=1V,?;$-6=S,WFN_'@5]!%)M*Q,?5A'^`JGV3$!(_%GCGR9F477VBP6USTB ML==Q;M3_PH1>#,?NL$7_\/4$L! M`AX#%`````@`]X`&1T0=.A45C```X%<'`!$`&````````0```*2!`````&%X M9VXM,C`Q-3`V,S`N>&UL550%``.1OL-5=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`]X`&1_:]+X@""@``JHH``!4`&````````0```*2!8(P``&%X9VXM M,C`Q-3`V,S!?8V%L+GAM;%54!0`#D;[#575X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`/>`!D<&-F;G/Q$````C`0`5`!@```````$```"D@;&6``!A>&=N M+3(P,34P-C,P7V1E9BYX;6Q55`4``Y&^PU5U>`L``00E#@``!#D!``!02P$" M'@,4````"`#W@`9'W=%;6ZE````*$00`%0`8```````!````I($_J```87AG M;BTR,#$U,#8S,%]L86(N>&UL550%``.1OL-5=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`]X`&1TV_67\0)@``WMT"`!4`&````````0```*2!-^D``&%X M9VXM,C`Q-3`V,S!?<')E+GAM;%54!0`#D;[#575X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`/>`!D?]Y4MV60P``.]_```1`!@```````$```"D@98/`0!A M>&=N+3(P,34P-C,P+GAS9%54!0`#D;[#575X"P`!!"4.```$.0$``%!+!08` 1````!@`&`!H"```Z'`$````` ` end XML 17 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment
6 Months Ended

Jun. 30, 2015

Property and Equipment

Property and Equipment

4. Property and Equipment

Property and equipment consist of the following:



June 30,



December 31,



2015

2014

(unaudited)

Furniture and equipment

$

955,743

$

873,824

Leasehold improvements

300,697

285,697

Processing equipment

1,230,285

1,194,712

Less: accumulated depreciation and amortization

(1,822,815)

(1,735,205)

Property and equipment

$

663,910

$

619,028

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Intangible Assets (Details)
3 Months Ended 6 Months Ended

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

product

Jun. 30, 2014

USD ($)

Sales and Marketing Expense

Intangible assets

Royalty fees included in sales and marketing expense $ 121,000 $ 85,000 $ 217,000 $ 145,000

Licensing Agreements

Intangible assets

License agreements extended period 60 days

Minimum royalty of agreements $ 12,500

Milestone fee upon receiving a Phase II Small Business Innovation Research $ 15,000

Number of products under development | product 0

Licensing Agreements | Minimum

Intangible assets

Royalty fees range under the license agreements 1.00%

Licensing Agreements | Maximum

Intangible assets

Royalty fees range under the license agreements 3.00%

Royalty stack cap for royalties paid to more than one licensor for sales of the same product 3.75%

X

- Definition
Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement.
+ References
No definition available.
+ Details

Name: axgn_MilestonePaymentContingentUponReceiptOfGrant

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements.
+ References
No definition available.
+ Details

Name: axgn_MinimumRoyaltyOfLicenseAgreement

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Notice period for termination of license agreements.
+ References
No definition available.
+ Details

Name: axgn_NoticePeriodForTerminationOfLicenseAgreements

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of products under development.
+ References
No definition available.
+ Details

Name: axgn_NumberOfProductsUnderDevelopment

Namespace Prefix: axgn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.
+ References
No definition available.
+ Details

Name: axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty fees percentage under license agreements.
+ References
No definition available.
+ Details

Name: axgn_RoyaltyFeesPercentageUnderLicenseAgreements

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Intangible Assets (Details)

Jun. 30, 2015

USD ($)

Future amortization of license and patent agreements

Remainder of 2015 $ 25,000

2016 48,000

2017 48,000

2018 48,000

2019 48,000

2020 $ 48,000

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Payable and Accrued Expenses (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Accounts Payable and Accrued Liabilities

Accounts payable $ 1,838,425 $ 1,160,859

Miscellaneous accruals 205,809 105,315

Accrued compensation 1,363,888 1,165,020

Accounts Payable and Accrued Expenses $ 3,408,122 $ 2,431,194

X

- Definition
Represents the accrued compensation.
+ References
No definition available.
+ Details

Name: axgn_AccruedCompensationCurrent

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the miscellaneous accruals.
+ References
No definition available.
+ Details

Name: axgn_MiscellaneousAccrualsCurrent

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 21 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Note Payable

Total Debt $ 25,426,647 $ 25,085,777

Term Loan And Revenue Interest Purchase Agreement

Note Payable

Long-term Notes Payable 25,426,647 25,085,777

Three Peaks | Term Loan

Note Payable

Long-term Notes Payable $ 25,426,647 $ 25,085,777

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_TermLoanAndRevenueInterestPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=axgn_ThreePeaksCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2015

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor. Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as product being shipped from our facility via courier to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. In the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $148,000 and $94,000 at June 30, 2015 and December 31, 2014, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:



June 30,



December 31,



2015

2014

Finished goods

$

2,403,791

$

2,072,235

Work in process

240,054

331,891

Raw materials

896,112

809,494

$

3,539,957

$

3,213,620

Inventories were net of reserve of approximately $653,000 and $404,000 at June 30, 2015 and December 31, 2014, respectively.

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:

Six months ended June 30,



2015



2014



Expected term (in years)

4

4

Expected volatility

76.24
%

79.80
%

Risk free rate

1.21
%

1.20
%

Expected dividends

—

%

—

%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2015 and 2014 as they were deemed insignificant.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis" ("ASU 2015-02") which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended

Nov. 12, 2014

Oct. 05, 2012

Aug. 14, 2012

Dec. 31, 2014

Oct. 05, 2012

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Nov. 13, 2014

Note Payable

Interest expense $ 1,023,774 $ 1,392,098 $ 2,018,522 $ 2,583,415

Revenue Interest Purchase Agreement | Three Peaks

Note Payable

Royalty percentage on net revenue 3.75%

Minimum annual payment amounts

Term 10 years

Revenue Interest Purchase Agreement | Three Peaks | Maximum

Note Payable

Royalty percentage on net revenue 4.80%

Revenue Interest Purchase Agreement | PDL

Note Payable

Royalty percentage on net revenue 9.95% 9.95%

Payment to extinguish royalty contract $ 30,300,000

Obligation under royalty contract $ 0 $ 0

Minimum annual payment amounts

Term 8 years

Internal rate of return on funded amount 20.00% 20.00%

Funded amount $ 19,050,000 $ 1,750,000 $ 20,800,000

Revenue Interest Purchase Agreement | PDL | Minimum

Note Payable

Payment amount $ 1,300,000

Revenue Interest Purchase Agreement | PDL | Maximum

Note Payable

Payment amount $ 2,500,000

Term Loan | Three Peaks

Note Payable

Total debt $ 25,000,000

Interest rate stated (as a percent) 9.00%

Basis spread on fixed rate, option 1 LIBOR LIBOR LIBOR

Basis spread on fixed rate, option 2 1.00%

Effective interest rate (as a percent) 10.00%

Minimum annual payment amounts

Term 6 years

X

- Definition
Percentage points added to the fixed to compute the total rate on the debt instrument.
+ References
No definition available.
+ Details

Name: axgn_DebtInstrumentBasisSpreadOnFixedRateOption2

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments for principal and interest required under the contract.
+ References
No definition available.
+ Details

Name: axgn_DebtInstrumentPeriodicPaymentPrincipalAndInterest

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The remaining obligation under the company's royalty contract.
+ References
No definition available.
+ Details

Name: axgn_ObligationUnderRoyaltyContract

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for extinguishing a royalty contract.
+ References
No definition available.
+ Details

Name: axgn_PaymentToExtinguishRoyaltyContract

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The required internal rate of return on the funded amount (including any delinquent interest) which the reporting entity will be required to repay in the event of a material adverse event or other condition specified in the agreement.
+ References
No definition available.
+ Details

Name: axgn_PutOptionRequiredInternalRateOfReturnPercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the royalty as a percentage of net revenue.
+ References
No definition available.
+ Details

Name: axgn_RoyaltyPercentageOfNetRevenue

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of any adjustments made to the stated rate to determine the effective rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermDebtByMaturityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_RevenueInterestPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=axgn_ThreePeaksCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=axgn_PDLEquitySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=axgn_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 15,622,932 $ 8,215,791

Accounts receivable, net of allowance for doubtful accounts of approximately $101,000 and $94,000, respectively 3,838,023 2,872,308

Inventory 3,539,957 3,213,620

Prepaid expenses and other 241,108 109,369

Total current assets 23,242,020 14,411,088

Property and equipment, net 663,910 619,028

Intangible assets 608,539 577,174

Deferred financing costs 908,684 793,499

Total Assets 25,423,153 16,400,789

Current liabilities:

Accounts payable and accrued expenses 3,408,122 2,431,194

Current Deferred Revenue 14,118 14,118

Total current liabilities 3,422,240 2,445,312

Note Payable - Revenue Interest Purchase Agreement 25,426,647 25,085,777

Long Term Deferred Revenue 104,589 115,380

Total liabilities 28,953,476 27,646,469

Shareholders' equity (deficit):

Common stock, $.01 par value; 50,000,000 shares authorized; 24,932,392 and 19,488,814 shares issued and outstanding 249,323 194,888

Additional paid-in capital 93,102,681 78,675,686

Accumulated deficit (96,882,327) (90,116,254)

Total shareholders' equity (deficit) (3,530,323) (11,245,680)

Total Liabilities and Shareholders' equity $ 25,423,153 $ 16,400,789

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Net amount of long-term deferred finance costs capitalized at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation
6 Months Ended

Jun. 30, 2015

Basis of Presentation

Basis of Presentation

1. Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of June 30, 2015 and December 31, 2014 and for the three and six month periods ended June 30, 2015 and 2014. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2014, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2014. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Public Offering of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Millions

Feb. 13, 2015

Feb. 05, 2015

Jun. 30, 2015

Dec. 31, 2014

Public Offering of Common Stock

Offering, issuance and sale of common shares under Underwriting Agreement 4,728,000

Par value of common stock $ 0.01 $ 0.01

Shares of common stock sold 5,437,200 24,932,392 19,488,814

Public offering price (in dollars per share) $ 2.75 $ 2.75

Number of days to underwriter to sell additional common shares 30 days

Additional Common Shares to cover over-allotments 709,200

Gross proceeds from issuance of common stock $ 15.0

Underwriting discounts, commissions and other estimated offering expenses $ 1.4

X

- Definition
Represents the additional common shares allocated to underwriter to cover over-allotments.
+ References
No definition available.
+ Details

Name: axgn_AdditionalCommonSharesToCoverOverAllotments

Namespace Prefix: axgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of days given to the underwriter to sell additional shares over the initial allotment.
+ References
No definition available.
+ Details

Name: axgn_NumberOfDaysToUnderwriterToSellAdditionalCommonShares

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the offering, issuance and sale of common shares under underwriting agreement.
+ References
No definition available.
+ Details

Name: axgn_OfferingIssuanceAndSaleOfCommonSharesUnderUnderwritingAgreement

Namespace Prefix: axgn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The gross cash inflow from the additional capital contribution to the entity.
+ References
No definition available.
+ Details

Name: axgn_ProceedsFromIssuanceOfCommonStockGross

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Expense related to distribution, servicing and underwriting fees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable (Tables)
6 Months Ended

Jun. 30, 2015

Notes Payable

Schedule of Notes payable



June 30,



December 31,



2015

2014

Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.

$

25,426,647

$

25,085,777

Long-term portion

$

25,426,647

$

25,085,777

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies (Details) - Apr. 21, 2015 - Ja-Cole

USD ($)

ft²

Commitments and Contingencies

Additional leased office space in square feet 2,100

Leased office space in square feet 5,400

Term of agreement 3 years

Annual lease expense | $ $ 60,000

X

- Definition
The amount of lease expense required annually under the terms of the lease agreement.
+ References
No definition available.
+ Details

Name: axgn_AnnualLeaseExpense

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the additional area of a real estate property due to agreement.
+ References
No definition available.
+ Details

Name: axgn_AreaOfRealEstatePropertyAdditional

Namespace Prefix: axgn_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
The period of time covered by the agreement.
+ References
No definition available.
+ Details

Name: axgn_TermOfAgreement

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Area of a real estate property.
+ References
No definition available.
+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=axgn_JaColeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Summary of Significant Accounting Policies

Finished goods $ 2,403,791 $ 2,072,235

Work in process 240,054 331,891

Raw materials 896,112 809,494

Inventory, Net 3,539,957 3,213,620

Inventory valuation reserves $ 653,000 $ 404,000

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 09

-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Organization and Business
6 Months Ended

Jun. 30, 2015

Organization and Business

Organization and Business

2. Organization and Business

Business Summary

AxoGen, Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

X

- References
No definition available.
+ Details

Name: axgn_OrganizationAndBusinessAbstract

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Condensed Consolidated Balance Sheets

Accounts receivable, allowance for doubtful accounts $ 148,000 $ 94,000

Common stock, Par value $ 0.01

Common stock, shares authorized 50,000,000

Common stock, shares issued 24,932,392 19,488,814

Common stock, shares outstanding 24,932,392 19,488,814

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2015

Summary of Significant Accounting Policies

Revenue Recognition

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor. Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as product being shipped from our facility via courier to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. In the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $148,000 and $94,000 at June 30, 2015 and December 31, 2014, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:



June 30,



December 31,



2015

2014

Finished goods

$

2,403,791

$

2,072,235

Work in process

240,054

331,891

Raw materials

896,112

809,494

$

3,539,957

$

3,213,620

Inventories were net of reserve of approximately $653,000 and $404,000 at June 30, 2015 and December 31, 2014, respectively.

Income Taxes

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:

Six months ended June 30,



2015



2014



Expected term (in years)

4

4

Expected volatility

76.24
%

79.80
%

Risk free rate

1.21
%

1.20
%

Expected dividends

—

%

—

%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2015 and 2014 as they were deemed insignificant.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis" ("ASU 2015-02") which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5212-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5093-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Aug. 05, 2015

Document and Entity Information

Entity Registrant Name AxoGen, Inc.

Entity Central Index Key 0000805928

Document Type 10-Q

Document Period End Date Jun. 30, 2015

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 24,932,392

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

X

- References
No definition available.
+ Details

Name: axgn_DocumentAndEntityInformationAbstract

Namespace Prefix: axgn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2015

Summary of Significant Accounting Policies

Schedule of inventories



June 30,



December 31,



2015

2014

Finished goods

$

2,403,791

$

2,072,235

Work in process

240,054

331,891

Raw materials

896,112

809,494

$

3,539,957

$

3,213,620

Schedule of weighted-average assumptions for options granted

Six months ended June 30,



2015



2014



Expected term (in years)

4

4

Expected volatility

76.24
%

79.80
%

Risk free rate

1.21
%

1.20
%

Expected dividends

—

%

—

%

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Condensed Consolidated Statements of Operations

Revenues $ 6,417,253 $ 4,214,193 $ 11,368,569 $ 7,352,449

Cost of goods sold 1,039,841 887,820 2,022,722 1,589,121

Gross profit 5,377,412 3,326,373 9,345,847 5,763,328

Costs and expenses:

Sales and marketing 4,812,262 3,354,912 8,744,783 6,075,619

Research and development 736,399 555,758 1,407,435 1,368,373

General and administrative 1,982,020 1,713,447 3,890,602 3,608,222

Total costs and expenses 7,530,681 5,624,117 14,042,820 11,052,214

Loss from operations (2,153,269) (2,297,744) (4,696,973) (5,288,886)

Other income (expense):

Interest expense (1,023,774) (1,392,098) (2,018,522) (2,583,415)

Interest expense-deferred financing costs (31,210) (52,217) (64,956) (103,432)

Other income (expense) 17,380 588 14,378 (5,303)

Total other income (expense) (1,037,604) (1,443,727) (2,069,100) (2,692,150)

Net Loss $ (3,190,873) $ (3,741,471) $ (6,766,073) $ (7,981,036)

Weighted Average Common Shares outstanding - basic and diluted 24,928,435 17,461,332 23,729,558 17,422,773

Loss Per Common share - basic and diluted (in dollars per share) $ (0.13) $ (0.21) $ (0.29) $ (0.46)

X

- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Notes Payable
6 Months Ended

Jun. 30, 2015

Notes Payable

Notes Payable

7. Notes Payable

Notes Payable consists of the following:



June 30,



December 31,



2015

2014

Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.

$

25,426,647

$

25,085,777

Long-term portion

$

25,426,647

$

25,085,777

Note Payable

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 million to $2.5 million per quarter to begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%. The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract. The Company has no further obligations under the Royalty Contract.

On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL. The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a (“Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80% AxoGen has to maintain certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations. In the event of default per the terms of the Term Loan Agreement Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.

Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share. Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

The Company records interest using its best estimate of the effective interest rate. This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks. The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement. From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams. Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Payable and Accrued Expenses
6 Months Ended

Jun. 30, 2015

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consists of the following:



June 30,



December 31,



2015

2014

Accounts payable

$

1,838,425

$

1,160,859

Miscellaneous accruals

205,809

105,315

Accrued compensation

1,363,888

1,165,020

Accounts Payable and Accrued Expenses

$

3,408,122

$

2,431,194

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Significant Accounting Policies (Details) - USD ($)
6 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Accounts Receivable and Concentration of Credit Risk

Reserve for accounts deemed uncollectible (as a percent) 100.00%

Allowance for doubtful accounts reserve balance $ 148,000 $ 94,000

Minimum

Accounts Receivable and Concentration of Credit Risk

Age of doubtful accounts 60 days

Age 61 to 90 Days

Accounts Receivable and Concentration of Credit Risk

Reserve for doubtful accounts (as a percent) 5.00%

Age 61 to 90 Days | Minimum

Accounts Receivable and Concentration of Credit Risk

Age of doubtful accounts 61 days

Age 61 to 90 Days | Maximum

Accounts Receivable and Concentration of Credit Risk

Age of doubtful accounts 90 days

Age Over 90 Days

Accounts Receivable and Concentration of Credit Risk

Reserve for doubtful accounts (as a percent) 20.00%

Age Over 90 Days | Minimum

Accounts Receivable and Concentration of Credit Risk

Age of doubtful accounts 90 days

X

- Definition
Represents the age of specific types of trade accounts and notes receivable.
+ References
No definition available.
+ Details

Name: axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable

Namespace Prefix: axgn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the valuation allowance for receivables due, that are expected to be uncollectible, expressed as a percentage.
+ References
No definition available.
+ Details

Name: axgn_AllowanceForDoubtfulAccountsReceivablePercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the reserve for accounts deemed uncollectible, expressed as a percentage.
+ References
No definition available.
+ Details

Name: axgn_ReserveForAccountsReceivableDeemedUncollectiblePercentage

Namespace Prefix: axgn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: axgn_AccountsNotesAndLoansReceivableAgeAxis=axgn_Age61To90DaysMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: axgn_AccountsNotesAndLoansReceivableAgeAxis=axgn_AgeOver90DaysMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment (Tables)
6 Months Ended

Jun. 30, 2015

Property and Equipment

Schedule of Property and equipment



June 30,



December 31,



2015

2014

(unaudited)

Furniture and equipment

$

955,743

$

873,824

Leasehold improvements

300,697

285,697

Processing equipment

1,230,285

1,194,712

Less: accumulated depreciation and amortization

(1,822,815)

(1,735,205)

Property and equipment

$

663,910

$

619,028

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies.

Commitments and Contingencies

10. Commitments and Contingencies

Commercial Lease

On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc. (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas. The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year. The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.

Processing Agreement

Under an Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia. As a result of business requirements of LifeNet Health and their need for additional space, on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the LifeNet Agreement effective February 27, 2016. AxoGen has entered into an agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) as a result this termination.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Options
6 Months Ended

Jun. 30, 2015

Stock Options

Stock Options

8. Stock Options

The Company granted stock options to purchase 295,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the six months ended June 30, 2015. Stock-based compensation expense was $328,376 and $216,602 for the three months ended June 30, 2015 and 2014, respectively and $696,625 and $474,144 for the six months ended June 30, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,996,000 at June 30, 2015.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Public Offering of Common Stock
6 Months Ended

Jun. 30, 2015

Public Offering of Common Stock

Public Offering of Common Stock

9. Public Offering of Common Stock

On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share. The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.

The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.

As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Subsequent Events
6 Months Ended

Jun. 30, 2015

Subsequent Event

Subsequent Events

11. Subsequent Events

License and Services Agreement

On August 6, 2015, AxoGen Corporation (“AxoGen”) entered into a License and Services Agreement (the “Agreement”) with CTS. Headquartered in Dayton, Ohio, CTS is a nonprofit quality, ethical provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts. CTS, an accredited member of the AATB, is one of the largest nonprofit tissue banks in the United States having in 2014 distributed more than 355,000 tissue grafts to over 5,000 hospitals, physicians and surgeons. Pursuant to the Agreement, AxoGen will process and package its Avance® Nerve Graft using its employees and equipment located at CTS. It is anticipated that processing currently being performed at LifeNet Health, will be transferred completely to the CTS facility by the end of first quarter of 2016.

The Agreement is for a 5 year term, subject to earlier termination by either party for cause, or after the two year anniversary of the Agreement without cause, upon 180 days’ notice. Under the Agreement AxoGen pays CTS a facility fee for clean room/processing, storage and office space. CTS also provides services in support of AxoGen’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support. The service fee is based on a per donor batch rate. It is anticipated that the Company will have approximately $400,000 of capital expenditures for the placement of equipment and build-out at this facility.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock Options (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Stock Options

Stock options granted under 2010 Stock Incentive Plan (in shares) 295,500

Stock-based compensation $ 328,376 $ 216,602 $ 696,625 $ 474,144

Total future stock compensation expense related to nonvested awards $ 1,996,000 $ 1,996,000

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 46 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Accounts Payable and Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2015

Accounts Payable and Accrued Expenses

Schedule of accounts payable and accrued expenses



June 30,



December 31,



2015

2014

Accounts payable

$

1,838,425

$

1,160,859

Miscellaneous accruals

205,809

105,315

Accrued compensation

1,363,888

1,165,020

Accounts Payable and Accrued Expenses

$

3,408,122

$

2,431,194

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Property and Equipment (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

Property and equipment

Less: accumulated depreciation and amortization $ (1,822,815) $ (1,735,205)

Property and equipment 663,910 619,028

Furniture and Office Equipment

Property and equipment

Property and equipment, Gross 955,743 873,824

Leasehold Improvements

Property and equipment

Property and equipment, Gross 300,697 285,697

Processing equipment

Property and equipment

Property and equipment, Gross $ 1,230,285 $ 1,194,712

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Cash flows from operating activities:

Net loss $ (6,766,073) $ (7,981,036)

Adjustments to reconcile net loss to net cash used for operating activities:

Depreciation 87,610 67,887

Amortization of intangible assets 22,710 22,099

Amortization of deferred financing costs 64,957 103,432

Share-based compensation 696,625 474,144

Stock grants 60,125

Interest added to note 340,870 1,878,894

Change in assets and liabilities:

Accounts receivable (965,715) (633,254)

Inventory (326,337) (12,004)

Prepaid expenses and other (131,739) 151,744

Accounts payable and accrued expenses 976,928 155,113

Deferred revenue (10,791) (7,143)

Net cash used for operating activities (6,010,955) (5,719,999)

Cash flows from investing activities:

Purchase of property and equipment (132,492) (283,476)

Acquisition of intangible assets (54,075) (30,305)

Net cash used for investing activities (186,567) (313,781)

Cash flows from financing activities:

Proceeds from exercise of stock options 14,071 134,362

Proceeds from issuance of common stock 13,770,734

Debt issuance costs (180,142)

Net cash provided by financing activities 13,604,663 134,362

Net increase/(decrease) in cash and cash equivalents 7,407,141 (5,899,418)

Cash and cash equivalents, beginning of year 8,215,791 20,069,750

Cash and cash equivalents, end of period 15,622,932 14,170,332

Supplemental disclosures of cash flow activity:

Cash paid for interest $ 1,649,881 $ 664,546

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Intangible Assets
6 Months Ended

Jun. 30, 2015

Intangible Assets

Intangible Assets

5. Intangible Assets

The Company’s intangible assets consist of the following:



June 30,



December 31,



2015

2014

(unaudited)

License agreements

$

860,006

$

850,859

Patents

124,924

79,996

Less: accumulated amortization

(376,391)

(353,681)

Intangible assets, net

$

608,539

$

577,174

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2015, the patents were fully amortized, and the remaining patents of $124,924 were pending patent costs and were not amortizable. Amortization expense was approximately $11,000 and $11,000 for the three months ended June 30, 2015 and 2014, respectively, and approximately $23,000 and $22,000 for the six months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, future amortization of license agreements for the next five years is expected to be $25,000 for the remainder of 2015 and $48,000 for 2016 through 2020.

License Agreements

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

·

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

·

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

·

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

·

Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

Royalty fees were approximately $121,000 and $85,000 during the three months ended June 30, 2015 and 2014, respectively, and were $217,000 and $145,000 for the six months ended June 30, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Intangible Assets (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Intangible assets consist of:

Less: accumulated amortization $ (376,391) $ (376,391) $ (353,681)

Intangible assets, net 608,539 608,539 577,174

Amortization of Intangible Assets 11,000 $ 11,000 22,710 $ 22,099

Licensing Agreements

Intangible assets consist of:

Finite-lived intangible assets, gross 860,006 $ 860,006 850,859

Licensing Agreements | Minimum

Intangible assets consist of:

Amortization period of intangible assets 17 years

Licensing Agreements | Maximum

Intangible assets consist of:

Amortization period of intangible assets 20 years

Patents

Intangible assets consist of:

Finite-lived intangible assets, gross $ 124,924 $ 124,924 79,996

Amortization period of intangible assets 3 years

Non-amortizable pending costs $ 124,924

X

- Definition
Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross.
+ References
No definition available.
+ Details

Name: axgn_NonamortizablePendingPatentCosts

Namespace Prefix: axgn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 66 167 1 false 19 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.axogeninc.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 10201 - Disclosure - Organization and Business Sheet http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10401 - Disclosure - Property and Equipment Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 10501 - Disclosure - Intangible Assets Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssets Intangible Assets Notes 10 false false R11.htm 10601 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 10701 - Disclosure - Notes Payable Notes http://www.axogeninc.com/role/DisclosureNotesPayable Notes Payable Notes 12 false false R13.htm 10801 - Disclosure - Stock Options Sheet http://www.axogeninc.com/role/DisclosureStockOptions Stock Options Notes 13 false false R14.htm 10901 - Disclosure - Public Offering of Common Stock Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock Public Offering of Common Stock Notes 14 false false R15.htm 11001 - Disclosure - Commitments and Contingencies Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 11101 - Disclosure - Subsequent Events Sheet http://www.axogeninc.com/role/DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.axogeninc.com/role/DisclosurePropertyAndEquipment 19 false false R20.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.axogeninc.com/role/DisclosureIntangibleAssets 20 false false R21.htm 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses 21 false false R22.htm 30703 - Disclosure - Notes Payable (Tables) Notes http://www.axogeninc.com/role/DisclosureNotesPayableTables Notes Payable (Tables) Tables http://www.axogeninc.com/role/DisclosureNotesPayable 22 false false R23.htm 40301 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 40302 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailss Summary of Significant Accounting Policies (Details) Details http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 40303 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsss Summary of Significant Accounting Policies (Details) Details http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 40401 - Disclosure - Property and Equipment (Details) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables 26 false false R27.htm 40501 - Disclosure - Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables 27 false false R28.htm 40502 - Disclosure - Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetailss Intangible Assets (Details) Details http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables 28 false false R29.htm 40503 - Disclosure - Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetailsss Intangible Assets (Details) Details http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables 29 false false R30.htm 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) Details http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables 30 false false R31.htm 40701 - Disclosure - Notes Payable (Details) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetailsss Notes Payable (Details) Details http://www.axogeninc.com/role/DisclosureNotesPayableTables 31 false false R32.htm 40702 - Disclosure - Notes Payable (Details) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetailss Notes Payable (Details) Details http://www.axogeninc.com/role/DisclosureNotesPayableTables 32 false false R33.htm 40703 - Disclosure - Notes Payable (Details) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails Notes Payable (Details) Details http://www.axogeninc.com/role/DisclosureNotesPayableTables 33 false false R34.htm 40801 - Disclosure - Stock Options (Details) Sheet http://www.axogeninc.com/role/DisclosureStockOptionsDetails Stock Options (Details) Details http://www.axogeninc.com/role/DisclosureStockOptions 34 false false R35.htm 40901 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) Details http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock 35 false false R36.htm 41001 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies 36 false false R37.htm 41101 - Disclosure - Subsequent Events (Details) Sheet http://www.axogeninc.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.axogeninc.com/role/DisclosureSubsequentEvents 37 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Balance Sheets (Parenthetical)'', column(s) 4, 5 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. axgn-20150630.xml axgn-20150630_cal.xml axgn-20150630_def.xml axgn-20150630_lab.xml axgn-20150630_pre.xml axgn-20150630.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Intangible Assets (Tables)
6 Months Ended

Jun. 30, 2015

Intangible Assets

Schedule of intangible assets



June 30,



December 31,



2015

2014

(unaudited)

License agreements

$

860,006

$

850,859

Patents

124,924

79,996

Less: accumulated amortization

(376,391)

(353,681)

Intangible assets, net

$

608,539

$

577,174

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Notes Payable (Details) - USD ($)			1 Months Ended	3 Months Ended
Notes Payable (Details) - USD ($)	Nov. 12, 2014	Oct. 05, 2012	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2015	Feb. 13, 2015	Feb. 05, 2015	Nov. 13, 2014
Credit facility disclosures
Shares of common stock sold			19,488,814		24,932,392	5,437,200
Value of common stock sold			$ 194,888		$ 249,323
Public offering price (in dollars per share)						$ 2.75	$ 2.75
PDL
Credit facility disclosures
Shares of common stock sold	643,382
Value of common stock sold	$ 1,750,000
Public offering price (in dollars per share)	$ 2.72
Three Peaks
Credit facility disclosures
Shares of common stock sold	1,375,969
Value of common stock sold	$ 3,550,000
Public offering price (in dollars per share)	$ 2.58
Term Loan \| Three Peaks
Credit facility disclosures
Term	6 years
Interest payable	9.00%
Face amount	$ 25,000,000
Basis spread on fixed rate, option 1	LIBOR		LIBOR	LIBOR
Basis spread on fixed rate, option 2	1.00%
Effective interest rate (as a percent)								10.00%
Optional future additional borrowing	$ 7,000,000
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date	120.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date	135.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date	150.00%
Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date	16.25%
Upon certain events, the additional percentage of the originally advanced Term Loan amount owed	3.00%
Revenue Interest Purchase Agreement \| PDL
Credit facility disclosures
Term		8 years
Royalty percentage on net revenue		9.95%
Revenue Interest Purchase Agreement \| Three Peaks
Credit facility disclosures
Term	10 years
Royalty percentage on net revenue	3.75%
Revenue Interest Purchase Agreement \| Three Peaks \| Maximum
Credit facility disclosures
Royalty percentage on net revenue	4.80%
Royalty revenue per year	$ 30,000,000

Summary of Significant Accounting Policies (Details)	6 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2015	Jun. 30, 2014
Summary of Significant Accounting Policies
Expected term	4 years	4 years
Expected volatility (as a percent)	76.24%	79.80%
Risk free rate (as a percent)	1.21%	1.20%

Subsequent Events (Details) - Aug. 05, 2015 - License and Services Agreement - Subsequent Events	USD ($) item
Subsequent Events
Term of agreement	5 years
Number of tissue grafts	355,000
Number of hospitals	5,000
Number of anniversary after which the agreement could be terminated	2
Notice period for termination of contract	180 days
Forecast
Subsequent Events
Capital expenditures \| $	$ 400,000

Intangible Assets (Details)	3 Months Ended		6 Months Ended
Intangible Assets (Details)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) product	Jun. 30, 2014 USD ($)
Sales and Marketing Expense
Intangible assets
Royalty fees included in sales and marketing expense	$ 121,000	$ 85,000	$ 217,000	$ 145,000
Licensing Agreements
Intangible assets
License agreements extended period			60 days
Minimum royalty of agreements			$ 12,500
Milestone fee upon receiving a Phase II Small Business Innovation Research			$ 15,000
Number of products under development \| product			0
Licensing Agreements \| Minimum
Intangible assets
Royalty fees range under the license agreements			1.00%
Licensing Agreements \| Maximum
Intangible assets
Royalty fees range under the license agreements			3.00%
Royalty stack cap for royalties paid to more than one licensor for sales of the same product			3.75%

Intangible Assets (Details)	Jun. 30, 2015 USD ($)
Future amortization of license and patent agreements
Remainder of 2015	$ 25,000
2016	48,000
2017	48,000
2018	48,000
2019	48,000
2020	$ 48,000

Accounts Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities
Accounts payable	$ 1,838,425	$ 1,160,859
Miscellaneous accruals	205,809	105,315
Accrued compensation	1,363,888	1,165,020
Accounts Payable and Accrued Expenses	$ 3,408,122	$ 2,431,194

Notes Payable (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Note Payable
Total Debt	$ 25,426,647	$ 25,085,777
Term Loan And Revenue Interest Purchase Agreement
Note Payable
Long-term Notes Payable	25,426,647	25,085,777
Three Peaks \| Term Loan
Note Payable
Long-term Notes Payable	$ 25,426,647	$ 25,085,777

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 15,622,932	$ 8,215,791
Accounts receivable, net of allowance for doubtful accounts of approximately $101,000 and $94,000, respectively	3,838,023	2,872,308
Inventory	3,539,957	3,213,620
Prepaid expenses and other	241,108	109,369
Total current assets	23,242,020	14,411,088
Property and equipment, net	663,910	619,028
Intangible assets	608,539	577,174
Deferred financing costs	908,684	793,499
Total Assets	25,423,153	16,400,789
Current liabilities:
Accounts payable and accrued expenses	3,408,122	2,431,194
Current Deferred Revenue	14,118	14,118
Total current liabilities	3,422,240	2,445,312
Note Payable - Revenue Interest Purchase Agreement	25,426,647	25,085,777
Long Term Deferred Revenue	104,589	115,380
Total liabilities	28,953,476	27,646,469
Shareholders' equity (deficit):
Common stock, $.01 par value; 50,000,000 shares authorized; 24,932,392 and 19,488,814 shares issued and outstanding	249,323	194,888
Additional paid-in capital	93,102,681	78,675,686
Accumulated deficit	(96,882,327)	(90,116,254)
Total shareholders' equity (deficit)	(3,530,323)	(11,245,680)
Total Liabilities and Shareholders' equity	$ 25,423,153	$ 16,400,789

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2015
Basis of Presentation
Basis of Presentation	1. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of June 30, 2015 and December 31, 2014 and for the three and six month periods ended June 30, 2015 and 2014. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2014, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2014. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

Public Offering of Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 13, 2015	Feb. 05, 2015	Jun. 30, 2015	Dec. 31, 2014
Public Offering of Common Stock
Offering, issuance and sale of common shares under Underwriting Agreement		4,728,000
Par value of common stock		$ 0.01	$ 0.01
Shares of common stock sold	5,437,200		24,932,392	19,488,814
Public offering price (in dollars per share)	$ 2.75	$ 2.75
Number of days to underwriter to sell additional common shares		30 days
Additional Common Shares to cover over-allotments		709,200
Gross proceeds from issuance of common stock	$ 15.0
Underwriting discounts, commissions and other estimated offering expenses	$ 1.4

Commitments and Contingencies (Details) - Apr. 21, 2015 - Ja-Cole	USD ($) ft²
Commitments and Contingencies
Additional leased office space in square feet	2,100
Leased office space in square feet	5,400
Term of agreement	3 years
Annual lease expense \| $	$ 60,000

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies
Finished goods	$ 2,403,791	$ 2,072,235
Work in process	240,054	331,891
Raw materials	896,112	809,494
Inventory, Net	3,539,957	3,213,620
Inventory valuation reserves	$ 653,000	$ 404,000

Organization and Business	6 Months Ended
Organization and Business	Jun. 30, 2015
Organization and Business
Organization and Business	2. Organization and Business Business Summary AxoGen, Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 148,000	$ 94,000
Common stock, Par value	$ 0.01
Common stock, shares authorized	50,000,000
Common stock, shares issued	24,932,392	19,488,814
Common stock, shares outstanding	24,932,392	19,488,814

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 05, 2015
Document and Entity Information
Entity Registrant Name	AxoGen, Inc.
Entity Central Index Key	0000805928
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,932,392
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounts Receivable and Concentration of Credit Risk
Reserve for accounts deemed uncollectible (as a percent)	100.00%
Allowance for doubtful accounts reserve balance	$ 148,000	$ 94,000
Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	60 days
Age 61 to 90 Days
Accounts Receivable and Concentration of Credit Risk
Reserve for doubtful accounts (as a percent)	5.00%
Age 61 to 90 Days \| Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	61 days
Age 61 to 90 Days \| Maximum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	90 days
Age Over 90 Days
Accounts Receivable and Concentration of Credit Risk
Reserve for doubtful accounts (as a percent)	20.00%
Age Over 90 Days \| Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	90 days

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2015
Commitments and Contingencies.
Commitments and Contingencies	10. Commitments and Contingencies Commercial Lease On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc. (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas. The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year. The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations. Processing Agreement Under an Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia. As a result of business requirements of LifeNet Health and their need for additional space, on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the LifeNet Agreement effective February 27, 2016. AxoGen has entered into an agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) as a result this termination.

Stock Options	6 Months Ended
Stock Options	Jun. 30, 2015
Stock Options
Stock Options	8. Stock Options The Company granted stock options to purchase 295,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the six months ended June 30, 2015. Stock-based compensation expense was $328,376 and $216,602 for the three months ended June 30, 2015 and 2014, respectively and $696,625 and $474,144 for the six months ended June 30, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,996,000 at June 30, 2015.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2015
Subsequent Event
Subsequent Events	11. Subsequent Events License and Services Agreement On August 6, 2015, AxoGen Corporation (“AxoGen”) entered into a License and Services Agreement (the “Agreement”) with CTS. Headquartered in Dayton, Ohio, CTS is a nonprofit quality, ethical provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts. CTS, an accredited member of the AATB, is one of the largest nonprofit tissue banks in the United States having in 2014 distributed more than 355,000 tissue grafts to over 5,000 hospitals, physicians and surgeons. Pursuant to the Agreement, AxoGen will process and package its Avance® Nerve Graft using its employees and equipment located at CTS. It is anticipated that processing currently being performed at LifeNet Health, will be transferred completely to the CTS facility by the end of first quarter of 2016. The Agreement is for a 5 year term, subject to earlier termination by either party for cause, or after the two year anniversary of the Agreement without cause, upon 180 days’ notice. Under the Agreement AxoGen pays CTS a facility fee for clean room/processing, storage and office space. CTS also provides services in support of AxoGen’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support. The service fee is based on a per donor batch rate. It is anticipated that the Company will have approximately $400,000 of capital expenditures for the placement of equipment and build-out at this facility.

Stock Options (Details) - USD ($)	3 Months Ended		6 Months Ended
Stock Options (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock Options
Stock options granted under 2010 Stock Incentive Plan (in shares)			295,500
Stock-based compensation	$ 328,376	$ 216,602	$ 696,625	$ 474,144
Total future stock compensation expense related to nonvested awards	$ 1,996,000		$ 1,996,000

Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property and equipment
Less: accumulated depreciation and amortization	$ (1,822,815)	$ (1,735,205)
Property and equipment	663,910	619,028
Furniture and Office Equipment
Property and equipment
Property and equipment, Gross	955,743	873,824
Leasehold Improvements
Property and equipment
Property and equipment, Gross	300,697	285,697
Processing equipment
Property and equipment
Property and equipment, Gross	$ 1,230,285	$ 1,194,712

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (6,766,073)	$ (7,981,036)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	87,610	67,887
Amortization of intangible assets	22,710	22,099
Amortization of deferred financing costs	64,957	103,432
Share-based compensation	696,625	474,144
Stock grants		60,125
Interest added to note	340,870	1,878,894
Change in assets and liabilities:
Accounts receivable	(965,715)	(633,254)
Inventory	(326,337)	(12,004)
Prepaid expenses and other	(131,739)	151,744
Accounts payable and accrued expenses	976,928	155,113
Deferred revenue	(10,791)	(7,143)
Net cash used for operating activities	(6,010,955)	(5,719,999)
Cash flows from investing activities:
Purchase of property and equipment	(132,492)	(283,476)
Acquisition of intangible assets	(54,075)	(30,305)
Net cash used for investing activities	(186,567)	(313,781)
Cash flows from financing activities:
Proceeds from exercise of stock options	14,071	134,362
Proceeds from issuance of common stock	13,770,734
Debt issuance costs	(180,142)
Net cash provided by financing activities	13,604,663	134,362
Net increase/(decrease) in cash and cash equivalents	7,407,141	(5,899,418)
Cash and cash equivalents, beginning of year	8,215,791	20,069,750
Cash and cash equivalents, end of period	15,622,932	14,170,332
Supplemental disclosures of cash flow activity:
Cash paid for interest	$ 1,649,881	$ 664,546

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Intangible Assets (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Intangible assets consist of:
Less: accumulated amortization	$ (376,391)		$ (376,391)		$ (353,681)
Intangible assets, net	608,539		608,539		577,174
Amortization of Intangible Assets	11,000	$ 11,000	22,710	$ 22,099
Licensing Agreements
Intangible assets consist of:
Finite-lived intangible assets, gross	860,006		$ 860,006		850,859
Licensing Agreements \| Minimum
Intangible assets consist of:
Amortization period of intangible assets			17 years
Licensing Agreements \| Maximum
Intangible assets consist of:
Amortization period of intangible assets			20 years
Patents
Intangible assets consist of:
Finite-lived intangible assets, gross	$ 124,924		$ 124,924		79,996
Amortization period of intangible assets			3 years
Non-amortizable pending costs					$ 124,924